Identifying the right treatment starts with the right test. c‑MET CDx for NSCLC IHC provides clear insights into HGF receptor (c-Met) protein overexpression to inform care strategies for EGFR wild‑type NSCLC: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…
#oncologytesting #biomarkers #nsclc
NeoGenomics
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. More on Wikipedia
-
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Our digital #pathology library is rich with real clinical context—built to support your AI models and fuel discovery. Let’s talk image-powered research: neogenomics.com/oncology-data-solutions.
#digitalpathology #aiinoncology #neogenomics -
NeoGenomics
@NeoGenomics
Pathologists, laboratory leaders, and industry partners: we’d love to connect at #amp2026.
📍 Meet with the #neogenomics team at booth #2312.
📅 November 10-14
🔗 Schedule time with our team: mailchi.mp/neogenomics.com/amp2026
#moleculardiagnostics #pathology #precisiononcology #amp2026 -
NeoGenomics
@NeoGenomics
Today, we honor and express our deep gratitude to all the veterans who have served our country. Your bravery, sacrifice, and resilience inspire us daily. Thank you for your service.
#neogenomics #lifeatneo #workatneo #hiringourheroes #veteransday #veteransday26 -
NeoGenomics
@NeoGenomics
Our expanding oncology IHC portfolio includes newly validated, off-the-shelf B7-H3, CD137, EZH2, PRMT5, and TROP2 biomarkers to help pharma partners make data-driven decisions that support patient selection, trial optimization, and clinical progress: www.neogenomics.com/biopharma-partnerships
-
NeoGenomics
@NeoGenomics
#neogenomics is proud to offer the c-MET CDx for NSCLC IHC testing to help oncologists and pathologists identify patients who may benefit from this breakthrough: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…. c-MET is a new actionable biomarker with an FDA-approved targeted therapy for NSCLC patients.
-
NeoGenomics
@NeoGenomics
Pathologists, laboratory leaders and industry partners: we’d love to connect at #amp2026.
📅 November 10-14
🔗 Schedule time with our team: mailchi.mp/neogenomics/amp2026.
#moleculardiagnostics #pathology #precisiononcology -
NeoGenomics
@NeoGenomics
Have a safe & happy Halloween!
#halloween2026 -
NeoGenomics
@NeoGenomics
Team Neo brought the creativity this week! 💚 From individual and group costumes to festive pets, we loved seeing everyone join in the fun for our annual #neogenomics costume contest!
#lifeatneo #neospirit #workatneo -
NeoGenomics
@NeoGenomics
Today, #neogenomics announced third-quarter 2026 results, with total revenue increasing 11% year over year to $209 million and clinical revenue growing 13%, driven by NGS growth of 29%. To read the full #pressrelease, visit: ir.neogenomics.com/news-events/press-releases/detail/342/…
-
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth is an important time to highlight tools supporting better #patientcare. RaDaR® ST, which is indicated for use in #breastcancer (neogenomics.com/providers/oncology-solutions/RaDaR®st-mrd), is designed to support confidence across the cancer continuum of care.
-
NeoGenomics
@NeoGenomics
#neogenomics Oncology Data Solutions team members are in Madrid, connecting with researchers, sponsors, and industry leaders to discuss the power of high-quality clinicogenomic data in oncology research at #esmo2026.
📍 Booth #8028
🔗 Request a meeting: mailchi.mp/neogenomics/esmo2026 -
NeoGenomics
@NeoGenomics
The NeoGenomics Pharma and Oncology Data Solutions teams are excited to be in Madrid for #esmo2026. Visit us during the congress at booth #8028 or request dedicated time with our team at: mailchi.mp/neogenomics/esmo2026.
-
NeoGenomics
@NeoGenomics
If you're at #esmo2026, have you stopped by to learn how NeoGenomics supports oncology drug development with both advanced testing services and clinicogenomic data solutions? We're waiting for you! Meet our Pharma Services and Oncology Data Solutions teams at booth #8028.
-
NeoGenomics
@NeoGenomics
By partnering with Epic Aura, NeoGenomics delivers genomic testing that fits naturally into Epic workflows, eliminating unnecessary manual steps and reducing errors tied to transcription and re‑entry.
🔗 www.neogenomics.com/providers/client-support-resources/eh… -
NeoGenomics
@NeoGenomics
Looking for deeper insights to support your oncology program? Visit us at #esmo2026 to learn how our Pharma Services and Oncology Data Solutions teams help biopharma organizations accelerate therapeutic development.
📍 Booth 8028
📅 October 23-27
🔗 mailchi.mp/neogenomics/esmo2026 -
NeoGenomics
@NeoGenomics
#neogenomics has expanded its partnership with Indica Labs, a global leader in AI-powered digital pathology: ir.neogenomics.com/news-events/press-releases/detail/341/….
-
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth is an important time to highlight tools supporting better #patientcare. RaDaR® ST, which is specifically indicated for use in #breastcancer (neogenomics.com/providers/oncology-solutions/RaDaR®st-mrd), is designed to support confidence across the cancer continuum of care.
-
NeoGenomics
@NeoGenomics
Warren Stone, #neogenomics' current President and COO, has been appointed CEO and a member of the Board, effective January 4, 2027.
Tony Zook, current CEO and member of the Board, will transition to Executive Chair on January 4, 2027. -
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth begins today🎗️ All month long, we will be sharing education and resources, highlighting our testing solutions, and more.
#breastcancerawarenessmonth #breastcancerawareness2025 #cancertesting #oncology #neogenomics -
NeoGenomics
@NeoGenomics
Learning, growing, and leading together. 💙💚 Recently, leaders from across the organization came together at our HQ in Fort Myers, FL, for hands-on learning focused on business acumen and change resiliency.
#workatneo #neospirit #lifeatneo -
NeoGenomics
@NeoGenomics
RaDaR® ST provides clear, actionable answers: neogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd -
NeoGenomics
@NeoGenomics
RaDaR® ST helps pharma partners identify high-risk, ctDNA-positive patients, enriching your trial population for better outcomes. See how to stratify smarter with RaDaR ST: www.neogenomics.com/partners/biopharma-services/radar-st-….
-
NeoGenomics
@NeoGenomics
Predict cancer’s recurrence with RaDaR® ST. It detects molecular residual disease with high sensitivity, helping forecast disease progression before clinical symptoms arise.
🔗 Learn more about RaDaR® ST for Pharma Partners: neogenomics.com/partners/biopharma-services/radar-st-phar…. -
NeoGenomics
@NeoGenomics
Claudin 18.2 (CLDN18.2) is an actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Learn more about 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma: www.neogenomics.com/providers/test/APH-CLAP-01AX/claudin-….
-
NeoGenomics
@NeoGenomics
Today, we pause to remember those whose lives were lost and to honor the first responders, military members, and all those who showed extraordinary courage to save others on September 11, 2001. #patriotday
-
NeoGenomics
@NeoGenomics
Biomarker-informed decision-making is transforming lung cancer care. c-MET CDx for NSCLC IHC testing (neogenomics.com/providers/test/APH-CMET-01AX/c-met-cdx-fo…) identifies NSCLC patients eligible for a new FDA-approved targeted therapy, offering new personalized treatment opportunities.
-
NeoGenomics
@NeoGenomics
Get DNA and RNA alterations in a single test for a complete genomic view with Neo Comprehensive® – Myeloid Disorders: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe….
-
NeoGenomics
@NeoGenomics
Happy Labor Day! #laborday #laborday2026
-
NeoGenomics
@NeoGenomics
PTEN IHC CDx is now available as part of PanTracer Pro, pairing IHC-based PTEN deficiency identification with comprehensive genomic profiling for a more complete biomarker picture. Learn more: neogenomics.com/providers/test/APH-PTFD-01AX/pten-fda-for….
#prostatecarcinoma #oncology #comprehensivegenomicprofiling -
NeoGenomics
@NeoGenomics
Wearing green for #mentalhealthawareness 💚 At #neogenomics, we believe supporting mental health and well-being is just as important as supporting physical health. If you're interested in an organization committed to supporting emotional well-being, visit jobs.jobvite.com/neogenomics.
-
NeoGenomics
@NeoGenomics
See the impact of diverse population data: neogenomics.com/oncology-data-solutions. Tap into a dataset representing the entire U.S. population—over 3M patient profiles from 4,400 healthcare organizations.
-
NeoGenomics
@NeoGenomics
Paletrra offers advanced spatial analytics aligned to your exact specifications. Gain deeper insights into the tumor microenvironment: www.neogenomics.com/paletrratm
-
NeoGenomics
@NeoGenomics
As the NSCLC treatment landscape evolves, actionable biomarkers like c‑MET play an increasingly critical role. The c‑MET CDx for NSCLC IHC supports precision‑driven testing to guide targeted therapy decisions: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…
#neogenomics #nsclc #precisionmedicine #cmet -
NeoGenomics
@NeoGenomics
Our integration with Epic Aura enables in‑workflow genomic test ordering and returns discrete results directly into Epic, replacing fragmented systems and reducing reliance on portals and faxes: www.neogenomics.com/providers/client-support-resources/eh…
-
NeoGenomics
@NeoGenomics
We’re always innovating, because your patients deserve the chance to uncover targeted therapy options. Visit us online to learn about how we’ve expanded our companion diagnostic portfolio with The PD-L1 22C3 FDA for Ovarian Carcinoma assay: neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22c3-f….
-
NeoGenomics
@NeoGenomics
Our newly validated, off-the-shelf biomarkers B7-H3, CD137, EZH2, PRMT5, and TROP2 help uncover target expression patterns that support more precise patient selection and stronger development strategies. Contact us to learn more: contactpharma@neogenomics.com.
-
NeoGenomics
@NeoGenomics
Fill data gaps with access to our growing specimen library of slides and genomic isolates. Go deeper into emerging biomarkers with NeoExplore™: Sample Archive 🔗 neogenomics.com/oncology-data-solutions.
-
NeoGenomics
@NeoGenomics
The PTEN IHC CDx is now FDA-approved to help identify patients with PTEN deficiency who may be eligible for targeted therapy in metastatic hormone-sensitive prostate cancer (mHSPC). Learn more: www.neogenomics.com/providers/test/APH-PTFD-01AX/pten-fda….
-
NeoGenomics
@NeoGenomics
Missed our webinar on how to apply liquid biopsy testing for diagnosis & treatment selection? Stream it here: www.neogenomics.com/providers/oncology-solutions/pantrace…. From clinical applications to real-world case studies and implementation strategies, don’t miss your chance to catch all the insights on-demand.
-
NeoGenomics
@NeoGenomics
Introducing faster turnaround times for Neo Comprehensive® – Heme Cancers and Neo Comprehensive® – Myeloid Disorders! Learn more: www.neogenomics.com/providers/oncology-solutions/hematolo….
#hematology #precisionmedicine #genomicprofiling #oncology -
NeoGenomics
@NeoGenomics
Our FDA-approved companion diagnostic IHC assay helps identify patients with PTEN deficiency in metastatic hormone-sensitive prostate cancer (mHSPC) who may benefit from a new targeted therapy option.
Learn more: ir.neogenomics.com/news-events/press-releases/detail/334/…. -
NeoGenomics
@NeoGenomics
See the impact of diverse population data: neogenomics.com/oncology-data-solutions. Tap into a dataset representing the entire U.S. population—over 3M patient profiles from 4,400 healthcare organizations.
-
NeoGenomics
@NeoGenomics
Biomarker‑informed decision‑making continues to transform lung cancer care. c‑MET CDx for NSCLC IHC testing (www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…) helps identify patients eligible for a new FDA‑approved targeted therapy—unlocking more personalized treatment options.
-
NeoGenomics
@NeoGenomics
Comprehensive genomic profiling isn’t just a test—it’s a roadmap for better outcomes. Solve challenging cases with Neo Comprehensive® – Myeloid Disorders: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe….
-
NeoGenomics
@NeoGenomics
Our FDA-approved companion diagnostic IHC assay helps identify patients with PTEN deficiency in metastatic hormone-sensitive prostate cancer (mHSPC) who may benefit from a new targeted therapy option.
Learn more: neogenomics.com/providers/test/APH-PTFD-01AX/pten-fda-for…. -
NeoGenomics
@NeoGenomics
Access tumor-specific genomic insights quickly and noninvasively with PanTracer LBx. Click to cover 500+ genes, from guideline-recommended to emerging alterations: www.neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pant….
-
NeoGenomics
@NeoGenomics
Have a safe & happy 4th of July!
-
NeoGenomics
@NeoGenomics
📊 MRD insights that matter.
RaDaR® ST enables tracking of patient response to investigational therapies—differentiating responders from non-responders.
Explore the benefits of RaDaR® ST for Pharma Partners: www.neogenomics.com/partners/biopharma-services/radar-st-… -
NeoGenomics
@NeoGenomics
Dive deep with our scientific expertise: neogenomics.com/oncology-data-solutions. Work with one of the largest oncology reference labs in the U.S. Our deep diagnostic knowledge powers precision oncology.
-
NeoGenomics
@NeoGenomics
PanTracer Pro ensures you have the insights tailored to your patient’s tumor type and clinical context needed to guide precision oncology: www.neogenomics.com/providers/oncology-solutions/pantrace….
#oncology #pantracerpro #neogenomics #cancertesting -
NeoGenomics
@NeoGenomics
From forecasting to diagnostic trend analysis, we deliver data solutions tailored to your product goals and timelines: neogenomics.com/oncology-data-solutions.
#oncology #oncologydata -
NeoGenomics
@NeoGenomics
Accurate risk stratification starts with the right test. Neo Comprehensive® – Myeloid Disorders delivers precision for myeloid disorders, including MDS and CMML: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe…
Better data, better care. -
NeoGenomics
@NeoGenomics
NeoGenomics is pleased to offer the PD-L1 22C3 FDA for Ovarian Carcinoma assay with a rapid 2-day turnaround time (TAT) to support timely patient care and clinical decision-making: www.neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22….
#ovariancancer #oncology #cancertesting -
NeoGenomics
@NeoGenomics
The c‑MET CDx for NSCLC IHC assay is available to support precision oncology for patients with EGFR wild‑type NSCLC: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…
And, this IHC assay detects HGF Receptor (c-Met) protein expression and integrates seamlessly into PanTracer Tissue workflows. -
NeoGenomics
@NeoGenomics
TSO500 delivers the molecular clarity biopharma teams need across the therapeutic development — from biomarker discovery to resistance detection, trial enrollment, longitudinal monitoring, and patient stratification: www.neogenomics.com/tso500.
-
NeoGenomics
@NeoGenomics
Our digital #pathology library is rich with real clinical context—built to support your AI models and fuel discovery. Let’s talk image-powered research: neogenomics.com/oncology-data-solutions.
#digitalpathology #aiinoncology #neogenomics -
NeoGenomics
@NeoGenomics
When cancer leaves only a trace… can you still detect it? Join us for a #webinar with Basem Goueli, MD, PhD, MBA, as he explores how RaDaR® ST is advancing MRD detection down to 1 part per million (ppm): www.engagez.net/neowebinar16.
-
NeoGenomics
@NeoGenomics
During #cancersurvivor Month, we’re recognizing the importance of tools informed by science. RaDaR® ST is supported by an expanding base of clinical evidence, contributing to continued learning in cancer care and survivorship. Learn more: www.neogenomics.com/providers/oncology-solutions/radarst-mrd
-
NeoGenomics
@NeoGenomics
Register for Liquid Biopsy: Advancing Precision Care in Oncology 🔗 www.engagez.net/neowebinar15. This #webinar will explore how a minimally invasive approach can complement tissue testing & improve patient outcomes through faster, more personalized treatment decisions.
-
NeoGenomics
@NeoGenomics
The NEO AML Express assay offers class-leading turnaround times, a single report that provides a comprehensive NGS-based assessment, and rapid diagnostic, prognostic, and therapeutic information to inform personalized treatment decisions: neogenomics.com/providers/test/NTG-AMEP-02BX/neo-aml-express.
-
NeoGenomics
@NeoGenomics
RaDaR® ST offers a streamlined workflow for actionable insights, helping pharma partners monitor therapeutic response with precision.
See how it works: www.neogenomics.com/partners/biopharma-services/radar-st-… -
NeoGenomics
@NeoGenomics
#asco26 just wrapped up! We had the chance to connect with so many people & discuss how we can work together to advance personalized cancer care across the care continuum. If we didn’t get to meet, or you’d like to continue the discussion, let's connect: mailchi.mp/neogenomics/asco2026.
-
NeoGenomics
@NeoGenomics
The PD-L1 22c3 FDA for Ovarian Carcinoma (neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22c3-f…) seamlessly integrates into your existing molecular diagnostic workflow to provide comprehensive patient profiling through our PanTracer™ Portfolio and NeoTYPE® Ovarian assays.
-
NeoGenomics
@NeoGenomics
It’s Day 1 at the 2026 ASCO® Annual Meeting! Walk over to our booth at #32130, or plan ahead by booking a meeting here: mailchi.mp/neogenomics/asco2026.
-
NeoGenomics
@NeoGenomics
During #asco26, step into an interactive journey through the cancer care continuum and see how comprehensive clinical solutions, therapeutic development support, and data-driven insights are shaping more informed, individualized decisions at every stage.
-
NeoGenomics
@NeoGenomics
We’re showcasing our latest research at the 2026 ASCO® Annual Meeting on June 1st from 9 AM – 12 PM.
Contact us to discuss our findings and their implications for clinical care: mailchi.mp/neogenomics/asco2026. -
NeoGenomics
@NeoGenomics
Whether you’ve just started hearing the term or just had to Google it, we’re here to bring clinicogenomic insights to life. Come see us at #asco26, booth #32130, to explore how #clinicogenomic data is advancing precision oncology.
-
NeoGenomics
@NeoGenomics
On Memorial Day, we remember & honor those who made the ultimate sacrifice for our country. While touring historic #sandiego veteran sites, including the USS Midway and Rosecrans National Cemetery, we paused in quiet reflection. We invite you to join us in this moment of silence.
This media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
NeoGenomics’ c‑MET CDx for NSCLC IHC assay is part of our comprehensive #lungcancer testing portfolio—advancing precision oncology through biomarker‑driven care: neogenomics.com/providers/test/APH-CMET-01AX/c-met-cdx-fo…
#nsclc #oncologydiagnostics -
NeoGenomics
@NeoGenomics
We’re gearing up for #asco26! Request a meeting with us here: mailchi.mp/neogenomics/asco2026 to see how we’re advancing personalized cancer care across the care continuum.
See all that #neogenomics is sharing this year, from poster presentations to an interactive video experience. -
NeoGenomics
@NeoGenomics
To obtain confidence in every result, and simplify complex myeloid cases, #neogenomics provides clarity: www.neogenomics.com/providers/oncology-solutions/hematolo…
Neo Comprehensive – Myeloid Disorders uses DNA and RNA NGS to uncover actionable insights for MDS and CMML.
#mds #cmml #myeloid #hematologicalcancer -
NeoGenomics
@NeoGenomics
We’re always innovating, because your patients deserve the chance to uncover targeted therapy options. Visit us online to learn about how we’ve expanded our companion diagnostic portfolio with The PD-L1 22C3 FDA for Ovarian Carcinoma assay: neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22c3-f….
-
NeoGenomics
@NeoGenomics
Happy Mother’s Day! Today, we're celebrating each & every one of the amazing women who inspire us with their boundless love, patience, dedication, & wisdom. We are so proud to support mothers at NeoGenomics, from lactation rooms to gifts—like this one that we send to new mothers.
-
NeoGenomics
@NeoGenomics
PanTracer Pro combines broad genomic profiling with tumor-specific testing, including IHC and HRD scoring, to deliver therapy-guiding insights in one order: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
Make confident, data-driven genomic decisions even when tumor tissue is limited or unavailable with TSO 500 ctDNA v2. Contact us to learn more: neogenomics.com/tso500
-
NeoGenomics
@NeoGenomics
Did you miss us at #asbrs2026—or want to continue the conversation? 🔗 mailchi.mp/neogenomics/asbrs2026
Thank you for an incredible meeting! We loved connecting with the breast surgery community at the American Society of Breast Surgeons 2026 Annual Meeting.
#movetheneedle -
NeoGenomics
@NeoGenomics
𝐑𝐞𝐚𝐥-𝐭𝐢𝐦𝐞 𝐚𝐥𝐞𝐫𝐭𝐬. 𝐒𝐦𝐚𝐫𝐭𝐞𝐫 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬. Stay ahead with NeoGenomics’ data triggers—patient and physician-level alerts that keep your strategy proactive, not reactive: neogenomics.com/oncology-data-solutions.
#oncologyinsights #datatriggers #neogenomics -
NeoGenomics
@NeoGenomics
Our tailored data and market insights help you see the road ahead—so your launch strategy is guided, not guessed: neogenomics.com/oncology-data-solutions.
#prelaunchstrategy #diagnostics #oncologydata -
NeoGenomics
@NeoGenomics
RaDaR® ST’s coverage helps ensure more patients can benefit from MRD-guided insights while giving your practice greater certainty and smoother billing workflows: www.neogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd -
NeoGenomics
@NeoGenomics
Day 1 at #asbrs2026 is here! Visit NeoGenomics at booth 338 to see how RaDaR ST brings molecular residual disease into focus. #movetheneedle
-
NeoGenomics
@NeoGenomics
RaDaR® ST delivers tumor-informed MRD insights with high sensitivity, helping biopharma partners unlock deeper molecular insights. Learn more about RaDaR ST for Pharma Partners: neogenomics.com/partners/biopharma-services/radar-st-phar….
-
NeoGenomics
@NeoGenomics
Day 1 of #coa2026 just kicked off! Stop by booth 202 to explore the latest in precision oncology, including the PanTracer™ portfolio for comprehensive genomic profiling and RaDaR® ST MRD detection. Come visit us!
-
NeoGenomics
@NeoGenomics
NeoEngage: Commercialization Support 🔗 Learn more: www.neogenomics.com/oncology-data-solutions. Drive biomarker adoption and precision oncology with real-time insights and analytics. Partner with us to amplify your diagnostic strategy.
-
NeoGenomics
@NeoGenomics
c‑MET for NSCLC IHC testing helps determine eligibility for a new second‑line targeted therapy, supporting confident, informed treatment decisions. Add c‑MET CDx for NSCLC IHC to your PanTracer Tissue orders: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…
#oncology #nsclc #cmetcdx #egfrwildtype -
NeoGenomics
@NeoGenomics
With bright lights and big energy, #labweek hit a whole new level with our Glow Party! From neon vibes to nonstop laughs, this is what #neospirit looks like. True to our 2026 Lab Week's Toy Story theme, they glow to infinity & beyond 🚀✨
-
NeoGenomics
@NeoGenomics
We are excited to share that Kristi McKeown has joined NeoGenomics as as Chief Commercial Officer.
-
NeoGenomics
@NeoGenomics
The 'Lab Story' keeps rolling with even more fun, including deputy badges, caricatures & lots of smiles along the way. 💙🧪 As we celebrate #labweek2026, we’re proud to recognize our incredible lab professionals whose expertise & dedication help advance #patientcare every day.
-
NeoGenomics
@NeoGenomics
The #neogenomics oncology data solutions team is excited to be at #aacr26! Schedule a meeting with them here: mailchi.mp/neogenomics/aacr2026 and learn more below about how multimodal data is driving the next era of translational research.
-
NeoGenomics
@NeoGenomics
We're on year 5 of this photo tradition with Kate and it keeps getting better. We take this picture each #labweek, and from solo splits to baby bump to babies in arms, this captures more than just #neospirit, it’s a reminder that our lives are growing right alongside our careers.
-
NeoGenomics
@NeoGenomics
Happy #labweek! We're celebrating our amazing lab professionals whose dedication & expertise help advance #patientcare every day. We're taking this time to thank everyone for all that they do with a Toy Story–inspired week full of recognition & appreciation across our locations.
-
NeoGenomics
@NeoGenomics
Happy #labweek! We’re proud to celebrate the expertise, dedication & commitment of our laboratory professionals. In honor of this year’s #labstory national theme, we're enjoying a fun, Toy Story–inspired week filled with appreciation events, activities & celebrations.
-
NeoGenomics
@NeoGenomics
Happy #labweek! We’re proud to celebrate our incredible laboratory professionals and the vital role they play in advancing patient care every single day. In honor of the national theme, we're enjoying a Toy Story–inspired week with appreciation events, activities & celebrations.
-
NeoGenomics
@NeoGenomics
RaDaR® ST delivers intuitive, easy-to-interpret reports that translate complex molecular data into clear clinical guidance: eogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd -
NeoGenomics
@NeoGenomics
Our tailored data and market insights help you see the road ahead—so your launch strategy is guided, not guessed: neogenomics.com/oncology-data-solutions.
#prelaunchstrategy #diagnostics #oncologydata -
NeoGenomics
@NeoGenomics
We love to share pictures of #lifeatneo, and today, here are some snaps of a team celebrating wins together! 🎉 Members of the #neogenomics accounting team got together in Carlsbad after the successful filing of our annual 10‑K and audit. #neospirit #workatneo
-
NeoGenomics
@NeoGenomics
How much CLDN18.2 positivity did real-world data find in gastric/GEJ cases? Read our new white paper to discover: neogenomics.com/oncology-data-solutions
#targetedtherapy #gastriccancer #biomarkerinnovation -
NeoGenomics
@NeoGenomics
Join us at Community Oncology Conference April 28–29 at the Walt Disney World Dolphin Hotel in Orlando!
See you at #coa2026! -
NeoGenomics
@NeoGenomics
Accelerate your cell therapy program with our end-to-end multi-modal solutions, off-the-shelf and custom assays, and unmatched expert support: www.neogenomics.com/partners
-
NeoGenomics
@NeoGenomics
c‑MET for NSCLC IHC testing helps determine eligibility for a new second‑line targeted therapy, supporting confident, informed treatment decisions. Add c‑MET CDx for NSCLC IHC to your PanTracer Tissue orders: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd…
#oncology #nsclc #cmetcdx #egfrwildtype -
NeoGenomics
@NeoGenomics
Are you headed to the American Society of Breast Surgeons 2026 Annual Meeting? Let’s meet: mailchi.mp/neogenomics/asbrs2026. See you April 29–May 3!
#asbrs2026 #movetheneedle -
NeoGenomics
@NeoGenomics
Over 80% of early MDS cases lack clear evidence by traditional methods. CGP* changes that. Detect what others miss with Neo Comprehensive – Myeloid Disorders: neogenomics.com/providers/oncology-solutions/hematologica…
*Comprehensive Genomic Profiling
#myeloiddisorders #hematological #cancertesting #neogenomics -
NeoGenomics
@NeoGenomics
From molecular reclassification & #mrd as a surrogate endpoint to AI-enabled digital #hematopathology, this #webinar maps out the integrated advanced methodologies accelerating decision-making & improving the probability of clinical and commercial success: xtalks.com/webinars/redefining-hematologic-malignancy-dru…
-
NeoGenomics
@NeoGenomics
PanTracer Pro ensures you have the insights tailored to your patient’s tumor type and clinical context needed to guide precision oncology: neogenomics.com/providers/oncology-solutions/pantracer-po…
#oncology #pantracerpro #neogenomics #cancertesting -
NeoGenomics
@NeoGenomics
#neogenomics announced today it will present eight scientific posters and one oral presentation at #aacr26: ir.neogenomics.com/news-events/press-releases/detail/325/….
-
NeoGenomics
@NeoGenomics
Diagnosing MDS is challenging because low blood counts can be caused by many non-cancer conditions. Neo Comprehensive® – Myeloid Disorders provides diagnostic precision and clarity: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe….
#myeloid #oncology #cancertesting #mdsdiagnosis #blooddisorders -
NeoGenomics
@NeoGenomics
AI is transforming oncology. Explore how digital pathology and AI are reshaping screening and diagnosis in our new white paper: neogenomics.com/oncology-data-solutions
#aidigitalpathology #precisiononcology #neogenomics -
NeoGenomics
@NeoGenomics
New white paper! From Data to Decision: Biomarkers Driving Precision Medicine: neogenomics.com/oncology-data-solutions. Gastric cancer remains the 4th leading cause of cancer-related death worldwide, but #biomarker-driven therapies are changing the game.
#oncologydata #neogenomics -
NeoGenomics
@NeoGenomics
Watch this webinar on demand: neogenomics.com/partners and discover how AI-driven spatial proteomics is uncovering whole-tissue insights, preserving histological context, and revealing critical spatial relationships in NSCLC.
#spatialbiology #oncologyclinical Trials #biomarkers -
NeoGenomics
@NeoGenomics
Neo AML Express™ provides rapid, accurate testing of key genes essential for a precise diagnosis and tailored treatment plans for AML in emergency settings, where a fast turnaround is crucial: www.neogenomics.com/providers/test/NTG-AMEP-02BX/neo-aml-…
-
NeoGenomics
@NeoGenomics
From clinical to economic to real-world evidence, NeoGenomics supports your HEOR needs with high-quality, actionable insights: www.neogenomics.com/oncology-data-solutions
Let’s elevate your outcomes with the right data.
#heor #healtheconomics #realworlddata -
NeoGenomics
@NeoGenomics
Happy Easter! #easter #happyeaster #easter2026
-
NeoGenomics
@NeoGenomics
We’re excited to connect at #aacr26 and share how our end‑to‑end Pharma and Oncology Data Solutions capabilities are accelerating translational research and precision oncology. Book a meeting here: mailchi.mp/cda6649e6d3f/aacr2026
-
NeoGenomics
@NeoGenomics
Discover how PanTracer Pro supports confident decisions: neogenomics.com/pantracer-portfolio. With one order, you get comprehensive genomic profiling plus IHC and HRD testing based on tumor type and clinical context.
-
NeoGenomics
@NeoGenomics
We’re live at NextGen Omics Spatial & Data US 2026 in Boston! Stop by booth #27 to meet the NeoGenomics team and learn how our AI-driven spatial solutions, CAR‑T/ADC support, and comprehensive pharma services accelerate translational research.
-
NeoGenomics
@NeoGenomics
#icymi, we launched PD-L1 22c3 FDA for Ovarian Carcinoma (neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22c3-f…), to help uncover targeted therapy options for patients with recurrent #ovariancarcinoma, particularly platinum-resistant or platinum-refractory disease, for whom treatment options may be limited.
-
NeoGenomics
@NeoGenomics
Discover how PanTracer Pro supports confident decisions: neogenomics.com/pantracer-portfolio. With one order, you get comprehensive genomic profiling plus IHC and HRD testing based on tumor type and clinical context.
-
NeoGenomics
@NeoGenomics
🎯 Target the right patients with RaDaR ST for Pharma Partners: www.neogenomics.com/partners/biopharma-services/radar-st-…. Use RaDaR® ST to stratify and enrich trial populations, identifying ctDNA-positive individuals most likely to benefit from investigational therapies.
-
NeoGenomics
@NeoGenomics
We're having an incredible time at #uscap2026! Thank you to everyone who has stopped by booth #639 so far. Our team is energized by the conversations, collaboration, and shared commitment to improving patient care.
Stop by if you haven’t yet, we’re at booth #639! -
NeoGenomics
@NeoGenomics
We can’t wait to meet you! Visit #neogenomics at booth #639 at the USCAP 115th Annual Meeting to explore innovations driving precision oncology forward. #uscap2026 #pathology #oncologydiagnostics
-
NeoGenomics
@NeoGenomics
If you're at #uscap2026, stop by booth #639 to explore our latest in innovative solid tumor & NSCLC solutions, heme diagnostic solutions, tech-only services to support your practice, and more. Request to schedule a meeting online: mailchi.mp/neogenomics/uscap2026
-
NeoGenomics
@NeoGenomics
The PD-L1 22c3 FDA for Ovarian Carcinoma test (neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22c3-f…) integrates into the PanTracer™ Pro workflow and includes FOLR1 and HRD assessments for a comprehensive analysis and targeted therapy options.
-
NeoGenomics
@NeoGenomics
We’re excited to connect at #aacr26 and share how our end‑to‑end Pharma and Oncology Data Solutions capabilities are accelerating translational research and precision oncology. Book a meeting here: mailchi.mp/cda6649e6d3f/aacr2026
-
NeoGenomics
@NeoGenomics
Heading to #uscap2026? Here’s a sneak peek of what you’ll find at booth #639. Book a meeting with us here: mailchi.mp/neogenomics/uscap2026
#pathology #oncologydiagnostics -
NeoGenomics
@NeoGenomics
Let’s make your career as lucky as a four-leaf clover! 🍀 Your next career opportunity could be just around the corner! Explore our open jobs & join a team that values hard work and growth: jobs.jobvite.com/neogenomics. #stpatricksday #careeropportunities #luckytoworkhere #joinourteam
-
NeoGenomics
@NeoGenomics
Wherever the signal starts, you can find it with RaDaR ST: neogenomics.com/providers/oncology-solutions/radarst-mrd
Its highly sensitive MRD technology detects tumor DNA, long before imaging, revealing the earliest signs of recurrence and supports timely, confident decisions.
#neogenomics #precisiononcology -
NeoGenomics
@NeoGenomics
Join NeoGenomics at NextGen Omics Spatial & Data US 2026 for a special presentation: Mapping Immunotherapy Resistance: Unlocking Spatial Biology Insights Across the Tumor Microenvironment.
-
NeoGenomics
@NeoGenomics
Join us at #uscap2026! Visit booth 639 to learn about our latest innovations in cancer diagnostics, from solid tumor solutions to tech-only services.
#pathology #oncologydiagnostics -
NeoGenomics
@NeoGenomics
NeoGenomics is headed to NextGen Omics Spatial & Data US 2026 in Boston on March 31–April 1!
Visit us at Booth #27. We look forward to connecting with you in Boston! -
NeoGenomics
@NeoGenomics
We are pleased to announce the launch of PD-L1 22c3 FDA for Ovarian Carcinoma: www.neogenomics.com/providers/test/APH-PDLO-01AX/pd-l1-22….
NeoGenomics
@NeoGenomics
This assay can help identify patients who may be eligible for a new targeted therapy, supporting precision oncology for patients with recurrent ovarian carcinoma, particularly those with platinum-resistant or platinum-refractory disease, for whom treatment options may be limited.
-
NeoGenomics
@NeoGenomics
RaDaR® ST minimizes false positives and supports precise, timely care decisions: neogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd
.
.
.
*Detection down to 1 part per million (ppm) under study-specific conditions -
NeoGenomics
@NeoGenomics
RaDaR® ST is supported by a growing foundation of clinical evidence. neogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd -
NeoGenomics
@NeoGenomics
RaDaR® ST identifies the unique tumor profile of each patient to provide clear answers: neogenomics.com/providers/oncology-solutions/radarst-mrd.
#neogenomics #radarst #precisiononcology #mrd -
NeoGenomics
@NeoGenomics
Neo Comprehensive® – Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe…
#neogenomics #cancertesting #oncologyinsights -
NeoGenomics
@NeoGenomics
𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: #neogenomics has launched RaDaR® ST, our circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD): ir.neogenomics.com/news-events/press-releases/detail/322/…
-
NeoGenomics
@NeoGenomics
𝐈𝐭’𝐬 𝐚𝐥𝐦𝐨𝐬𝐭 𝐡𝐞𝐫𝐞: RaDaR® ST, for clinical use, is a highly sensitive MRD test to detect circulating tumor DNA.
🔗 neogenomics.com/providers/oncology-solutions/radarst-mrd
#neogenomics #radarst #precisiononcology #mrd #molecularresidualdisease -
NeoGenomics
@NeoGenomics
If we haven’t met, let’s fix that. NeoGenomics supports your oncology journey with data-backed insights that help close gaps in care and strengthen your strategy. Let’s connect and talk goals: www.neogenomics.com/oncology-data-solutions
-
NeoGenomics
@NeoGenomics
𝐒𝐨𝐦𝐞𝐭𝐡𝐢𝐧𝐠 𝐛𝐢𝐠 𝐢𝐬 𝐜𝐨𝐦𝐢𝐧𝐠. Follow us to learn about our #mrd innovation from adjuvant therapy through surveillance: RaDaR® ST.
#neogenomics #precisiononcology #radarst -
NeoGenomics
@NeoGenomics
Don't miss this new PharmaBoardroom interview with Tony Zook, NeoGenomics Laboratories CEO, where he shares how decades in pharmaceutical leadership shape his view of diagnostics as the backbone of precision #oncology: pharmaboardroom.com/interviews/tony-zook-ceo-neogenomics-….
-
NeoGenomics
@NeoGenomics
MRD detection with RaDaR ST can help improve clinical trial efficiency: www.neogenomics.com/partners/biopharma-services/radar-st-…
• Stratify and enrich clinical trial populations
• Track response to experimental therapies
• Use as a surrogate endpoint
#neogenomics #pharmapartners #clinicaltrial #oncology -
NeoGenomics
@NeoGenomics
PanTracer Pro streamlines molecular testing into a single order, eliminates order complexity, and ensures every patient receives the right tests.
Explore PanTracer Pro: neogenomics.com/providers/oncology-solutions/pantracer-po…
#neogenomics #cancertesting #pantracer #molecular -
NeoGenomics
@NeoGenomics
At the heart of Paletrra™ is partnership. We’ve empowered over 100 translational partners to see the full picture and move forward with confidence. 🔗 www.neogenomics.com/partners
-
NeoGenomics
@NeoGenomics
Happy Valentine's Day! Love, NeoGenomics 💝
-
NeoGenomics
@NeoGenomics
Press release: ir.neogenomics.com/news-events/press-releases/detail/319/…. #neogenomics announced the availability of PanTracer Pro, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage #solidtumors.
-
NeoGenomics
@NeoGenomics
Introducing PanTracer Pro, the newest addition to the PanTracer portfolio: www.neogenomics.com/providers/oncology-solutions/pantrace…
This integrated solution pairs comprehensive genomic profiling (CGP) with cancer type-directed IHC and ancillary testing to deliver therapy-guiding insights in a single order. -
NeoGenomics
@NeoGenomics
48% of MDS patients have clinically significant alterations detected through CGP. Neo Comprehensive® – Myeloid Disorders delivers the full picture: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe….
.
.
.
Reference: www.researchgate.net/figure/Array-CGH-detects-cryptic-alt… -
NeoGenomics
@NeoGenomics
We are excited to share that Abhishek Jain has joined NeoGenomics as Executive Vice President, Finance, and will transition to the role of Chief Financial Officer on March 2, 2026.
-
NeoGenomics
@NeoGenomics
Biomarker-informed decision-making is transforming lung cancer care. c-MET CDx for NSCLC IHC testing (neogenomics.com/providers/test/APH-CMET-01AX/c-met-cdx-fo…) identifies NSCLC patients eligible for a new FDA-approved targeted therapy, offering new personalized treatment opportunities.
-
NeoGenomics
@NeoGenomics
TSO500 delivers the molecular clarity biopharma teams need across the therapeutic development—from biomarker discovery to resistance detection, trial enrollment, longitudinal monitoring, and patient stratification: www.neogenomics.com/tso500
-
NeoGenomics
@NeoGenomics
Backed by over a decade of scientific expertise, Paletrra™ can unlock key insights to support your clinical decisions and fast-track therapeutic development: neogenomics.com/Paletrratm/
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
PanTracer LBx is a CGP panel for advanced stage pan-solid tumors, offering minimally invasive comprehensive genomic profiling if tissue is unavailable or insufficient.
neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
Behind every biomarker is a patient story. These white papers highlight how advanced testing and analytics can unlock better outcomes through precision care: www.neogenomics.com/oncology-data-solutions/
#personalizedmedicine #oncologyinnovation #neogenomics -
NeoGenomics
@NeoGenomics
While traditional methods can miss early MDS, our CGP approach detects subtle genetic changes for an accurate diagnosis. Click to explore our solution, Neo Comprehensive® – Myeloid Disorders: neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe….
#precisiononcology #comprehensivegenomicprofiling #neogenomics -
NeoGenomics
@NeoGenomics
With Paletrra™, deep tumor microenvironment insights is powered by AI-driven image analysis and advanced spatial analytics—bringing clarity where it matters most: www.neogenomics.com/partners/
-
NeoGenomics
@NeoGenomics
Neo Comprehensive® – Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe…
#neogenomics #cancertesting #oncologyinsights -
NeoGenomics
@NeoGenomics
Comprehensive molecular panels combining tissue and plasma testing now form the backbone of personalized oncology. See the full OncView series: cancernetwork.com/view/comprehensive-genomic-profiling-is… . #precisiononcology
-
NeoGenomics
@NeoGenomics
Looking to inform your research or pipeline strategy? Access data-rich publications on tumor profiling, biomarker prevalence, and more—powered by #neogenomics. Start reading: www.neogenomics.com/oncology-data-solutions/
-
NeoGenomics
@NeoGenomics
PanTracer Tissue provides CGP coverage of cancer-related DNA and RNA biomarkers in a single assay. This approach detects a breadth of genomic alterations beyond those found in smaller cancer-specific profiles: www.neogenomics.com/providers/oncology-solutions/pantrace…
-
NeoGenomics
@NeoGenomics
In honor of #mlkday, we've invited Neo team members to share quotes from Dr. King that inspire, actions they'll take to carry his legacy forward, or their favorite words from him. Thank you to everyone who's shared meaningful words and inspiration!
-
NeoGenomics
@NeoGenomics
Did you miss the live event? The on-demand replay of Revolutionizing Oncology Clinical Trials: Real-Time Tumor Insights with RaDaR® ST is available:
www.neogenomics.com/partners/
#oncologyresearch #clinicaltrials #mrd #radar #neogenomicspharma #precisiononcology -
NeoGenomics
@NeoGenomics
At the heart of Paletrra™ is partnership. We’ve empowered over 100 translational partners to see the full picture and move forward with confidence. 🔗 www.neogenomics.com/partners/
-
NeoGenomics
@NeoGenomics
Elevate your oncology pipeline with a single-sourced, multi-modality EGFR testing approach designed to advance clinical trials and develop new treatments: care.neogenomics.com/l/434902/2025-07-29/31wk8p4
-
NeoGenomics
@NeoGenomics
If we haven’t met, let’s fix that. NeoGenomics supports your oncology journey with data-backed insights that help close gaps in care and strengthen your strategy. Let’s connect and talk goals: www.neogenomics.com/oncology-data-solutions/
-
NeoGenomics
@NeoGenomics
When tissue runs out, liquid biopsy can keep the answers flowing. The PanTracer portfolio provides the future of CGP in #oncology: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
The c-MET CDx for NSCLC IHC: www.neogenomics.com/providers/test/APH-CMET-01AX/c-met-cd… is now available to support precision oncology, especially for EGFR wild type, NSCLC.
This IHC assay enables detection of MET protein expression and can be seamlessly added to PanTracer Tissue workflows. -
NeoGenomics
@NeoGenomics
Happy New Year! #newyear26 #newyear2026
-
NeoGenomics
@NeoGenomics
Wishing you a safe and happy New Year, from our #neogenomics family to yours!
#newyearseve #newyear2026 #newyear26 -
NeoGenomics
@NeoGenomics
Sending season's greetings from our #neogenomics family to yours. #happyholidays #seasonsgreetings
-
NeoGenomics
@NeoGenomics
Comprehensive genomic insights are critical for rare cancers. We profile biliary tract cancers by tissue and liquid biopsy and deliver actionable results: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
Sending season's greetings from our #neogenomics family to yours. #happyholidays
-
NeoGenomics
@NeoGenomics
We understand what matters in #bloodcancer:
✅ Sensitivity
✅ Timing
✅ Accurate diagnosis
Learn how our #hematology solution enables genomic-driven decisions in blood cancers: neogenomics.com/providers/oncology-solutions/hematologica… -
NeoGenomics
@NeoGenomics
Paletrra™ goes beyond the surface with whole-tissue visualization that accelerates therapeutic discovery and development: neogenomics.com/Paletrratm/
-
NeoGenomics
@NeoGenomics
Gain expert perspectives on the evolving landscape of novel ADCs, and their clinical applicability highlighting several oncology case studies. Stream the webinar: www.neogenomics.com/partners/
-
NeoGenomics
@NeoGenomics
PanTracer Tissue + HRD supports more informed, precise, and effective treatment strategies across the #ovariancancer care continuum:
www.neogenomics.com/providers/oncology-solutions/gynecolo… -
NeoGenomics
@NeoGenomics
We presented new data at the 67th ASH® Annual Meeting and Exposition! If you didn’t get a chance to learn more during #ash25, let's schedule a post-meeting discussion: www.neogenomics.com/about-neogenomics/events/67th-ash-ann…
#newdata #oncology #rwd -
NeoGenomics
@NeoGenomics
This suite of white papers can help you stay informed and navigate the evolving landscape of targeted therapies and biomarker testing. Explore the collection: care.neogenomics.com/ODS-publications
#pathology #cancertesting #clinicaloncology #neogenomics -
NeoGenomics
@NeoGenomics
Our team had a blast at the 12th annual ASH Foundation Run/Walk this morning. We were excited to participate in this fun and philanthropic activity. Congratulations to everyone who took part today!
#ash25 -
NeoGenomics
@NeoGenomics
Neo Comprehensive – Myeloid Disorders is a highly accurate NGS solution for genomic profiling of myeloid neoplasms. 🔗 neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehe…
-
NeoGenomics
@NeoGenomics
We are live at the 67th ASH® Annual Meeting and Exposition! Visit #neogenomics at booth 1971 during #ash25 to explore how we are advancing precision hematology.
-
NeoGenomics
@NeoGenomics
Heme or solid tumor? We’ve got the data. www.neogenomics.com/oncology-data-solutions/
NeoGenomics delivers high-quality insights across hematologic malignancies and solid tumors to help you power oncology innovation with confidence.
#oncologydata #hemesolutions #solidtumorinsights -
NeoGenomics
@NeoGenomics
From signaling pathway insights to resistance mechanisms—discover how a unified EGFR testing strategy can advance clinical trials and accelerate drug development: care.neogenomics.com/l/434902/2025-07-29/31wk8p4
-
NeoGenomics
@NeoGenomics
Better data leads to better decisions. Our collection of peer-reviewed and expert-led white papers showcases how molecular insights are driving the next generation of #oncologysolutions.
Dive into the details: www.neogenomics.com/oncology-data-solutions/
#ngs #biomarkers #neogenomics -
NeoGenomics
@NeoGenomics
We hope your day is filled with good food, fun, and time spent with loved ones. #happythanksgiving 🍁🦃
-
NeoGenomics
@NeoGenomics
Better data leads to better decisions. This collection of white papers showcases how molecular insights are driving the next generation of oncology solutions. Dive into the details: care.neogenomics.com/ODS-publications
#ngs #biomarkers #oncologysolutions #neogenomics -
NeoGenomics
@NeoGenomics
Don’t miss this informative series discussing the value of implementing complementary CGP testing workflows for advanced lung cancer.
#oncology #oncview -
NeoGenomics
@NeoGenomics
From biopsy to blood draw, PanTracer™ is an advanced CGP assay that detects genomic alterations relevant to therapy selection and clinical trial enrollment: neogenomics.com/providers/oncology-solutions/pantracer-po…
This media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
A no-cost test could identify a targeted therapy option for eligible patients with acute myeloid leukemia (AML): www.neogenomics.com/providers/oncology-solutions/hematolo…
-
NeoGenomics
@NeoGenomics
In a disease that can be known for late detection, genomic insights are vital. Our #cancertesting solutions can help identify actionable mutations.
The PanTracer portfolio provides powerful, simple solutions for therapy selection: neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
Thank you to everyone who connected with us at AMP 2025! We’re proud to support oncology innovation and provide solutions that empower molecular pathology and drug development.
Let’s keep the conversation going: www.neogenomics.com/about-neogenomics/events/amp-2025-ann…
#ampath25 #neogenomics -
NeoGenomics
@NeoGenomics
Join the official #ampath25 Scavenger Hunt. Stop by Booth #1132 to scan our QR code!
✅ Answer our question
✅ Earn points
✅ Climb the leaderboard
Winners score bragging rights—and you’ll discover how #neogenomics helps drive innovation in molecular oncology. -
NeoGenomics
@NeoGenomics
Dr. Pillei, NeoGenomics Director of Molecular Pathology Services, and Dr. Bender, NeoGenomics Head of Genomics Analysis, Pathology, led an engaging vendor workshop session on real-world data analysis for tissue and hematologic cancers at AMP 2025. #amp2025
-
NeoGenomics
@NeoGenomics
This Veterans Day, we’re proud to recognize our NeoGenomics teammates who have served. Check out this Honor Wall, displayed digitally on monitors at #neogenomics, which celebrates their service and sacrifice. Thank you for all you’ve done, and continue to do. #veteransday
-
NeoGenomics
@NeoGenomics
(1/2) 🎖️Celebrating 250 years of courage, honor, and commitment! In honor of the United States Marine Corps’ historic anniversary, our Veterans Employee Resource Group and NeoGenomics team members gathered in our Aliso Viejo, CA office for a ceremonial cake-cutting,
NeoGenomics
@NeoGenomics
(2/2) Led by Joe Pereira, retired Marine Corps Major (NeoGenomics, Associate Director, Business Continuity and Physical Security). Thank you to all Marines—past and present—for your service. Semper Fi!
-
NeoGenomics
@NeoGenomics
Today, we honor and express our deep gratitude to all the veterans who have served our country. Your bravery, sacrifice, and resilience inspire us daily. Thank you for your service.
#neogenomics #lifeatneo #workatneo #hiringourheroes #veteransday #veteransday25 -
NeoGenomics
@NeoGenomics
#sitc25 is underway! Stop by Booth 329 to meet with #neogenomics and explore how our services, including ADC, cell therapy, and targeted therapy solutions, multi-modal testing, and integrated data analysis, can help accelerate your therapeutic development journey.
-
NeoGenomics
@NeoGenomics
Reliable. Timely. Impactful. That’s the standard we set for our oncology data at #neogenomics. With insights built from our own lab operations, you can make smarter decisions—faster. Trust the data that delivers.
www.neogenomics.com/oncology-data-solutions/
#oncologyinsights #realworlddata -
NeoGenomics
@NeoGenomics
Have a safe & happy Halloween!
#happyhalloween #halloween2025 #neospirit -
NeoGenomics
@NeoGenomics
(1/2) #neowearspink at NeoGenomics Laboratories! 💗 In honor of #breastcancerawarenessmonth, our team proudly wore pink to stand in solidarity with patients, survivors, and families impacted by breast cancer.
This meaningful tradition is a powerful reminder to schedule your
NeoGenomics
@NeoGenomics
#mammogram & to raise awareness about the importance of cancer testing solutions & #genomicprofiling. We held a company picnic at our Global HQ in Fort Myers, FL, to celebrate with team spirit and purpose, living out the values that make us proud to be part of #neogenomics.
-
NeoGenomics
@NeoGenomics
Did you know? Up to 20% of breast tumors have higher levels of a protein known as HER2.¹
Browse our HER2 test offerings: neogenomics.com/test-menu/her2-breast-cancer
#her2 #her2positive #breastcancer #her2cancer #cancertesting #pathology
1: www.cancer.org/cancer/types/breast-cancer/understanding-a… -
NeoGenomics
@NeoGenomics
Enhance clinical decision-making for your MDS and CMML patients with Neo Comprehensive – Myeloid Disorders, a guideline-driven CGP assay designed to clarify complex diagnoses and guide treatment.
Learn more: www.neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comp…
#myeloid #cmml #cgp -
NeoGenomics
@NeoGenomics
See how multi-modality EGFR testing is shaping the future of oncology trials: care.neogenomics.com/l/434902/2025-07-29/31wk8p4
#egfr #oncology #neogenomics #whitepaper -
NeoGenomics
@NeoGenomics
Thank you for visiting us during #jadprolive! Did we miss you? Send us a message here to schedule a post-meeting discussion: www.neogenomics.com/about-neogenomics/events/2025-jadpro-…
-
NeoGenomics
@NeoGenomics
Let’s discuss accelerating your oncology trials at #targets25. Find us at Booth 111📍From cell therapy, ADCs & therapeutic development, spatial analysis & genomics, our advanced services help drive smarter, faster decisions.
#neogenomics #precisiononcology #cancertherapeutics -
NeoGenomics
@NeoGenomics
From biopsy to blood draw: PanTracer™ is an advanced CGP assay that detects genomic alterations relevant to therapy selection and clinical trial enrollment.
neogenomics.com/providers/oncology-solutions/pantracer-po…
#neogenomics #pantracer #oncology #cgpThis media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
#neogenomics colleagues are at #jadprolive sharing about our liquid and tissue comprehensive genomic profiling (#cgp) testing solutions for #oncologists.
#oncologytesting #precisiononcology -
NeoGenomics
@NeoGenomics
Don’t miss your chance to learn more about the MRD solution that everyone is talking about. If we didn’t get a chance to connect during #esmo25 about RaDaR ST, let’s set up a post-meeting discussion: www.neogenomics.com/about-neogenomics/events/european-soc…
#neogenomics #pharma #mrd -
NeoGenomics
@NeoGenomics
Every cancer has a unique genomic signature. Genomic testing with PanTracer™ LBx by NeoGenomics helps doctors:
● Identify genomic alterations
● Choose targeted treatments
● Reduce unnecessary therapies
● Connect patients with clinical trials
learnlooklocate.com/how-genomic-testing-helps-personalize… -
NeoGenomics
@NeoGenomics
If you missed our #webinar, there’s still time to stream. Visit online to watch: www.fiercebiotech.com/premium/webinar/1372513?pk=NeoGenom…
In Unlock the Power of Emerging Biomarkers, hear how lab data is being translated into a market strategy, and the role that emerging biomarkers play in it. -
NeoGenomics
@NeoGenomics
Let’s discuss accelerating your oncology trials at #targets25. From cell therapy, ADCs and therapeutic development, spatial analysis & genomics, our advanced services help drive smarter, faster decisions. Find us at booth 111.
#neogenomics #precisiononcology #cancertherapeutics -
NeoGenomics
@NeoGenomics
We are highlighting our MRD solution, RaDaR ST, at the 2025 ESMO Congress!
RaDaR ST is available as part of our pharma services test menu. Read the press release: ir.neogenomics.com/news-events/press-releases/detail/308/… -
NeoGenomics
@NeoGenomics
Visit #neogenomics during #esmo25 at booth 4012 to learn how our advanced lab services and powerful oncology data solutions can help you accelerate therapeutic development.
-
NeoGenomics
@NeoGenomics
#esmo25 is underway! Visit us at booth #4012 to discuss how our advanced lab services and powerful oncology data solutions can help you accelerate therapeutic development.
-
NeoGenomics
@NeoGenomics
We're highlighting our MRD solution, RaDaR ST, at #esmo25! RaDaR ST is available as part of our pharma services test menu.
Let’s meet to discuss how our advanced lab services and powerful oncology data solutions can help you accelerate therapeutic development. -
NeoGenomics
@NeoGenomics
For your patients with HCC, #comprehensivegenomicprofiling can provide actionable genomic insights for confident, real-time treatment decisions in therapy selection. See how the #pantracer portfolio can support your #livercancer management: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
In case you missed it, we are highlighting our MRD solution, 𝐑𝐚𝐃𝐚𝐑 𝐒𝐓, at the 2025 ESMO Congress! Read the press release: ir.neogenomics.com/news-events/press-releases/detail/308/…. RaDaR ST is available as part of our pharma services test menu.
#neogenomics #pharma #esmo25 -
NeoGenomics
@NeoGenomics
We're proud to offer the c-MET CDx for NSCLC IHC testing to help #oncologists and #pathologists identify patients who may benefit from this breakthrough: neogenomics.com/providers/test/APH-CMET-01AX/c-met-cdx-fo…
c-MET is a new actionable #biomarker with an FDA-approved targeted therapy for #nsclc patients. -
NeoGenomics
@NeoGenomics
We are highlighting our MRD solution, 𝐑𝐚𝐃𝐚𝐑 𝐒𝐓, at the 2025 ESMO Congress! Read the press release: ir.neogenomics.com/news-events/press-releases/detail/308/….
RaDaR ST is available as part of our pharma services test menu.
#neogenomics #pharma #esmo25 -
NeoGenomics
@NeoGenomics
We’re excited to share an updated assay: MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-15, CALR, and MPL is now available by next-generation sequencing (NGS).
🔗 neogenomics.com/providers/test/NGS-MPJB-03BZ/mpn-jak2-v61…
#oncologytesting #ngs #mpn #precisiononcology -
NeoGenomics
@NeoGenomics
Elevate your oncology pipeline with a single-sourced, multi-modality EGFR testing approach designed to advance clinical trials and develop new treatments: care.neogenomics.com/l/434902/2025-07-29/31wk8p4
-
NeoGenomics
@NeoGenomics
Explore Paletrra, the spatial proteomics solution transforming every tissue into deep visual insights that fuel confident decisions and accelerate informed clinical advancement, backed by over a decade of expertise in MultiOmyx™, a cyclic immunofluorescence technology.
This media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
Paletrra is a comprehensive, end-to-end AI-driven spatial proteomics solution that transforms your precious tissue into deep visual insights to fuel confident decisions and accelerate informed clinical advancement: neogenomics.com/Paletrratm/
-
NeoGenomics
@NeoGenomics
We’re exhibiting at JADPRO Live 2025! Join us, along with over 1,500 advanced practitioners in oncology to discuss the innovations in cancer care.
Stop by booth #429. For more information about JADPRO Live, visit
www.jadprolive.com. #jadprolive -
NeoGenomics
@NeoGenomics
Access tumor-specific genomic insights quickly and noninvasively with PanTracer LBx. Click to cover 500+ genes, from guideline-recommended to emerging alterations: neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pantrace…
-
NeoGenomics
@NeoGenomics
Thank you to everyone who joined us at #biomuk2025. We loved connecting with you and sharing how our Paletrra™ #spatialproteomics solution transforms tissue into actionable insight. Keep exploring Paletrra™ online: neogenomics.com/Paletrratm
#paletrra #precisionmedicine -
NeoGenomics
@NeoGenomics
Did you know? The IDHNow for AML Sponsored Testing Program provides no-cost rapid PCR testing to eligible patients with acute myeloid leukemia (AML): www.neogenomics.com/IDHNOW_STP
-
NeoGenomics
@NeoGenomics
Let’s meet during the ESMO Congress 2025 to discuss how our advanced lab services and powerful oncology data solutions can help you accelerate therapeutic development. Book a meeting online: www.neogenomics.com/about-neogenomics/events/european-soc…
#esmo25 #neogenomics #precisiononcology #berlin #datasolutions -
NeoGenomics
@NeoGenomics
Thanks to everyone who stopped by during #biomuk2025 to learn how our Paletrra™ AI-driven #spatialproteomics solution transforms your precious tissue into deep visual insights to fuel confident decisions and accelerate informed clinical advancement.
🔗 neogenomics.com/Paletrratm -
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth begins today🎗️ All month long, we will be sharing education and resources, highlighting our testing solutions, and more.
#breastcancerawarenessmonth #breastcancerawareness2025 #cancertesting #oncology #neogenomics -
NeoGenomics
@NeoGenomics
#genomic insights into #prostate cancer can identify disease progression, #theraputic targets, and more.
See how #pantracer Tissue can support your prostate cancer management: neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
Claudin18.2 (CLDN18.2) can help patients with gastric or gastroesophageal junction adenocarcinoma determine eligibility for select targeted therapies.
#pathologist #pathology #gastriccancer
NeoGenomics
@NeoGenomics
CLDN18.2 is detected through IHC testing, and its accurate interpretation is crucial for guiding targeted therapies: neogenomics.com/providers/test/APH-CLAP-01AX/claudin-18-f…
.
.
.
Reference: www.gastriccancerbiomarkers.com -
NeoGenomics
@NeoGenomics
🚨 We’re headed to London! Join #neogenomics at the Biomarkers & Precision Medicine Conference, from Sep 30–Oct 1.
📍 Booth #18
📢 Don’t miss Kirsteen Maclean, PhD presenting:
Spatial proteomic characterization of renal cell carcinomas and metabolic reprogramming of the TME.
NeoGenomics
@NeoGenomics
🔗 Learn more about Paletrra™: neogenomics.com/Paletrratm
#spatialproteomics #oncology #pharma #biomuk2025 -
NeoGenomics
@NeoGenomics
September is Ovarian Cancer Awareness Month.
#neogenomics is proud to offer PanTracer Tissue + HRD, to support more informed, precise, and effective treatment strategies across the #ovariancancer care continuum: neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
Thank you for visiting us during #cap25! Did we miss you? Send us a message here to schedule a post-meeting discussion: neogenomics.com/about-neogenomics/events/cap25-pathologis…
-
NeoGenomics
@NeoGenomics
Advanced diagnostics can help differentiate, classify, and target #lymphoma subtypes.
Explore our lymphoma testing solutions, including IHC, flow, and NGS: www.neogenomics.com/providers/oncology-solutions/hematolo… -
NeoGenomics
@NeoGenomics
Today, we pause to remember those whose lives were lost and to honor the first responders, military members, and all those who showed extraordinary courage to save others on September 11, 2001. #patriotday
-
NeoGenomics
@NeoGenomics
We were excited to pack #careermonth with classes and activities designed to inspire and grow our teams.
One highlight was our Coffee and Career Chats, which gave team members a chance to connect, explore opportunities, and fuel their future (with breakfast snacks, too!).
NeoGenomics
@NeoGenomics
The career fair, which was run entirely by team members, brought departments together to share more about what they do, highlight available opportunities, and showcase the passion behind their work.
-
Explore open roles: jobs.jobvite.com/neogenomics
#neocareers #workatneo #neospirit -
NeoGenomics
@NeoGenomics
PanTracer Tissue offers broad, tissue-based CGP designed to support oncologists in delivering personalized care, while having minimal specimen requirements to support broader patient access: neogenomics.com/providers/test/NTG-PTTT-03AX/neo-pantrace…
-
NeoGenomics
@NeoGenomics
#oncologists know that a rapid turnaround time is a critical tool when treating acute myeloid leukemia. On this #worldleukemiaday, we’re spotlighting a test that delivers an accurate diagnosis and actionable insights in 3-5 days: neogenomics.com/providers/test/NTG-AMEP-02BX/neo-aml-express
-
NeoGenomics
@NeoGenomics
Happy Labor Day! #laborday #laborday2025
-
NeoGenomics
@NeoGenomics
Hear from an expert about how dual genomic profiling —combining liquid biopsy and tissue testing to identify actionable mutations—is unlocking precision medicine for lung cancer #cancer patients: www.cancernetwork.com/view/comprehensive-genomic-profilin…
#oncology #precisionmedicine -
NeoGenomics
@NeoGenomics
#cap25 The Pathologists' Meeting returns September 13 at the Marriott Orlando World Center in Florida. We have a lot to share with you this year and can't wait to meet you!
Learn more: neogenomics.com/about-neogenomics/events/cap25-pathologis…
#florida #pathology #pathologist -
NeoGenomics
@NeoGenomics
In today’s landscape, data is more than a resource—it’s essential. Discover how matched imaging, tissue & molecular datasets are fueling innovation in biomarker discovery, clinical development & AI model validation. Our expert-led webinar is on demand:
care.neogenomics.com/NeoDiscover-webinar -
NeoGenomics
@NeoGenomics
NeoGenomics gives you needed insights to develop, refine & commercialize therapies that can change patient lives.
💡Smarter development
🚀 Faster market entry
📊 More confident decisions
Let’s talk about how we can support your next oncology breakthrough: www.neogenomics.com/oncology-data-solutions/ -
NeoGenomics
@NeoGenomics
#neogenomics colleagues have been in San Antonio, Texas, for the HealthTrust University Conference. We appreciated the opportunity to share with HealthTrust members how our comprehensive solutions make us a trusted partner.
-
NeoGenomics
@NeoGenomics
It has been great connecting with everyone at the HealthTrust University Conference in San Antonio! Thank you to everyone who has stopped by booth #836 to meet the #neogenomics team and explore how our solutions can support HealthTrust members.
-
NeoGenomics
@NeoGenomics
We’re excited to connect at the HealthTrust University Conference! Discover the full breadth of our solutions and see how #neogenomics can be a valuable partner for HealthTrust members.
-
NeoGenomics
@NeoGenomics
Claudin18.2 may have been on your radar for years – and now, it’s an actionable target. We are proud to be one of the leading labs offering Claudin18.2 testing. Ready to put Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma into practice? Learn more: www.neogenomics.com/providers/oncology-solutions/gastric-…
-
NeoGenomics
@NeoGenomics
IHC testing for CLDN18.2 is an important tool when creating treatment plans for gastric/GEJ patients. Learn more: www.neogenomics.com/providers/oncology-solutions/gastric-…
NeoGenomics
@NeoGenomics
References:
1: Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci 2019;44(2):141-52.
2: Hu YJ, Wang YD, Tan FQ, Yang WX. Regulation of paracellular permeability: factors and mechanisms. Mol Biol Rep 2013;40:6123-42.
NeoGenomics
@NeoGenomics
3: Shitara K, Lordick F, Bang YJ, et al. Lancet 2023 Apr 14:S0140-6736(23)00620-7. Xu RH, Shitara K, Ajani JA, et al. #405736. Presented at: March American Society of Clinical Oncology Plenary Series; March 22, 2023.
-
NeoGenomics
@NeoGenomics
Lung cancer demands precision. Comprehensive #genomicprofiling can reveal actionable insights and targeted therapy options.
Explore our comprehensive tissue and #liquidbiopsy solutions: neogenomics.com/providers/oncology-solutions/lung-cancer -
NeoGenomics
@NeoGenomics
PanTracer LBx provides minimally invasive, guideline-driven testing for over 500 genes, with results delivered within 7 days to enable real-time decision-making. Improving patient care is only a click away: neogenomics.com/providers/test/NTG-PTLB-02SX/neo-pantrace…
-
NeoGenomics
@NeoGenomics
The HealthTrust University Conference is August 18-20 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Find #neogenomics at booth #836!
-
NeoGenomics
@NeoGenomics
NeoGenomics is attending the 2025 Oncology Clinical Updates conference in Napa Valley, CA, August 2–3. Stop by our table at the Hyatt Regency Sonoma Wine Country—we’d love to connect!
🔗 totalhealthoncology.com -
NeoGenomics
@NeoGenomics
Sarcoma is rare—and accurate testing is critical. #neogenomics offers advanced testing solutions to help guide care for soft tissue and bone sarcomas.
Explore our Sarcoma Comprehensive NGS Fusion Panel:
www.neogenomics.com/providers/test/MOG-SCFP-03AX/sarcoma-… -
NeoGenomics
@NeoGenomics
#neogenomics is a sponsor of ASCO Direct™ Denver! Make plans to visit us and learn about our #oncology solutions for solid tumors, hematological cancers, and more. We’ll see you July 26 and 27 in Denver, #colorado.
-
NeoGenomics
@NeoGenomics
Thank you to everyone who visited us during #breakthroughs25! We enjoyed the great conversations and look forward to continuing the momentum.
-
NeoGenomics
@NeoGenomics
#breakthroughs25 is underway in National Harbor, MD. Visit #neogenomics at booth #1617 to see how we're helping #oncologists drive smarter, more personalized solutions.
-
NeoGenomics
@NeoGenomics
#breakthroughs25 kicks off today! Visit us at our booth to see how we're helping #oncologists drive smarter, more personalized solutions.
-
NeoGenomics
@NeoGenomics
#neogenomics is a sponsor of ASCO Direct™ Denver! Make plans to visit us and learn about our #oncology solutions for solid tumors, hematological cancers, and more. We’ll see you July 26 and 27 in Denver, #colorado.
-
NeoGenomics
@NeoGenomics
Two samples, one story: Meet PanTracer™, the future of CGP in oncology.
neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
PanTracer™ Tissue and Liquid Biopsy are available for #pharma partners to provide pan-tumor, comprehensive genomic profiling across both tissue and liquid biopsy.
Learn more: neogenomics.com/PanTracer-LDT -
NeoGenomics
@NeoGenomics
Have a safe and happy Fourth of July!
-
NeoGenomics
@NeoGenomics
PanTracer™ is now available for #pharma partners, delivering pan-tumor, comprehensive genomic profiling across both tissue and liquid biopsy. From sample to insight, this seamless solution can accelerate precision #oncology.
Learn more: www.neogenomics.com/pantracer-LDT -
NeoGenomics
@NeoGenomics
𝐍𝐨𝐰 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞: PanTracer™ Tissue + HRD, expanding our comprehensive genomic profiling (#cgp) capabilities to better support personalized care in ovarian cancer.
Read our #pressrelease: ir.neogenomics.com/news-events/press-releases/detail/302/… -
NeoGenomics
@NeoGenomics
(1/2) We’re proud to recognize Kara O’Brien, #neogenomics’ Vice President, Enterprise Product Management, for her incredible contributions to the Precision Cancer Consortium (PCC). As a PCC Wayfinder, Kara was instrumental in launching the PCC Ambassador Programme—building a
NeoGenomics
@NeoGenomics
vibrant network of advocates to elevate precision #oncology across the diagnostic community.
-
NeoGenomics
@NeoGenomics
We’re excited to be exhibiting at #breakthroughs25.
Looking forward to connecting with premier members and showcasing how we’re driving innovation together. See you July 15-17 in National Harbor, MD! -
NeoGenomics
@NeoGenomics
The future of comprehensive genomic profiling in #oncology is PanTracer™ Tissue, a comprehensive, guideline-aligned CGP test that helps oncologists deliver personalized care by identifying key biomarkers for therapy selection & clinical trial enrollment: www.neogenomics.com/providers/oncology-solutions/pantrace…
-
NeoGenomics
@NeoGenomics
The countdown is on for the release of the PanTracer™ Tissue. Learn more: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
#neogenomics is a sponsor of ASCO Direct™ Hawaii! Make plans to visit our booth and learn about our #oncology solutions for patients with solid tumors, hematological cancers, and more. We’ll see you June 28 and 29 in Honolulu, #hawaii.
-
NeoGenomics
@NeoGenomics
You need #acutemyeloidleukemia (#aml) diagnostic solutions now. Neo AML Express™, an NGS-based panel that detects clinically relevant DNA and RNA alterations in over 40 genes, delivers critical therapeutic and prognostic information in 3–4 days.
care.neogenomics.com/NEO-AML-Express -
NeoGenomics
@NeoGenomics
(1/2) We’re excited to announce the launch of PanTracer™ Tissue, the enhanced and rebranded version of our pan-solid tumor NGS panel, Neo Comprehensive – Solid Tumor, on 6/23. This #oncology solution for patients with advanced stage solid tumors is a simple yet powerful tool
NeoGenomics
@NeoGenomics
for therapy selection: www.neogenomics.com/providers/oncology-solutions/pantrace…
-
NeoGenomics
@NeoGenomics
During #asco25, we introduced PanTracer™—our latest innovation in oncology solutions. Catch up on what you may have missed: neogenomics.com/providers/oncology-solutions/pantracer-po…
-
NeoGenomics
@NeoGenomics
(1/2) The IDHNow for AML Sponsored Testing Program provides no-cost rapid PCR testing to eligible patients with acute myeloid leukemia (AML). We are so proud to offer this testing solution to providers to support the clinical practice guidelines that recommend performing
NeoGenomics
@NeoGenomics
(2/2) molecular testing to identify IDH mutations in AML patients.¹ We invite you to visit us online to learn more: www.neogenomics.com/IDHNOW_STP
#acutemyeloidleukemia #aml #oncology
1. Arber DA et al. Arch Pathol Lab Med. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP -
NeoGenomics
@NeoGenomics
(1/2) When creating treatment plans for gastric/GEJ cancer patients, there’s a new tool to help personalize plans. Claudin18.2 is an actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma.
NeoGenomics
@NeoGenomics
(2/2) The specificity of CLDN18.2 to gastric tissues allows for more effective and precise treatment, improving patient outcomes. Learn more: neogenomics.com/cldn182
#adenocarcinoma #gastriccancer #claudin #solidtumor -
NeoGenomics
@NeoGenomics
If you missed the 2025 ASCO® Annual Meeting, let us catch you up! Contact us for a post-show discussion on how our oncology solutions can support your patient care: care.neogenomics.com/ASCO-2025
#asco25 #oncology #cancercare -
NeoGenomics
@NeoGenomics
If you missed the 2025 ASCO® Annual Meeting, let us catch you up! Contact us for a post-show discussion on how our oncology solutions can support your patient care: care.neogenomics.com/ASCO-2025
#asco25 #oncology #cancercare -
NeoGenomics
@NeoGenomics
Thank you to everyone who visited our booth during #asco25; it was a pleasure to have the opportunity to discuss how we can work together to combat cancer’s complex challenges.
-
NeoGenomics
@NeoGenomics
It's been an inspiring few days of connection, collaboration & conversations about moving #cancercare forward at #asco25. We're excited to share a few moments from the conference. There's still time to stop by our booth & learn more: care.neogenomics.com/ASCO-2025
#neogenomics #oncology -
NeoGenomics
@NeoGenomics
Explore PanTracer™, the latest in next-generation diagnostic solutions for patients with advanced-stage solid tumors.
• Visit us at #asco25: care.neogenomics.com/ASCO-2025
• Visit us online: neogenomics.com/providers/oncology-solutions/pantracer-po… -
NeoGenomics
@NeoGenomics
Stop by booth #11093 to connect with our team and learn more about our #oncology solutions.
care.neogenomics.com/ASCO-2025
#asco25 #oncologyinnovation #meettheteam -
NeoGenomics
@NeoGenomics
Two samples, one story: Meet PanTracer™, the future of CGP in oncology.
• Visit us at #asco25: care.neogenomics.com/ASCO-2025
• Visit us online: neogenomics.com/providers/oncology-solutions/pantracer-po…
.
.
.
CGP=Comprehensive genomic profiling -
NeoGenomics
@NeoGenomics
Visit booth #11093 during #asco25 to check out our interactive PanTracer™ experience. Just say, "Hey, Neo!"
-
NeoGenomics
@NeoGenomics
Our Oncology Data Solutions team is at #asco25, sharing how NeoEngage—our expansive biomarker and clinical data solution—can power your targeted therapy strategy. Visit us at booth #11093 to learn more.
-
NeoGenomics
@NeoGenomics
Our #oncology experts are excited to be at #asco25 to discuss how we can support your patient care and improve outcomes. Visit booth #11093 or online: care.neogenomics.com/ASCO-2025
-
NeoGenomics
@NeoGenomics
#neogenomics colleagues are excited to be in #chicago to meet with #oncologists, #pathologists & #healthcare professionals to discuss how we can work together to meet cancer’s complex challenges with our #oncology solutions. Request a meeting here: care.neogenomics.com/ASCO-2025
-
NeoGenomics
@NeoGenomics
Don't miss at #asco25: 𝐑𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐟𝐨𝐥𝐚𝐭𝐞 𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 𝐚𝐥𝐩𝐡𝐚 (𝐅𝐑α; 𝐅𝐎𝐋𝐑𝟏) 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐢𝐧 𝐩𝐚𝐧-𝐭𝐮𝐦𝐨𝐫 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 𝐟𝐫𝐨𝐦 𝐨𝐯𝐞𝐫 𝟔𝟎𝟎𝟎 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐒.
ir.neogenomics.com/news-events/press-releases/detail/300/… -
NeoGenomics
@NeoGenomics
We are debuting the PanTracer™ family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Join us at #asco25: ir.neogenomics.com/news-events/press-releases/detail/300/… -
NeoGenomics
@NeoGenomics
Paletrra™ revolutionizes spatial biology, translating precious tissue into therapeutic advancements. We’re excited to debut this solution during #asco25: care.neogenomics.com/ASCO-2025
-
NeoGenomics
@NeoGenomics
(1/2) Join retired Marines and #neogenomics Veterans Employee Resource Group leaders Frank Daugherty (Assistant General Counsel) and Joe Pereira (Associate Director, Business Continuity and Physical Security) as they honor #memorialday by touring historic San Diego veteran sites,
This media couldn't be displayed. See it on the original post.
NeoGenomics
@NeoGenomics
including the USS Midway and Rosecrans National Cemetery, where we invite you to join us in a moment of silence.
We proudly support veterans through our Hiring Our Heroes program and Veterans Employee Resource Group. Learn more about #lifeatneo online: jobs.jobvite.com/neogenomics/jobs/lifeatneo -
NeoGenomics
@NeoGenomics
𝐈𝐭'𝐬 𝐚𝐥𝐦𝐨𝐬𝐭 𝐡𝐞𝐫𝐞! The 2025 ASCO® Annual Meeting returns to #chicago next week, and we have so much to share with you this year.
Book a meeting to speak with the experts in precision #oncology: care.neogenomics.com/ASCO-2025 -
NeoGenomics
@NeoGenomics
Read #neogenomics President and CEO Warren Stone’s comments on innovation in healthcare and technology, as featured in Newsweeks’ New Era of Life Sciences, 2025 edition: d.newsweek.com/en/file/478006/new-era-life-sciences-futur…
#healthcareinnovation #newsweek #investmentreports #futureofhealth -
NeoGenomics
@NeoGenomics
𝐏𝐫𝐞𝐬𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: The c-MET CDx for advanced non-small cell lung cancer patients is now available. Full press release available online: ir.neogenomics.com/news-events/press-releases/detail/299/…
NeoGenomics
@NeoGenomics
Up to 50% of advanced NSCLC patients show c-MET overexpression¹—making MET status a critical biomarker for guiding treatment. The c-MET CDx IHC assay has a 48-hour turnaround time to support fast, informed therapeutic decisions.
#nsclc #lungcancer #oncology
NeoGenomics
@NeoGenomics
Reference: Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023;41(5):1105-1115. doi:10.1200/JCO.22.00739
-
NeoGenomics
@NeoGenomics
Introducing PanTracer™ Tissue and PanTracer™ LBx, advanced diagnostic solutions for patients with advanced-stage solid tumors.
Learn more during the 2025 ASCO® Annual Meeting: care.neogenomics.com/ASCO-2025 -
NeoGenomics
@NeoGenomics
Introducing Paletrra™, the cutting-edge, AI-driven spatial proteomics solution, during #asco25. Paletrra™ can transform your precious tissue into deep visual insights that fuel confident decisions and accelerate informed clinical advancement. care.neogenomics.com/ASCO-2025
-
NeoGenomics
@NeoGenomics
𝐇𝐞𝐲, 𝐍𝐞𝐨. During #asco25, visit booth #11093 to try out our voice-enabled experience #heyneo and discover how our tests, including PanTracer LBx and PanTracer Tissue, can support your patient care.
care.neogenomics.com/ASCO-2025 -
NeoGenomics
@NeoGenomics
We're going to introduce our Neo PanTracer™ Tissue & Liquid tests at #asco25. These pan-cancer assays help guide therapy selection & identify clinical trial options for patients with advanced-stage solid tumors. Speak to the experts in precision oncology: care.neogenomics.com/ASCO-2025
-
NeoGenomics
@NeoGenomics
𝐇𝐞𝐲, 𝐍𝐞𝐨. During #asco25, visit booth #11093 to try out our voice-enabled experience #heyneo and discover how our tests, including PanTracer LBx and PanTracer Tissue, can support your patient care.
care.neogenomics.com/ASCO-2025 -
NeoGenomics
@NeoGenomics
𝐖𝐡𝐞𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐥𝐞𝐚𝐯𝐞𝐬 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐲𝐨𝐮𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐝𝐚𝐫𝐤, #neogenomics 𝐢𝐬 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐥𝐢𝐠𝐡𝐭 𝐭𝐡𝐞 𝐰𝐚𝐲. We’ll be shining a spotlight on our #oncology solutions at #asco25.
Book a meeting online: care.neogenomics.com/ASCO-2025 -
NeoGenomics
@NeoGenomics
The 2025 ASCO® Annual Meeting is nearly here, and our oncology experts are excited to discuss how we can support your patient care and improve outcomes. Stop by booth #11093 or visit us online to book a meeting: care.neogenomics.com/ASCO-2025
#asco25 #oncology #patientcare -
NeoGenomics
@NeoGenomics
Claudin 18.2 (CLDN18.2) is an actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Learn more about 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma: www.neogenomics.com/providers/test/APH-CLAP-01AX/claudin-…
-
NeoGenomics
@NeoGenomics
Experience innovation at the intersection of technology and patient care. Coming soon, the Neo PanTracer™ Portfolio. Follow us to learn more and visit us during #asco25.
-
NeoGenomics
@NeoGenomics
Victor, a #neogenomics Talent Acquisition Specialist, had a great time representing us at the UC Irvine Spring #careerfair, where students from all years and majors came ready to explore their futures. It was an energizing day of conversations, curiosity, and #career exploration.
-
NeoGenomics
@NeoGenomics
Claudin 18.2 (CLDN18.2) is an actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma.
Learn more about Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma: www.neogenomics.com/providers/test/APH-CLAP-01AX/claudin-… -
NeoGenomics
@NeoGenomics
#coa2025 just wrapped up in #orlando, Florida. It was a pleasure getting to meet so many outstanding healthcare professionals and look forward to continuing the conversation about how our solutions can support your patient care.
-
NeoGenomics
@NeoGenomics
When it comes to developing a prognosis and identifying treatment options for skin cancer patients – we’re here to help. Our comprehensive menu offers dozens of tests relevant to melanoma and skin cancer: neogenomics.com/test-menu?search=&methodology=All&disease…
-
NeoGenomics
@NeoGenomics
Thank you for a fantastic week in #chicago for the American Association for Cancer Research® (AACR) Annual Meeting 2025. Let's schedule a post-meeting discussion if we missed you during #aacr25. Request one online: care.neogenomics.com/AACR-2025
#aacr25 #cancerresearch #neogenomics -
NeoGenomics
@NeoGenomics
We are excited for another day at #aacr25. Come see us at booth #2449.
To book a meeting and learn more about our poster presentations, visit: care.neogenomics.com/AACR-2025
#neogenomics #oncology #cancerresearch -
NeoGenomics
@NeoGenomics
𝐖𝐞're 𝐩𝐥𝐞𝐚𝐬𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐬𝐡𝐚𝐫𝐢𝐧𝐠 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐥𝐚𝐮𝐧𝐜𝐡 𝐨𝐟 𝐍𝐞𝐨𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 at the American Association for Cancer Research® (AACR) Annual Meeting 2025. Visit us at booth #2449 or book a meeting with us during #aacr25 here: care.neogenomics.com/AACR-2025
NeoGenomics
@NeoGenomics
(2/3) NeoDiscover empowers clinical and translational research teams to accelerate their product journey through integrated multi-modal oncology data and a uniquely robust specimen archive. With one of the industry’s only dedicated specimen archives, we offer unparalleled access
NeoGenomics
@NeoGenomics
(3/3) to high-quality biospecimens, enabling deeper biomarker insights, faster validation, and smarter decision-making across the development life-cycle.
-
NeoGenomics
@NeoGenomics
The conference doors are about to open at the Walt Disney World Dolphin Hotel for The Community Oncology Conference. Make plans to visit #neogenomics today or tomorrow at booth #121.
#communityoncology #coa2025 -
NeoGenomics
@NeoGenomics
We're presenting multiple abstracts this morning at #aacr25. High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection is in Section 1, Poster 14.
-
NeoGenomics
@NeoGenomics
We're showcasing multiple abstracts at #aacr25. Accurate, high-throughput spatial profiling of whole slide samples with the Paletrraᵀᴹ multiplexed image analysis pipeline is being presented right now in Section 46, Poster 29. care.neogenomics.com/AACR-2025
#cancerresearch #neogenomics -
NeoGenomics
@NeoGenomics
The doors open soon for the second day of exhibits at The American Association for Cancer Research® (AACR) Annual Meeting 2025. Stop by booth #2449 to visit us, or go online (care.neogenomics.com/AACR-2025) to request a meeting.
#aacr25 #cancerresearch #oncology -
NeoGenomics
@NeoGenomics
The American Association for Cancer Research® (AACR) Annual Meeting 2025 is underway, and exhibits are open! Visit us at booth #2449.
Stop by today, or visit us online (care.neogenomics.com/AACR-2025) to request a meeting.
#aacr25 #cancerresearch #oncology -
NeoGenomics
@NeoGenomics
The American Association for Cancer Research® (AACR) Annual Meeting 2025 kicks off today! #neogenomics will be exhibiting at booth #2449 through Wednesday, April 30th. Stop by to see us or request a meeting online: care.neogenomics.com/AACR-2025
#aacr25 #cancerresearch #oncology -
NeoGenomics
@NeoGenomics
It’s #earthday! Our NeoGreen Employee Resource Group champions environmental sustainability year-round, working to support green initiatives that make a lasting impact. Our UK colleagues recently rolled up their sleeves to plant trees and give back to nature–one tree at a time.
NeoGenomics
@NeoGenomics
#earthday25 #planttrees #teamgreen #sustainabilityinaction
-
Interested in working for an organization that supports its team members with ERGs? Browse our open positions! jobs.jobvite.com/neogenomics -
NeoGenomics
@NeoGenomics
🎉 It’s Lab Week 2025! 🎉
We’re celebrating all week long with giveaways, dress-up days, and virtual events like trivia with DJ Will Gill and a mystery to solve. Today, we're kicking off the week with this special message from Warren Stone, President and Chief Operating Officer.
NeoGenomics
@NeoGenomics
Lab Week is all about honoring the incredible work of our lab professionals and the impact they make on patients’ lives every day. Let’s show our #neospirit and make this week unforgettable!
#labweek2025 #lifeatneo #workatneo -
NeoGenomics
@NeoGenomics
Happy Easter! #easter #happyeaster #easter2025
-
NeoGenomics
@NeoGenomics
We’re excited to showcase multiple, groundbreaking abstracts at the American Association for Cancer Research® (AACR) Annual Meeting 2025.
Check out the replies in this post to learn more.
NeoGenomics
@NeoGenomics
Join us as we present cutting-edge research and innovative #oncology insights. Don’t miss these impactful posters highlighting advancements in cancer diagnostics and treatment.
-
NeoGenomics
@NeoGenomics
(1/2) #multiplemyeloma month may have just ended, but we want to bring attention to it all year round and highlight the importance of comprehensive genomic profiling in understanding and treating this complex disease. By identifying key genetic factors, we can help guide
NeoGenomics
@NeoGenomics
(2/2) personalized treatment plans and improve outcomes for patients.
Explore our hematology solutions:
www.neogenomics.com/providers/oncology-solutions/hematolo… -
NeoGenomics
@NeoGenomics
There is a new sponsored testing program that your acute myeloid leukemia (AML) patients may be eligible for. The IDHNow for AML Sponsored Testing Program provides the IDH PCR test to eligible patients who meet these criteria: (Continued in replies)
NeoGenomics
@NeoGenomics
• Patient has newly diagnosed AML, not previously treated
• Patient does not have a known IDH1 mutation from a previous test
• Patient lives and receives treatment in the United States or a US territory
• Patient has not previously been tested under this program
NeoGenomics
@NeoGenomics
To learn more and order today, visit: www.neogenomics.com/providers/oncology-solutions/hematolo… #oncology #acutemyeloidleukemia #aml #cancertesting
-
NeoGenomics
@NeoGenomics
The Community Oncology Conference returns on April 29 and 30th, and we can’t wait to see you in Orlando, FL, at the Walt Disney World Dolphin Hotel!
#coa2025 #oncology #florida -
NeoGenomics
@NeoGenomics
Developed with coauthors from @Zymeworks, look for this poster during #aacr25. Abstract #1230 and will be presented during the Tumor Biology – 3D Models and Bioprinting session. Continue to follow us for more updates and insights from our team.
#cancerresearch #adcs #biotech -
NeoGenomics
@NeoGenomics
#neogenomics' successful acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory, was shared on the iconic Nasdaq Tower in Times Square, New York City.
For more details, check out the full story here: ir.neogenomics.com/news-events/press-releases/detail/293/… -
NeoGenomics
@NeoGenomics
Thank you to everyone who attended our recent webinar with Leica Biosystems! If you missed it, visit us online to watch on-demand: care.neogenomics.com/l/434902/2025-03-21/31w59yn
-
NeoGenomics
@NeoGenomics
At #aacr25, our experts will be discussing how we can empower your drug development with precision & speed.
✅Advanced oncological testing capabilities
✅End-to-end cell therapy, ADC & targeted therapy options
✅Expert in-house scientific support
✅Custom development & validation
NeoGenomics
@NeoGenomics
Not affiliated with or endorsed by AACR
-
NeoGenomics
@NeoGenomics
𝐓𝐨𝐝𝐚𝐲, 𝐰𝐞 𝐰𝐞𝐥𝐜𝐨𝐦𝐞 𝐓𝐨𝐧𝐲 𝐙𝐨𝐨𝐤, 𝐨𝐮𝐫 𝐧𝐞𝐰 𝐂𝐡𝐢𝐞𝐟 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐎𝐟𝐟𝐢𝐜𝐞𝐫. He has been a valuable #neogenomics Board of Directors member since 2023. He brings over thirty years of experience in diagnostics and biopharma, along with a proven
NeoGenomics
@NeoGenomics
track record of leadership in healthcare. We are thrilled to have him lead the organization into the future.
-
NeoGenomics
@NeoGenomics
#colorectalcancerawarenessmonth may be drawing to a close, but the conversation should continue all year long. We look forward to supporting your patient care with comprehensive solutions: neogenomics.com/providers/oncology-solutions/colorectal-c…
#cancertesting #pathologist #oncologist -
NeoGenomics
@NeoGenomics
We're pleased to share a picture from NextGen Omics US & Spatial, where members from the #neogenomics pharma team have been over the last few days! If we didn’t get to meet during the event, we’d still love to connect. Reach out to us here: www.neogenomics.com/contact-us/
-
NeoGenomics
@NeoGenomics
Thank you! We enjoyed the opportunity this week to visit with pharmaceutical & biotech professionals from all over the world at the Immuno-Oncology 360° Summit. If we didn’t get to meet with you, let’s schedule a post-meeting discussion: neogenomics.com/contact-us
-
NeoGenomics
@NeoGenomics
The Immuno-Oncology 360° Summit began today at the Sheraton Boston in Massachusetts. Our experts are on-site at booth #7, ready to discuss innovative testing solutions to advance oncology drug development.
#boston #neogenomics #cancertesting #oncology #immunooncology #io360 -
NeoGenomics
@NeoGenomics
We are once again exhibiting at the USCAP 114th Annual Meeting, and there is so much we are excited to share with you this year. Visit us at booth #234 or head to care.neogenomics.com/USCAP2025 to schedule a meeting!
#uscap2025 #pathology #oncology #boston #neogenomics -
NeoGenomics
@NeoGenomics
Exhibits are open at The United States and Canadian Academy of Pathology’s 114th Annual Meeting. Visit #neogenomics at booth #234, or make plans to visit us by scheduling a meeting here: care.neogenomics.com/USCAP2025
#uscap2025 #pathology #oncology -
NeoGenomics
@NeoGenomics
We are thrilled to be in Boston, MA, for The United States and Canadian Academy of Pathology’s 114th Annual Meeting. Drop by booth #234, or make plans to visit us by scheduling a meeting here: care.neogenomics.com/USCAP2025
#uscap2025 #pathology #oncology #neogenomics -
NeoGenomics
@NeoGenomics
At NextGen Omics & Spatial Biology US 2025, on Thursday, March 27, 12:25 p.m. EST, we invite you to a presentation by Kirsteen Maclean, Ph.D. Director/Principal Scientist, Scientific Affairs, #neogenomics.
-
NeoGenomics
@NeoGenomics
We are thrilled to be headed to Boston, MA, for The United States and Canadian Academy of Pathology’s 114th Annual Meeting. Drop by booth #234, or make plans to visit us by scheduling a meeting here: care.neogenomics.com/USCAP2025
#uscap2025 #pathology #oncology #neogenomics -
NeoGenomics
@NeoGenomics
We're exhibiting at NextGen Omics & Spatial Biology US 2025, which takes place March 27-28 at the Sheraton #boston. Visit us at booth #12, where members of our #pharma Team will be on-site to discuss how we can support your complex drug development program and #clinicaltrials.
-
NeoGenomics
@NeoGenomics
(1/3) Our continued dedication to innovation was recently highlighted in a Nature Medicine article titled, “CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial” by Thomas Condamine, et al (nature.com/articles/s41591-025-03495-z). The translational findings in
NeoGenomics
@NeoGenomics
(2/3) the publication demonstrate how the RNAscope™ and MultiOmyx™ assay from #neogenomics were used to validate the CAR-M mechanism of action, showing anti-tumor activity, TME remodeling, and induction of anti-tumor T cell immunity.
NeoGenomics
@NeoGenomics
(3/3) We’re proud to offer unparalleled services to our biopharma partners. Learn more about our innovative solutions today: neogenomics.com/partners/
-
NeoGenomics
@NeoGenomics
It’s that time of year again! We’re getting ready to head to #boston, MA, for The United States and Canadian Academy of Pathology’s 114th Annual Meeting. We're looking forward to spotlighting precision testing options for pathologists at booth #234.
#uscap2025
NeoGenomics
@NeoGenomics
We know how busy this week will be, so we’ve made it easier than ever to discuss how we can support your patient care. Simply visit this website to request a meeting and a member of our team will personally be in touch with you: care.neogenomics.com/USCAP2025
#pathology #oncology -
NeoGenomics
@NeoGenomics
Let’s make your career as lucky as a four-leaf clover! 🍀 Your next career opportunity could be just around the corner! Explore our open positions and join a team that values hard work and growth: jobs.jobvite.com/neogenomics
#stpatricksday #luckytoworkhere #joinourteam -
NeoGenomics
@NeoGenomics
#neogenomics colleagues have been in #london for NextGen Biomed 2025 to discuss how our Pharma team can support you. Thank you to everyone who visited our booth over the last few days!
#ngb2025 #nextgenbiomed2025 -
NeoGenomics
@NeoGenomics
The United States and Canadian Academy of Pathology’s 114th Annual Meeting is just around the corner. Mark your calendars for March 22-27, and look for us at booth #234 at the #boston Convention and Exhibition Center.
care.neogenomics.com/USCAP2025
#uscap2025 #neogenomics -
NeoGenomics
@NeoGenomics
NextGen Biomed 2025 kicks off on March 12th at Novotel London West. If you are attending, visit us through Friday at booth #70.
#ngb2025 #nextgenbiomed2025 -
NeoGenomics
@NeoGenomics
(1/2) We are thrilled to announce our acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens our commercial presence in the Northeast U.S., expanding service capabilities and enhancing access to molecular and
NeoGenomics
@NeoGenomics
hematology-oncology testing by establishing a local presence for #neogenomics in a rapidly growing geographical region of the country.
Learn more in our press release: ir.neogenomics.com/news-events/press-releases/detail/290/… -
NeoGenomics
@NeoGenomics
Celebrating the incredible women who inspire us every day! This International Women's Day, we're proud to share that ~60% of our workforce is female. Your talent, passion, and dedication are the heart of everything we do.
#iwd2025 #womenintheworkplace #workatneo #lifeatneo
NeoGenomics
@NeoGenomics
Reference
2024 ESG report: d1io3yog0oux5.cloudfront.net/_72772f3d9f5a5570899ea9b70be… -
NeoGenomics
@NeoGenomics
Patients with advanced or metastatic gastric (GEJ) adenocarcinoma may be eligible for biomarker-driven therapy. Determining eligibility through testing only takes 48 hours*. Let’s work together to improve outcomes for your gastric/GEJ patients neogenomics.com/cldn182
*48-hr TAT
NeoGenomics
@NeoGenomics
References:
1: Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci 2019;44(2):141-52.
2: Hu YJ, Wang YD, Tan FQ, Yang WX. Regulation of paracellular permeability: factors and mechanisms. Mol Biol Rep 2013;40:6123-42.
NeoGenomics
@NeoGenomics
References, continued
3: Shitara K, Lordick F, Bang YJ, et al. Lancet 2023 Apr 14:S0140-6736(23)00620-7. Xu RH, Shitara K, Ajani JA, et al. #405736. Presented at: March American Society of Clinical Oncology Plenary Series; March 22, 2023. -
NeoGenomics
@NeoGenomics
Today is Optimization of IHC & digital pathology workflows in the development of novel therapeutic ADCs, presented by Leica Biosystems and #neogenomics. There’s still time to reserve your seat: www.labroots.com/ms/webinar/optimization-ihc-digital-path…
-
NeoGenomics
@NeoGenomics
(1/2) Personalize your AML treatment plan with IDH1 testing. For the thousands of patients who will be diagnosed with acute myeloid leukemia (AML) this year, there may be a therapy option available. The IDH rapid PCR test through IDHNow for AML Sponsored Testing Program is
NeoGenomics
@NeoGenomics
(2/2) available at no-cost to eligible patients. Eligibility criteria is available online: www.neogenomics.com/IDHNOW_STP
NeoGenomics
@NeoGenomics
Graphic References:
1. seer.cancer.gov/statfacts/html/amyl.html
2. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282 -
NeoGenomics
@NeoGenomics
#colorectalcancermonth begins today. Follow us as we highlight testing solutions, share resources, and more each week.
#coloncancerawarenessmonth #crc #crcmonth #cancertesting #oncology -
NeoGenomics
@NeoGenomics
#worldcancerpreventionmonth is a time to focus on reducing risks and advancing solutions to combat cancer. At NeoGenomics, we promise to stand by your side, every step of the way, in the pursuit of better futures for people living with cancer. #cancerprevention #strongertogether
-
NeoGenomics
@NeoGenomics
Together with Leica Biosystems, we’re pleased to present 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐈𝐇𝐂 & 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐰𝐨𝐫𝐤𝐟𝐥𝐨𝐰𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐧𝐨𝐯𝐞𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐀𝐃𝐂𝐬, a webinar on March 5 at 8 a.m. PST/11 a.m. EST.
NeoGenomics
@NeoGenomics
Discover how tissue-based technologies and digital pathology are transforming ADC therapies by enabling precise biomarker identification and targeted treatment strategies. Our expert-led session will cover the latest advancements, challenges, and oncology case studies shaping
NeoGenomics
@NeoGenomics
the future of ADCs.
Save your virtual seat today: www.labroots.com/ms/webinar/optimization-ihc-digital-path…
#webinar #oncology #pathology -
NeoGenomics
@NeoGenomics
Happy Valentine's Day! Love, NeoGenomics 💝
-
NeoGenomics
@NeoGenomics
Testing for CLDN18.2 expression is a useful tool in the treatment of Gastric/GEJ (G/GEJ) cancers. This new biomarker offers an opportunity to advance care and improve outcomes for thousands of G/GEJ patients.
Learn more: neogenomics.com/cldn182
NeoGenomics
@NeoGenomics
References
1: seer.cancer.gov/statfacts/html/stomach.html
2: seer.cancer.gov/statfacts/html/esoph.html
3: www.gastriccancerbiomarkers.com
4: Xia JY, Aadam AA. Advances in screening and detection of gastric cancer. J Surg Oncol. 2022 Jun;125(7):1104-1109. doi: 10.1002/jso.26844. PMID: 35481909; PMCID: PMC9322671 -
NeoGenomics
@NeoGenomics
(1/3) On #worldcancerday, we stand united in the fight against cancer and are proud to affirm our commitment to enabling precision medicine.
We believe in a future where every patient receives a treatment plan tailored to their unique cancer profile. Together, we can make
NeoGenomics
@NeoGenomics
(2/3) personalized care the standard of care. We offer testing solutions designed for oncologists. We’ve developed a suite of products designed to work for every patient, even as cancers evolve. Our test menu is regularly updated to provide solutions that align to the latest
NeoGenomics
@NeoGenomics
(3/3) evidence and guidelines.
www.neogenomics.com
#worldcancerday2025 #precisiononcology -
NeoGenomics
@NeoGenomics
Claudin18.2 is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma.
There is an urgent need for first-line treatment options for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ)
NeoGenomics
@NeoGenomics
adenocarcinoma. CLDN18.2 is a new biomarker with a targeted therapy to treat G/GEJ cancer and may improve outcomes for patients. We are proud to offer Claudin18.2 testing: www.neogenomics.com/providers/oncology-solutions/gastric-…
Reference 1: www.claudin182.com -
NeoGenomics
@NeoGenomics
During #cervicalcancer Awareness Month, we’re shining a spotlight on testing solutions to support your therapy decisions, prognosis, and clinical research.
#cancertesting #oncology #cervicalcancerawarenessmonth
NeoGenomics
@NeoGenomics
NeoTYPE® Cervical Tumor Profile analyzes 43 biomarkers, characterizing primary or metastatic cervical tumors of any histological subtype for the most significant genetic changes relevant to treatment options and more: neogenomics.com/test-menu/neotyper-cervical-tumor-profile
NeoGenomics
@NeoGenomics
Neo Comprehensive™ - Solid Tumor is our largest and most up-to-date pan-cancer CGP test with coverage of over 500 cancer-relevant biomarkers across DNA and RNA sequencing: neogenomics.com/test-menu/neo-comprehensive-solid-tumor
-
NeoGenomics
@NeoGenomics
We recently announced a new sponsored testing program for patients with acute myeloid leukemia (AML). Up to 16% of AML patients may have an IDH1 mutation.¹ In partnership with Servier, the IDHNow for AML Sponsored Testing Program provides access to testing for eligible patients.
NeoGenomics
@NeoGenomics
For eligibility criteria & more: www.neogenomics.com/IDHNOW_STP
1. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282 -
NeoGenomics
@NeoGenomics
The American Cancer Society estimates that around 13,800 new cases of invasive #cervicalcancer will be diagnosed this year. During #cervicalcancerawarenessmonth, help spread education and resources about one of the most commonly diagnosed cancers in women: www.cancer.org/cancer/types/cervical-cancer/about/key-sta…
-
NeoGenomics
@NeoGenomics
We're excited to share a new website: neogenomics.com
Our site & trusted test menu have been streamlined to deliver what you need more quickly, designed to support what matters most in your day-to-day practice & research needs & offer the clarity & efficiency you deserve. -
NeoGenomics
@NeoGenomics
Today, we remember Dr. Martin Luther King Jr.
Our We S.T.A.N.D. employee resource group (ERG) sponsored activities honoring his life and legacy. We'll be sharing pictures from these special events, as well as of our MLK Jr. Food Drive.
#mlkjrday #drmartinlutherkingjr -
NeoGenomics
@NeoGenomics
We are thrilled to announce a partnership with Adaptive Biotechnologies to expand access to minimal residual disease (MRD) monitoring options for select blood cancer patients.
Our COMPASS® and CHART® comprehensive and personalized assessment services for complex blood cancers
NeoGenomics
@NeoGenomics
will be integrating Adaptive’s next-generation sequencing (NGS)-based clonoSEQ®, which detects MRD in lymphoid cancers, offering a unique multi-modal testing approach for patients.
To learn which blood cancers will be applicable for this innovative partnership, visit us online: -
NeoGenomics reposted
LUNGevity Foundation
@LUNGevity
Every day 643 people will be diagnosed with lung cancer. Share the facts and raise awareness that #anyonewithlungs can get lung cancer. Learn more by visiting lungevity.org
#lcsm #lungcancer #lungcancerawareness #transforminglungcancer -
NeoGenomics
@NeoGenomics
Episode #63 of the Precision Medicine Podcast (@PMPbyTrapelo), How Precision Medicine and Early Detection Transform Outcomes in Prostate Cancer Care, features Dr. William Oh discussing critical challenges and new advancements in #prostatecancer.
In this first installment of a
NeoGenomics
@NeoGenomics
two-part series on prostate #cancer, Dr. Oh sheds light on the complexities of the disease and how early screening can address rising incidence rates and persistent disparities, particularly among African American men. To stream, visit: www.trapelohealth.com/prostate-cancer-william-oh-part-01
#trapelo #podcast -
NeoGenomics
@NeoGenomics
Comprehensive genomic profiling (CGP) is revolutionary for hematologic oncology care, but many factors, including reimbursement challenges, hinder widespread adoption. In this recent article published on GenomeWeb, experts discuss how making CGP the gold standard for blood
NeoGenomics
@NeoGenomics
cancers can potentially improve patient outcomes by uncovering critical mutations and guiding targeted therapies: www.genomeweb.com/cancer/pathologists-see-value-balance-s…
#hematologiccancer #genomicprofiling #precisionmedicine #cgp #oncology #cancerresearch #neogenomics -
NeoGenomics
@NeoGenomics
Thank you. Since 2022, we've been partnered with ImmunoGen, now part of AbbVie, on a FOLR1 testing initiative, FR-ASSIST, ™ to provide eligible patients with testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer. This partnership has helped many
NeoGenomics
@NeoGenomics
patients determine eligibility for a biomarker-driven therapy. Effective December 29th, 2024, the ImmunoGen/AbbVie-sponsored FR-ASSIST™ FOLR1 Ovarian Cancer IHC Testing Program, will be discontinued.
NeoGenomics will continue to offer the FOLR1 companion diagnostic IHC test and
NeoGenomics
@NeoGenomics
support oncologists in making informed treatment decisions for their ovarian cancer patients. as a companion diagnostic test: neogenomics.com/test-menu/folr1-non-stp
NeoGenomics
@NeoGenomics
We look forward to supporting your patient care with our oncology solutions. Learn more about our test offerings at: neogenomics.com/diagnostic-services
-
NeoGenomics
@NeoGenomics
Sending season's greetings from our #neogenomics family to yours. #happyholidays
-
NeoGenomics
@NeoGenomics
#gastriccancerawareness: Let's spread the word about the impact that targeted therapies can have on the lives of patients.
Thousands of people with gastric cancer or gastroesophageal junction (G/GEJ) adenocarcinoma may be eligible for a new therapy option.
neogenomics.com/cldn182 -
NeoGenomics
@NeoGenomics
Sending season's greetings from our #neogenomics family to yours. #happyholidays
-
NeoGenomics
@NeoGenomics
(1/2) We are pleased to announce the launch of our AML MRD Flow Panel. Minimal residual disease (MRD) is becoming a fundamental factor in the management of hematologic disease and could improve outcomes for patients with acute myeloid leukemia (AML). This test can be used as a
NeoGenomics
@NeoGenomics
(2/2) prognostic and predictive assay for risk assessment, treatment decision-making, and to monitor for relapse.
For ordering information, visit: neogenomics.com/test-menu/aml-mrd-flow-panel
#aml #acutemyeloidleukemia #leukemia #mrd #oncology #cancertesting -
NeoGenomics
@NeoGenomics
We’ve been in San Diego for the 66th ASH® Annual Meeting and Exposition—and it was a fantastic time.
If we didn’t get to meet, let’s set up a post-meeting discussion. Reach out to us here: care.neogenomics.com/ASH2024 -
NeoGenomics
@NeoGenomics
The 66th ASH® Annual Meeting and Exposition is underway at the San Diego Convention Center. We are at booth #2347 with solutions to answer cancer’s challenges.
Visit our booth or book a meeting with our oncology experts online: care.neogenomics.com/ASH2024 -
NeoGenomics
@NeoGenomics
The 66th ASH® Annual Meeting and Exposition is underway at the San Diego Convention Center. We are at booth #2347 with solutions to answer cancer’s challenges.
Visit our booth or book a meeting with our oncology experts online: care.neogenomics.com/ASH2024 -
NeoGenomics
@NeoGenomics
Our team, NEO | Nucleus, is excited for the 11th annual ASH Foundation Run/Walk! We are proud to support this fun, healthy, and philanthropic activity. Good luck to everyone participating today.
#ash24 -
NeoGenomics
@NeoGenomics
Our team, NEO | Nucleus, is excited for the 11th annual ASH Foundation Run/Walk!
We are proud to support this fun, healthy, and philanthropic activity. Good luck to everyone participating today. -
NeoGenomics
@NeoGenomics
#oncology experts from #neogenomics are in San Diego for the 66th ASH® Annual Meeting and Exposition to discuss how we can support your patient care.
Visit us at booth #2347 or book a meeting online: care.neogenomics.com/ASH2024
#ash24 -
NeoGenomics
@NeoGenomics
#oncology experts from #neogenomics are in San Diego for the 66th ASH® Annual Meeting and Exposition to discuss how we can support your patient care.
Visit us at booth #2347 or book a meeting online: care.neogenomics.com/ASH2024 -
NeoGenomics
@NeoGenomics
Taking a quick popcorn break to refuel at the #neogenomics HQ in Fort Myers, Florida!
#lifeatneo #workatneo #neospirit -
NeoGenomics
@NeoGenomics
We're presenting data at the #esmo Asia Congress 2024. Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC), by Qingyan Au et al., is poster number 89P.
-
NeoGenomics
@NeoGenomics
The 66th ASH® Annual Meeting and Exposition kicks off tomorrow at the San Diego Convention Center. We’ll be at booth #2347 with solutions to answer cancer’s challenges.
To book a meeting with our oncology experts, visit: care.neogenomics.com/ASH2024 -
NeoGenomics
@NeoGenomics
Let’s cheer on our team, NEO | Nucleus, who will be taking part in the ASH Foundation Run/Walk during the 66th ASH® Annual Meeting and Exposition!
-
NeoGenomics
@NeoGenomics
NeoGenomics Laboratories is partnered with ImmunoGen, now part of AbbVie, on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients through December 29, 2024.
This testing program was designed
NeoGenomics
@NeoGenomics
to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients.
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA
NeoGenomics
@NeoGenomics
FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.
To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: neogenomics.com/diagnostic-services/sponsored-testing-pro… -
NeoGenomics
@NeoGenomics
Happy Thanksgiving to all who celebrate! We hope your day is filled with good food, fun, and time spent with loved ones. #happythanksgiving 🍁🦃
-
NeoGenomics
@NeoGenomics
Listen to this podcast of #oncologyoverdrive by Healio. Melody Harris, Chief Operations Officer & President of Informatics, and Shikha Jain, MD, discuss the evolution of precision medicine & what physicians & companies can do to help patients better understand precision oncology.
NeoGenomics
@NeoGenomics
• Stream online: www.healio.com/news/hematology-oncology/podcasts/oncology…
• Listen on Apple Podcasts: podcasts.apple.com/us/podcast/oncology-overdrive/id151248…
• Listen on Spotify: open.spotify.com/show/59oNFGJFmYEcOiQoBRMA1c
#precisionmedicine #precisiononcology #oncology #oncologyoverdrive -
NeoGenomics
@NeoGenomics
The AMP 2024 Annual Meeting & Expo was outstanding. We'll see you next year!
If we missed you at #ampath24, let's schedule a post-meeting discussion: care.neogenomics.com/AMP2024 -
NeoGenomics
@NeoGenomics
It has been a great week at #ampath24 in Vancouver, British Columbia, Canada. We enjoyed the chance to meet with attendees to discuss solutions that can answer the challenges of cancer care.
#pathology #cancercare -
NeoGenomics
@NeoGenomics
If you're attending #ampath24, visit #neogenomics at booth #830 today and tomorrow. Learn more and book a meeting with us online here: care.neogenomics.com/AMP2024
#vancouver #britishcolumbia #molecularpathology #pathology -
NeoGenomics
@NeoGenomics
We are excited to be in Vancouver for the AMP 2024 Annual Meeting & Expo! Visit us today and tomorrow at booth #830.
#ampath24 #vancouver #britishcolumbia #molecularpathology #pathology -
NeoGenomics
@NeoGenomics
We are excited to be in Vancouver for the AMP 2024 Annual Meeting & Expo! Visit us at booth #830 today through November 23rd.
#ampath24 #vancouver #britishcolumbia #molecularpathology #pathology -
NeoGenomics
@NeoGenomics
We are pleased to be presenting a Corporate Workshop 𝐭𝐨𝐝𝐚𝐲 during #ampath24! Don't miss "Clinical utility of comprehensive genomic profiling (CGP) for myeloid neoplasms," today from 8:00–8:50 a.m. in room 111 & 112, Level 1.
For more details, visit: www.linkedin.com/pulse/we-pleased-presenting-corporate-wo… -
NeoGenomics
@NeoGenomics
Our Lung Solution supports the care continuum with profiles that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options.
NeoGenomics
@NeoGenomics
We meet you and your patient where they are, whether they are in an early or advanced stage or when there is no tissue. Learn more: neogenomics.com/lung-cancer
-
NeoGenomics
@NeoGenomics
We are pleased to be presenting a Corporate Workshop during #ampath24! Bookmark these details:
· Corporate Workshop presented by Dr. Derek Lyle, Chief Medical Officer
· Wednesday, November 20, from 8:00–8:50 a.m.
· Located in room 111 & 112, Level 1
care.neogenomics.com/AMP2024 -
NeoGenomics
@NeoGenomics
Thank you for visiting us during #sitc2024.
If we missed you during #sitc2024, let’s schedule a meeting to discuss how we can address your needs throughout the entire continuum of oncology drug discovery and development: care.neogenomics.com/sitc2024 -
NeoGenomics
@NeoGenomics
(1/4) Today, we honor and express our deep gratitude to all the veterans who have served our country. Your bravery, sacrifice, and resilience inspire us daily. Thank you for your service. We at #neogenomics are passionate about and committed to supporting veterans. We are honored
Post not available here, view on X
NeoGenomics
@NeoGenomics
(3/4) environment that provides opportunities for community building and professional development of military Veterans at NeoGenomics and to provide value to the company, our members, and the communities we serve.
Today, we're hosting a no-sew blanket-making event, and the
NeoGenomics
@NeoGenomics
(4/4) finished blankets will be delivered to the Veterans Hospital in Long Beach, CA.
#neogenomics #lifeatneo #workatneo #hiringourheroes #veteransday #veteransday24 -
NeoGenomics
@NeoGenomics
The OneOncology Annual Conference wrapped up yesterday in Nashville, TN, and we want to say thank you to everyone who visited us.
#oncology #oneoncology #nashville #neogenomics
NeoGenomics
@NeoGenomics
If we didn’t get the opportunity to speak with you, we invite you to visit us online to learn more about our oncology solutions: neogenomics.com/diagnostic-services
-
NeoGenomics
@NeoGenomics
We are excited to be in Nashville for the OneOncology Annual Conference!
Experts from Neo are on-site to discuss how our #oncology solutions can meet the challenges of cancer care. Visit table T28 to get started.
#oneoncology #cancercare #patientcare -
NeoGenomics
@NeoGenomics
We're presenting new data from our whole-slide multiplex immunofluorescence platform at #sitc24. "Deep phenotyping and spatial interrogation of the NSCLC tumor microenvironment using the fully validated Next Generation MultiOmyx™ Platform" is abstract #1390.
#sitc2024 #nsclc
NeoGenomics
@NeoGenomics
How can we address your needs throughout the entire continuum of oncology drug discovery and development? Schedule a meeting to talk with our experts: care.neogenomics.com/sitc2024
-
NeoGenomics
@NeoGenomics
(1/2) #gastriccancerawarenessmonth is an important time to connect providers with resources to help them develop personalized treatment plans for gastric cancer or gastroesophageal junction (G/GEJ) adenocarcinoma patients. Approx. 70% of advanced G/GEJ cancers express CLDN18.2
NeoGenomics
@NeoGenomics
at any detectable amount and ~38% are considered positive for Claudin18.2 (CLDN18.2), a new actionable target¹.
Improving outcomes for your patient care is a few clicks away: www.neogenomics.com/providers/oncology-solutions/gastric-…
#gastriccancer #cancertesting #oncology
1: www.gastriccancerbiomarkers.com -
NeoGenomics
@NeoGenomics
We are excited to be in Nashville for the OneOncology Annual Conference!
Experts from Neo are on-site to discuss how our #oncology solutions can meet the challenges of cancer care. Visit table T28 to get started. -
NeoGenomics
@NeoGenomics
(1/2) 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝! Driven by our mission to save lives by improving patient care, NeoGenomics partnered with Boehringer-Ingelheim GmbH to advance ROR1 (Receptor tyrosine kinase-like orphan receptor 1) research for the development of novel therapeutic modalities.
NeoGenomics
@NeoGenomics
(2/2) Our collaborative study investigated the ROR1 tumor cell expression profile, analyzing 292 tumor specimens across 7 hematological malignancies. 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: journals.plos.org/plosone/article?id=10.1371/journal.pone…
-
NeoGenomics
@NeoGenomics
(1/2) We're presenting new data from our whole-slide multiplex immunofluorescence platform at #sitc24. "Deep phenotyping and spatial interrogation of the NSCLC tumor microenvironment using the fully validated Next Generation MultiOmyx™ Platform" is abstract #1390. It will be
NeoGenomics
@NeoGenomics
shared on Sat., November 9. Come by the poster to learn about NeoGenomics’ spatial capabilities for translational research.
How can we address your needs throughout the entire continuum of oncology drug discovery and development? Schedule a meeting here:
care.neogenomics.com/sitc2024 -
NeoGenomics
@NeoGenomics
#lungcancerawarenessmonth begins today! Each year, we use this special time to share education and resources, support survivors, highlight testing solutions, and more.
#lungcancerawarenessmonth #lungcancerawareness2024 #cancertesting #oncology #neogenomics -
NeoGenomics
@NeoGenomics
Happy Halloween! 🎃 #halloween2024 #halloween
-
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth may be drawing to a close, but the conversation should continue all year long. We look forward to supporting your patient care with comprehensive solutions: neogenomics.com/breast-cancer-awareness
#cancertesting #pathologist #oncologist -
NeoGenomics
@NeoGenomics
We will be exhibiting at the AMP 2024 Annual Meeting & Expo to discuss how our #oncology solutions can meet the challenges of cancer care.
#amp24 #vancouver #britishcolumbia -
NeoGenomics
@NeoGenomics
(1/2) There is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Claudin18.2 (CLDN18.2) is a new biomarker with a targeted therapy to treat gastric/GEJ cancer and can improve the outcome for patients.
To learn how CLDN18.2 testing
NeoGenomics
@NeoGenomics
(2/2) can enhance care and help your patients, we invite you to visit us online neogenomics.com/cldn182 or call us at 866.776.5907, option 3.
#gastric #adenocarcinoma #claudin182
.
.
.
References
1: seer.cancer.gov/statfacts/html/stomach.html
2: seer.cancer.gov/statfacts/html/esoph.html
3: www.gastriccancerbiomarkers.com -
NeoGenomics
@NeoGenomics
We were excited to present new data at the 2024 EORTC-NCI-AACR Symposium.
-
NeoGenomics
@NeoGenomics
#cap24 | The Pathologists’ Meeting is drawing to a close at the Wynn #lasvegas. Thank you to everyone who visited us–we enjoyed the chance to discuss how our solutions can meet your challenges of #cancercare. Contact us to get started: neogenomics.com/contact-us #pathology #oncology
-
NeoGenomics
@NeoGenomics
(1/3) "NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test."
NeoGenomics announced that the New York State Department of Health has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung,
NeoGenomics
@NeoGenomics
(2/3) allowing for immediate commercial access in the state of New York. These next-generation sequencing tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse #solidtumors, including
NeoGenomics
@NeoGenomics
(3/3) non-small cell lung cancer. Continue reading this press release online: ir.neogenomics.com/news-events/press-releases/detail/276/…
-
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
This testing program was designed to help reduce barriers to IHC testing
NeoGenomics
@NeoGenomics
for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx
NeoGenomics
@NeoGenomics
may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
#cap24 | The Pathologists’ Meeting is underway at the Wynn #lasvegas! Visit us at booth #219.
Learn about our new NGS profiles for #hematologic cancers and solid #tumors, and how our broad test menu allows you to develop personalized solutions and collaborative assessments.
NeoGenomics
@NeoGenomics
We have a motto that working at Neo is where passion meets purpose, and colleagues from our #neogenomics talent acquisition team are on-site to discuss #career opportunities.
#careeropportunities #lifeatneo #workatneo -
NeoGenomics
@NeoGenomics
As the #1 lab in breast cancer testing with over 20 years of expertise, we proudly offer a comprehensive suite of targeted and broad hashtag#NGS panels to support the entire breast cancer care continuum. From diagnosis to therapy selection, prognosis, and clinical trial options,
NeoGenomics
@NeoGenomics
we provide the expertise and precision needed at every stage of breast cancer care. Learn about our NeoGenomics breast cancer solution: neogenomics.com/breast-cancer-awareness #patientcare #cancertesting #precisionmedicine #breastcancer #oncology
-
NeoGenomics
@NeoGenomics
We can’t wait to meet with you at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
#sitc24 #sitc2024 -
NeoGenomics
@NeoGenomics
Every patient is unique – your testing should be, too. NEO | COMPASS® provides a personalized solution for your patient’s #hematologic malignancies, delivering individualistic insights to guide precise treatment strategies: neogenomics.com/diagnostic-services/specialty-testing/com…
#neogenomics #oncology -
NeoGenomics
@NeoGenomics
October is #healthliteracymonth! Understanding health terminology is crucial for making informed decisions. To assist patients in asking their providers the right questions, we are defining some commonly used words and phrases in #cancer care. neogenomics.com/patients/testing-terminology
-
NeoGenomics
@NeoGenomics
Melody Harris, Chief Operations Officer & President of Informatics, discussed the value of data in oncology testing, the role of automation, and the impact of machine learning in laboratory processes in this recent article on Healthcare Digital: healthcare-digital.com/ai-ml/neogenomics-data-in-oncology…
-
NeoGenomics
@NeoGenomics
(1/4) We are pleased to report that our team has weathered Hurricane Milton. Our team’s coordination has ensured minimal impact to patients and to our business. Ahead of the storm’s arrival, we enacted our Business Continuity Plan and closed our Fort Myers lab Tuesday afternoon.
NeoGenomics
@NeoGenomics
(2/4) All specimens were rerouted to our Aliso Viejo lab. After a full assessment this morning, we have determined there is no damage to our Fort Myers lab, and we will reopen tomorrow, October 11th. Our analysis lab in Tampa is without power, and employees have been instructed
NeoGenomics
@NeoGenomics
(3/4) to work from home until power is restored.
To care for our team that may have been impacted, we have set up shower and laundry stations on-site at headquarters. Our cafeteria is preparing hot meals for teammates and their families.
NeoGenomics
@NeoGenomics
(4/4) We are committed to providing the resources necessary for getting back to normal.
-
NeoGenomics
@NeoGenomics
(1/4) NeoGenomics response to Hurricane Milton
Hurricane Milton, classified as a Category 5 storm, is expected to land in our region within 48 hours. With sustained winds of up to 160 mph and a trajectory projected to affect our Fort Myers and Tampa locations directly, we arePost not available here, view on X
NeoGenomics
@NeoGenomics
due to evacuation orders, safety issues, and flooding. We anticipate minimal impact on turnaround time during these precautionary measures. We are closely monitoring the situation and will update as needed. If you have questions or concerns, please do not hesitate to contact our
NeoGenomics
@NeoGenomics
Client Service team at 866.776.5907, option 3.
-
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth Throughout October, we’re sharing content in honor of this observance. Today’s message focuses on the prevalence of #breastcancer and the power of #earlydetection. Schedule your #mammogram, encourage your loved ones to do the same, and spread the word.
-
NeoGenomics
@NeoGenomics
We are thrilled to announce the launch of our NEO | AML Express™ panel.
Make the right decision at the right time for your acute myeloid leukemia patients with a personalized solution, delivering patient-specific insights to help guide precise treatment strategies.
NeoGenomics
@NeoGenomics
With a class-leading turnaround time of 3-4 days, Neo | AML Express delivers comprehensive NGS-based assessment with timely diagnostic, prognostic and predictive biomarker information. We don't expect you to put your patients' cancer questions in the hands of just anyone.
NeoGenomics
@NeoGenomics
When it matters, it matters who you ask. Let’s work together to optimize patient care: neogenomics.com/test-menu/neo-aml-expresstm
#aml #acutemyeloidleukemia #ngs #cancertesting #oncology -
Post not available here, view on X
NeoGenomics
@NeoGenomics
A rigorous judging process determines these prestigious recognitions. Entries are evaluated by an international panel of independent industry experts, BHG senior analysts, and the BHG executive team. The judging criteria includes design of the program, functionality, innovation,
-
NeoGenomics
@NeoGenomics
We're pleased to share that we've been honored by the Brandon Hall Group (BHG). We received a gold award for Future Of Work: Best Program For Upskilling Employees for our program that develops trainees into certified lab technologists, and a bronze award for Best DEI&B Strategy.
-
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
This testing program was designed to help reduce barriers to IHC testing
NeoGenomics
@NeoGenomics
for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx
NeoGenomics
@NeoGenomics
may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit:
neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
#breastcancerawarenessmonth begins today 🎗️ All month long, we will be sharing education and resources, supporting survivors, highlighting our testing solutions, and more.
#breastcancerawarenessmonth #breastcancerawareness2024 #cancertesting #oncology #neogenomics -
NeoGenomics
@NeoGenomics
In this Clinical Lab Chat, Nathan Montgomery, MD, PhD, NeoGenomics' Vice President of Medical Services, sat down with Chris Wolski, Clinical Lab Products' Director of Business Intelligence, about how AI will transform #laboratory practices. Stream here: share.transistor.fm/s/8ae1c862
-
NeoGenomics
@NeoGenomics
Hematological cancers are complex, but we can offer a simple solution.
Neo Comprehensive™ - Heme Cancers is our largest and most comprehensive heme next-generation sequencing (NGS) genomic profile. It analyzes genes associated with hematologic malignancies from myeloid and
NeoGenomics
@NeoGenomics
lymphoid lineages to detect DNA and RNA alterations in one assay. neogenomics.com/diagnostic-services/specialty-testing/neo…
#ngs #dnarna #hemecancers
#bloodcancerawarenessmonth #bloodcancer -
NeoGenomics
@NeoGenomics
Let's promote knowledge, support research, and honor those affected by #ovariancancer.
#ovariancancerawarenessmonth #ovariancancerawareness -
NeoGenomics
@NeoGenomics
Early detection can make all the difference. Don't wait—talk to your doctor about screening options. Together, we can spread the word about testing and targeted treatment options and help save lives.
#prostatecancerawareness #prostatecancer #earlydetection #talktoyourdoctor -
NeoGenomics
@NeoGenomics
#gynecologicalcancer Awareness Month is a critical time to bring attention to how we can support gynecologic oncologists and their patient care. Our gynecologic solution provides profiles that detect genomic alterations relevant to diagnosis, therapy selection, prognosis,
NeoGenomics
@NeoGenomics
and clinical trial options.
Let’s get started today. Contact us at client.services@neogenomics.com. -
NeoGenomics
@NeoGenomics
Thank you! We appreciated the opportunity to speak with you during the AVAHO 2024 Annual Meeting.
#avahoannualmeeting #avaho #neogenomics #oncology -
NeoGenomics
@NeoGenomics
Today is World CML Day. This day is recognized on 9/22 because the genetic change of chromosomes 9 and 22 is the cause of chronic myeloid leukemia (CML)¹.
#wcmld24 #worldcmlday #chronicmyeloidleukemia #cml
.
.
.
Reference
1: cmladvocates.net/world-cml-day/. -
NeoGenomics
@NeoGenomics
ASCO Direct™ Philadelphia has just kicked off! We are excited to meet with you today and tomorrow.
-
NeoGenomics
@NeoGenomics
The AVAHO Annual Meeting runs through September 22nd in Atlanta, GA. We are proud to support AVAHO’s goal to increase the skills and abilities of veteran-centered cancer care professionals so they can provide the best possible care for our veterans.
#avahoannualmeeting -
NeoGenomics
@NeoGenomics
Our Fast Facts series brings you insights from our real-world data (#rwd). Today, we are shining a spotlight on #ovariancancer. To learn about NeoGenomics' real-world multi-modal data solutions: neogenomics.com/informatics-data-solutions
#ovariancancerawarenessmonth #folr1 #neogenomics -
NeoGenomics
@NeoGenomics
The AVAHO Annual Meeting has begun! Come visit us to learn about our oncology solutions.
#avahoannualmeeting #avaho #neogenomics #oncology -
NeoGenomics
@NeoGenomics
We are a proud sponsor of ASCO Direct™ Philadelphia! Let’s meet September 21 and 22 to discuss solutions for your solid tumor patients, hematological cancers, and more. We’ll see you at the Sonesta Philadelphia Rittenhouse Square in Philadelphia, PA.
-
NeoGenomics
@NeoGenomics
(1/2) The American Cancer Society estimates that about 44,020 new cases of thyroid cancer will be diagnosed this year¹.
We want to support your #thyroidcancer patient care with information that helps to make an accurate diagnosis and prognosis. The NeoTYPE® Thyroid Profile
NeoGenomics
@NeoGenomics
(2/2) analyzes 32 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC and includes a summary interpretation of all results to help guide treatment decisions. For ordering information, please visit: neogenomics.com/test-menu/neotyper-thyroid-profile
-
NeoGenomics
@NeoGenomics
We were pleased to be part of another outstanding #esmo Congress. We thank everyone who visited us and look forward to continuing the discussions about how we can support you from discovery to commercialization: care.neogenomics.com/esmo2024
#neogenomics #oncology #precisionmedicine -
NeoGenomics
@NeoGenomics
We are pleased to share pictures from the ESMO Congress 2024 in #barcelona! Thank you to everyone who has stopped by our booth (#438) to learn about our broad #oncology testing capabilities, in-house scientific expertise, project support team, real-world data, and more.
#esmo24 -
NeoGenomics
@NeoGenomics
We are excited to be in Barcelona for the ESMO Congress 2024. Visit us at booth #438 to learn about our broad oncology testing capabilities, in-house scientific expertise, project support team, real-world data, and more.
#esmo24 #neogenomics #barcelona #oncology -
NeoGenomics
@NeoGenomics
ASCO Direct™ DC has just kicked off! We are excited to meet with you today and tomorrow.
-
NeoGenomics
@NeoGenomics
We are a proud sponsor of ASCO Direct™ DC! Let’s meet tomorrow, 9/14, and Sunday, 9/15, to discuss solutions for your solid tumor patients, #hematological cancers, and more. We’ll see you at the Embassy Suites DC Convention Center in Washington, DC.
#ascodirect #washingtondc -
NeoGenomics
@NeoGenomics
We are excited to be in #barcelona for #esmo24. Visit us at booth #438 to learn about our broad #oncology testing capabilities, in-house scientific expertise, project support team, real-world data, and more.
Book a meeting with us here: care.neogenomics.com/esmo2024
#neogenomics -
NeoGenomics
@NeoGenomics
During #esmo24, meet with our experts, Amber Chevalier and Christopher G. Smith of our Clinical Programs teams, to discuss our new NEO | PanTracer™ LBx assay.
We look forward to connecting with you. You can book a meeting with us here: care.neogenomics.com/esmo2024
NeoGenomics
@NeoGenomics
(2/3) NEO | PanTracer™ LBx is NeoGenomics’ comprehensive liquid biopsy test for pan-solid tumors, with sensitive yet specific variant detection for over 500 genes for cancer research and discovery applications. It provides biomarker results from liquid biopsy samples (cfDNA),
NeoGenomics
@NeoGenomics
(3/3) even when sufficient tissue samples may not be available.
neogenomics.com/pharma-services/lab-services/molecular/li… -
NeoGenomics
@NeoGenomics
Today, we pause to remember the lives lost and to honor the first responders and everyone who showed extraordinary courage to save others on 9/11. We are reminded of the courage, resiliency, and strength demonstrated across the United States in the wake of tragedy. #patriotday
-
NeoGenomics
@NeoGenomics
During #esmo24, let's discuss how our powerful Informatics solutions can help you succeed sooner. To book a meeting: care.neogenomics.com/esmo2024
• CDx Launch Planning
• Translational Discovery
• External Control Arms
• Epidemiology/HEOR
• New Product Planning
• Market Access -
NeoGenomics
@NeoGenomics
The FDA approved a drug called Enhertu for HER2-positive patients who received systemic treatment without satisfactory results. Enhertu showed clinically meaningful responses across a broad range of tumors, making it the first tumor-agnostic therapy for such patients.
NeoGenomics
@NeoGenomics
Treatments start with tests. We support your patient care with tests to identify markers and help guide treatment decisions.
• Browse our tests:
neogenomics.com/test-menu?search=HER2&methodology=All&dis…
• Contact Client Services: client.services@neogenomics.com or 866.776.5907, option 3. -
NeoGenomics
@NeoGenomics
Best of ASCO Memphis has just begun! We are excited to meet with you today and tomorrow.
-
NeoGenomics
@NeoGenomics
The 14th World CB & CDx Summit just wrapped up in Boston! Thank you to everyone who visited us & attended our Expertise Partner presentation. We made many connections and look forward to continuing the discussions about how we can support you from discovery to commercialization.
-
NeoGenomics
@NeoGenomics
We are excited to be at the 14th World CB & CDx Summit. Through Friday, visit us at booth #28 to learn about our broad oncology testing capabilities, in-house scientific and regulatory expertise, project support team, and Informatics and data solutions.
-
NeoGenomics
@NeoGenomics
Happy Labor Day! #laborday #laborday2024
-
NeoGenomics
@NeoGenomics
1/3 #neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing
NeoGenomics
@NeoGenomics
2/3 for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay.
NeoGenomics
@NeoGenomics
This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, visit: neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
"Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy," published in the BMJ’s Journal for ImmunoTherapy of Cancer, is by #neogenomics and collaborators at The University of Sheffield: jitc.bmj.com/content/12/7/e009368
-
NeoGenomics
@NeoGenomics
We are a proud sponsor of Best of ASCO Memphis. Let’s meet September 7 and 8 to discuss solutions for your solid tumor patients, hematological cancers, and more. We’ll see you in Tennessee at the Hilton Memphis.
-
NeoGenomics
@NeoGenomics
Skin cancer is the most common type of cancer in the U.S., but reducing exposure reduces your skin cancer risk. The Skin Cancer Foundation offers these tips to help stay safe in the sun: skincancer.org/skin-cancer-prevention
#skincancer #cancertesting #sunsafety #summersun -
NeoGenomics
@NeoGenomics
Today we celebrate the progress made toward gender equality & reaffirm our commitment to creating a more inclusive workplace. We believe that empowering women is essential to driving innovation & success and we're proud to continue our efforts in building a more equitable future.
-
NeoGenomics
@NeoGenomics
In collaboration with our Women&Allies@Neo Employee Resource Group, we were proud to host the Dress for Success SW Florida "Women Empowered Through Employment" Series at our #neogenomics HQ in Fort Myers, Florida. Congratulations to this graduating cohort! #dressforsuccessswfl
-
NeoGenomics
@NeoGenomics
ASCO Direct™ Michigan kicks off today at the Kellogg Hotel & Conference Center in Lansing, MI. If you are attending, we can’t wait to meet you today and tomorrow.
-
NeoGenomics
@NeoGenomics
(1/2) A drug called Enhertu has been approved for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic therapy and have no satisfactory alternative treatment options. Enhertu was found to show
NeoGenomics
@NeoGenomics
(2/2) clinically meaningful responses across a broad range of tumors, making it the first tumor-agnostic HER2-directed therapy.
NeoGenomics’ HER2 testing: neogenomics.com/test-menu?search=HER2&methodology=All&dis…
.
ENHERTU is FDA-approved for the treatment of several types of cancer: enhertu.com -
NeoGenomics
@NeoGenomics
Speak with the experts in precision oncology during ESMO Congress 2024.
Let’s meet during #esmo24 to discuss how our testing capabilities, in-house expertise, and project support team can support you from discovery to commercialization. -
NeoGenomics
@NeoGenomics
On this Senior Citizens Day – let’s prioritize health. Regular check-ups and screenings are crucial parts of detecting cancer early.
#seniorcitizensday #seniorcitizensday24 #cancertesting #earlydetection
Source:
ncbi.nlm.nih.gov/pmc/articles/PMC5175057 -
NeoGenomics
@NeoGenomics
The AVAHO Annual Meeting runs September 20-22 in Atlanta, GA.
We are proud to support AVAHO’s goal to increase the skills and abilities of veteran-centered cancer care professionals so they can provide the best possible care for our veterans.
#avahoannualmeeting -
NeoGenomics
@NeoGenomics
NEO | PanTracer™ LBx is a solution for our biopharmaceutical partners for cancer research & discovery applications. This comprehensive liquid biopsy test for pan-solid tumor samples provides biomarker results from cfDNA, even when sufficient tissue samples may not be available.
-
NeoGenomics
@NeoGenomics
We will be exhibiting at the 14th World CB & CDx Summit from September 4-6, and we have a lot to share with you this year.
We look forward to meeting with you in Boston! -
NeoGenomics
@NeoGenomics
We're incredibly proud of our team members who pursue continued education, and we are passionate about supporting them with an education assistance fund. Meet three team members who furthered their education: www.linkedin.com/pulse/congradulations-jefre-shatondra-an…
Congratulations Jefre, Shatondra & Annette! -
NeoGenomics
@NeoGenomics
We had an excellent time at the HealthTrust University Conference. Thank you for visiting us!
-
NeoGenomics
@NeoGenomics
We're sharing about skin cancer and #melanoma all #summer long.
Education is empowering – understand the risks and talk to your doctor about screenings and early detection.
#skincancer #cancertesting #neogenomics -
NeoGenomics
@NeoGenomics
We’re pleased to share 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫: 𝐇𝐨𝐰 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐞𝐬 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐎𝐮𝐭𝐜𝐨𝐦𝐞𝐬: voice.ons.org/news-and-views/precision-medicine-in-lung-c…
Over the past two decades, targeted therapies and immunotherapy
NeoGenomics
@NeoGenomics
have revolutionized the treatment of metastatic non-small cell lung cancer (#nsclc). Comprehensive #biomarker testing, including next-generation sequencing (#ngs), is essential but underutilized. Experts recommend broad molecular profiling to guide treatment and improve outcomes.
NeoGenomics
@NeoGenomics
For optimized testing strategies, contact us at 866.776.5907 or client.services@neogenomics.com.
-
NeoGenomics
@NeoGenomics
The HealthTrust University Conference begins today at the Orange County Convention Center in Orlando, Florida! We would love to meet with you during this event.
-
NeoGenomics
@NeoGenomics
A recent study found that cancer screening improves outcomes. #nationalhealthcenterweek is an important reminder to stay proactive with your health and schedule a check-up today. Remember— #earlydetection can save lives!
#cancertesting
Source: ncbi.nlm.nih.gov/pmc/articles/PMC9664263/ -
NeoGenomics
@NeoGenomics
We are a sponsor of ASCO Direct™ Michigan. Let’s meet during this event to discuss solutions for your solid tumor patients, hematological cancers, and more.
We’ll see you August 24 and 25 at the Kellogg Hotel & Conference Center in Lansing, MI. -
NeoGenomics
@NeoGenomics
(1/2) We are pleased to announce the launch of our NEO | PanTracer™ LBx, a comprehensive, pan-solid tumor liquid biopsy NGS test for our biopharmaceutical partners. The NEO | PanTracer LBx detects variants in over 500 genes for cancer research and discovery applications,
NeoGenomics
@NeoGenomics
(2/2) providing biomarker results from cfDNA, even when sufficient tissue samples may not be available. Learn more: neogenomics.com/pharma-services/lab-services/molecular/li…
#ngs #liquidbiopsy #biopharmaceutical #neogenomics -
NeoGenomics
@NeoGenomics
(1/2) Please join us in sending a big congratulations to Brittany Bell! We are thrilled to share that Brittany Bell, NeoGenomics’ VP of Commercial Pharma Services, is a Top 5 honoree of the ASCP (American Society for Clinical Pathology) 40 Under Forty program. This prestigious
NeoGenomics
@NeoGenomics
(2/2) recognition honors her outstanding leadership, remarkable achievements and impact in pathology and laboratory medicine. This accolade is well-deserved, and we are so proud of you!
#40underforty #ascp #clinicalpathology #congratulations -
NeoGenomics
@NeoGenomics
A town hall meeting is held each quarter to review team performances and recognize significant milestones. A favorite part of the meeting is our #neospirt awards, which recognize team members who live out our core values. Follow us in the coming days as we announce the winners!
-
NeoGenomics
@NeoGenomics
Our flow cytometry services can support your drug development lifecycles. Learn about our in-house application expertise of heme neoplasms, MRD, immuno-oncology, ID, PD, and vaccines: neogenomics.com/pharma-services/lab-services/flow-cytometry
#neogenomics #flowcytometry #neoplasms #immunooncology
NeoGenomics
@NeoGenomics
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Planning for success! 📷Our sales team is together at the #neogenomics HQ in Fort Myers, Florida, for Summer Sales Meeting 2024. In these sessions, we've discussed innovative patient care strategies, advanced cancer testing solutions, and white-glove customer assistance.
NeoGenomics
@NeoGenomics
This week has been filled with teamwork, strategy, and lots of laughs along the way. We are excited about the rest of this year and beyond!
#teambuilding #salessuccess #planningforthefuture
NeoGenomics
@NeoGenomics
Providers – if you want to experience the #neogenomics difference, contact us to get started. NeoGenomics’ Client Services Advocate can be reached at client.services@neogenomics.com or 866.776.5907, option 3.
-
NeoGenomics
@NeoGenomics
Check out a snapshot from our lab in Fort Myers, Florida! Ready to find a career where passion meets purpose? Visit
jobs.jobvite.com/neogenomics to explore open positions.
#lifeatneo #workatneo #neospirit #careers #hiring #joinus -
NeoGenomics
@NeoGenomics
Proud to empower providers with critical information to guide treatment plans for sarcoma patients.
Did you know? You can search the #neogenomics test menu by disease. View tests for sarcoma patients: neogenomics.com/test-menu?search=&methodology=All&disease… -
NeoGenomics
@NeoGenomics
Sarcomas are a rare cancer that can form in the bones and soft tissue. Join NeoGenomics in raising awareness about #sarcomas and the importance of early detection.
#sarcomaawarenessmonth #sarcomaawareness #sarcoma -
NeoGenomics
@NeoGenomics
We're sharing about #sunsafety all summer long. UV radiation can cause skin damage and increase the risk of skin cancer.
• Seek shade
• Wear sunscreen
• Cover up while outdoors
• More tips from the CDC: www.fda.gov/consumers/consumer-updates/tips-stay-safe-sun…
#uvawareness #skinhealth #protectyourskin -
NeoGenomics
@NeoGenomics
Encouraging and inspiring the next generation of scientists is at the heart of our Science for a Day program. We're pleased to share a picture of our recent intern shadowing staff and getting some hands-on experience.
#lifeatneo #neogenomics #stem #stemeducation #futureleaders -
NeoGenomics
@NeoGenomics
Premier Breakthroughs 24 just wrapped up in National Harbor, Maryland. If we didn’t get to meet you at this event, learn more about our oncology solutions online: neogenomics.com/diagnostic-services
Thank you! -
NeoGenomics
@NeoGenomics
We had the pleasure of welcoming some bright young minds recently to our laboratory in Fort Myers, Florida! It was inspiring to see their curiosity and excitement as they toured the lab.
#neogenomics #laboratory #stem #stemeducation #futureleaders -
NeoGenomics
@NeoGenomics
Premier Breakthroughs 24 is underway! We’re proud to support this event with education and resources about oncology solutions that provide the right tests at the right time. We invite you to come see us at booth #1600.
-
NeoGenomics
@NeoGenomics
Premier Breakthroughs 24 is an event centered around advancing the full spectrum of healthcare objectives. We’re proud to support this focus with education & resources about oncology solutions that provide the right tests at the right time. At Breakthroughs 24, visit us at #1600.
-
NeoGenomics
@NeoGenomics
We believe that patient care isn't just done within the lab, and we're very passionate about ways we can support patients. At the #neogenomics HQ in Fort Myers, Florida, we assembled care packages full of essentials for cancer patients.
NeoGenomics
@NeoGenomics
We were thrilled to have Lee Health visit us and collect packages for cancer patients at #leehealth.
We're proud to support the community and contribute to the care and comfort of those in need.
#supportcancerpatients #communitysupport #oncologycare #cancercare -
NeoGenomics
@NeoGenomics
The Emergence of Multi-modal Real-world data: The power of Clinico-Genomic data versus traditional RWD Sources is a new #whitepaper that explores crucial and emerging topics, such as:
• Why biomarker and genomic data matters for life science
NeoGenomics
@NeoGenomics
• How these data sources unlock what’s been missing from traditional RWD sources
• How these newly created longitudinal data sets support drug development from discovery to trial to post-market
Visit us here to read now: neogenomics.com/informatics-data-solutions
#neogenomics #rwd #oncology -
NeoGenomics
@NeoGenomics
𝐂𝐨𝐧𝐠𝐫𝐚𝐭𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐐𝟏 𝟐𝟎𝟐𝟒 𝐍𝐞𝐨𝐒𝐩𝐢𝐫𝐢𝐭 𝐚𝐰𝐚𝐫𝐝 𝐰𝐢𝐧𝐧𝐞𝐫𝐬! This recognition celebrates outstanding #neogenomics colleagues for their hard work, performance, dedication, and commitment to living our core values and leadership attributes.
NeoGenomics
@NeoGenomics
Congratulations to:
𝐒𝐡𝐚𝐧𝐞 𝐄𝐬𝐛𝐞𝐫, Manager, Information Systems in Aliso Viejo
𝐄𝐝𝐝𝐢𝐞 𝐌𝐮𝐧𝐢𝐳, Histotechnologist I, R&D - Lab Operations in RTP
𝐑𝐞𝐲𝐧𝐚𝐧𝐭𝐞 𝐂𝐚𝐲𝐚𝐧𝐚𝐧, Laboratory Technician III, Flow in Aliso Viejo -
NeoGenomics
@NeoGenomics
We’re looking forward to seeing you in Orlando, Florida, for the HealthTrust University Conference. From August 12-13, we’ll be sharing about oncology solutions at booth #1024.
-
NeoGenomics
@NeoGenomics
NeoGenomics is pleased to share a newly released lite paper, “Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor-Agnostic Era.”
Visit us online to learn more: neogenomics.com/informatics-data-solutions -
NeoGenomics
@NeoGenomics
Our very own Brittany Bell, was nominated as an ASCP 40 Under Forty Nominee which recognizes members under 40 for their leadership and achievements who are making an impact on pathology and laboratory medicine.
Please take a minute to vote for Brittany - criticalvalues.org/2024-40-under-forty-honorees -
NeoGenomics
@NeoGenomics
Protecting your skin can help prevent cancer. #summer is an important time to share tips that help protect against harmful UV rays. Help us spread education and embrace sun-safe habits.
#skincancerawareness #sunsafety #protectyourskin -
NeoGenomics
@NeoGenomics
NeoGenomics is a sponsor of ASCO Direct™ Hawaii! Make plans to come by our booth and learn about our oncology solutions for solid tumor patients, hematological cancers, and more. We’ll see you July 13 and 14 at the ‘Alohilani Resort Waikiki Beach in Honolulu, Hawaii.
-
NeoGenomics
@NeoGenomics
An FDA committee recently unanimously ruled that MRD is a viable endpoint for Multiple Myeloma clinical trials. Learn how the NeoGenomics Pharma Services team can support your #multiplemyeloma trials with our clinical-grade #mrd tests: neogenomics.com/pharma-services/lab-services/flow-cytometry
#flowcytometry -
NeoGenomics
@NeoGenomics
Summertime may be synonymous with spending time outdoors, but it’s important to take precautions. The Skin Cancer Foundation has tips and recommendations: www.skincancer.org/skin-cancer-prevention/
#neogenomics #skincancer #cancertesting -
NeoGenomics
@NeoGenomics
To all who celebrate, we hope your Fourth of July is filled with family, friends, and fun!
_
#lifeatneo #neospirit #oneneo -
NeoGenomics
@NeoGenomics
Premier Breakthroughs 24 takes place July 23-25 at the Gaylord National Resort & Convention Center in National Harbor, Maryland. We look forward to meeting you there!
-
NeoGenomics
@NeoGenomics
Data plays a vital role in precision oncology. Learn about NeoGenomics' real-world multi-modal data solutions: neogenomics.com/informatics-data-solutions
#neogenomics #informatics #rwd #fastfacts -
NeoGenomics
@NeoGenomics
Stay connected with PharmaConnect!
It is an exciting time for pharma and biotech at #neogenomics, and the best way to be up-to-date on our news, recent publications, and more is with our NeoGenomics Pharma Connect quarterly newsletter. Sign up today: neogenomics.com/pharma-services -
NeoGenomics
@NeoGenomics
ASCO Direct™ Salt Lake City is underway! We look forward to meeting with you today and tomorrow to discuss oncology solutions for your patients.
-
NeoGenomics
@NeoGenomics
Check out the latest episode of the Precision Medicine Podcast, featuring Trevor Maxwell, CEO of Man Up To Cancer, a non-profit that inspires men to connect and avoid isolation during their cancer journeys. This episode of the @PMPbyTrapelo focuses on #colorectalcancer (CRC).
The Precision Medicine Podcast by Trapelo
@PMPbyTrapelo
#asco24 plz stop by the #manuptocancer booth to tell Trevor and team they are doing an INCREDIBLE job in helping men find the support they need during cancer and also in spreading awareness for early onset #crc ! www.trapelohealth.com/colorectal-cancer-trevor-maxwell
-
NeoGenomics
@NeoGenomics
NeoGenomics is a sponsor of ASCO Direct™ Salt Lake City! Make plans to come by our booth and learn about our oncology solutions for solid tumor patients, hematological cancers, and more. We’ll see you June 22 and 23 at the Hyatt Regency Salt Lake City!
-
NeoGenomics
@NeoGenomics
𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: 𝐅𝐨𝐫𝐭 𝐌𝐲𝐞𝐫𝐬’ 𝐌𝐚𝐲𝐨𝐫 𝐓𝐨 𝐏𝐫𝐨𝐜𝐥𝐚𝐢𝐦 𝐉𝐮𝐧𝐞 𝐀𝐬 𝐍𝐞𝐨𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬’ 𝐂𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐓𝐨 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐧𝐭𝐡
Mayor Anderson will formally announce the proclamation on 6/17. Read more:
ir.neogenomics.com/news-events/press-releases/detail/268/… -
NeoGenomics
@NeoGenomics
#neogenomics, in partnership with the LGBTQ@Neo Employee Resource Group, was a proud sponsor of Naples Pride!
#pridemonth #pride2024 -
NeoGenomics
@NeoGenomics
We had an excellent time at Spatial Biology East Coast US 2024. Thank you to everyone who visited us.
#spatialbiologyec24 #ogomics -
NeoGenomics
@NeoGenomics
During the 2024 ASCO® Annual Meeting, we revealed our revitalized brand. We remain committed to the providers, pharmaceutical partners, and patients we serve. Choosing the right company for cancer testing is vital. As an industry leader in cancer diagnostics, therapy selection
This media couldn't be displayed. See it on the original post.
NeoGenomics
@NeoGenomics
and customer service excellence, we strive to ensure the best possible outcomes. 𝐖𝐡𝐞𝐧 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬, 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐰𝐡𝐨 𝐲𝐨𝐮 𝐚𝐬𝐤.
-
NeoGenomics
@NeoGenomics
Spatial Biology East Coast US 2024 begins tomorrow at the Hyatt Regency Boston. Visit #neogenomics today and tomorrow at booth #23.
#spatialbiologyec24 #ogomics -
NeoGenomics
@NeoGenomics
We are pleased to be sharing a presentation at Spatial Biology East Coast US 2024. Join us on Monday, June 10, from 11:05 am - 11:30 pm to hear Kirsteen Maclean, PhD, Principal Scientist.
#spatialbiologyec24 #ogomics #neogenomics #headandneckcancer #carcinoma
NeoGenomics
@NeoGenomics
She will be speaking during Track 3: Spatial Biology in Drug Discovery & Development, and her presentation is titled, ‘Spatial Organization and Gene Expression Changes Affected by Smoking in the Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.’
-
NeoGenomics
@NeoGenomics
Meet team members from the #neogenomics Informatics team! Data plays a vital role in precision medicine. NeoGenomics is committed to advancing cancer care with real-world multi-modal oncology data solutions.
NeoGenomics
@NeoGenomics
To learn more about how NeoGenomics has the scientific expertise and innovation to support pharma companies, visit: neogenomics.com/informatics-data-solutions
#informatics #oncology #neogenomics #rwd -
NeoGenomics
@NeoGenomics
If you snapped a picture at our Together Against Cancer photo wall, there’s still time to post to support @ConquerCancerFd. Upload your picture to your with #neogivesback. For each post, we will donate $25 (up to $10,000) toward Conquer Cancer®, the ASCO Foundation.
-
NeoGenomics
@NeoGenomics
Thank you to everyone who took part in the Together Against Cancer photo opportunity!
#neogivesback
Asis Shrestha, MD, FACP
@asis_shr
Together against cancer… Never give up !!! #asco24 #neogivesback @MujtabaNaqvi20
-
NeoGenomics
@NeoGenomics
We love seeing photos from the Together Against Cancer photo opportunity.
#neogivesback
Fatima Qadri MD
@qad_Fatima
-
NeoGenomics
@NeoGenomics
Thank you to everyone who participated in the photo opportunity during the 2024 ASCO® Annual Meeting.
Mamtha Balla, MD, MPH, FACP
@MamthaB
What an incredible experience at #asco24! Learning so much and having a blast! @ASCO @KolluVidya @hemeoncfellow @WimedicineOrg #neogivesback @IMG_Oncologists @HemOncWomenDocs
-
NeoGenomics
@NeoGenomics
NeoGenomics has a unique photo activity at booth #31093 during #asco24. For everyone who snaps a picture at our Together Against Cancer photo wall & posts it on their social media with #neogivesback, we will donate $25 (up to $10,000) toward Conquer Cancer®, the ASCO Foundation.
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Help us make a difference during #asco24:
· Visit booth #31093
· Take a photo at our Together Against Cancer photo wall
· Post with #neogivesback
For everyone who posts their photo with #neogivesback, we're donating $25 (up to $10,000) toward Conquer Cancer®, the ASCO Foundation.
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Have you scheduled a meeting? We can’t wait to meet with you during the 2024 ASCO® Annual Meeting. care.neogenomics.com/ASCO24
-
NeoGenomics
@NeoGenomics
Warren Stone, Chief Commercial Officer, and Chris Smith, CEO, at the 2024 ASCO® Annual Meeting! #neogenomics is exhibiting at booth #31093.
-
NeoGenomics
@NeoGenomics
“Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples,” is the title of new data that we are presenting at the 2024 ASCO® Annual Meeting. View it today, Monday, June 3, from 9 a.m-12 p.m.
-
NeoGenomics
@NeoGenomics
When it matters, it matters who you ask. Come inside booth #31093 and speak to experts in precision oncology.
-
NeoGenomics
@NeoGenomics
We’re at booth #31093, where we’re sharing about solutions for your solid tumor and hematological patients. Let’s meet to discuss enhancing your patient care: care.neogenomics.com/ASCO24
#asco24
NeoGenomics
@NeoGenomics
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
#neogenomics team members can’t wait to meet with you at booth #31093!
#asco24 -
NeoGenomics
@NeoGenomics
“Comparative analysis of actionable gene reporting in targeted panels versus comprehensive NGS testing for solid tumor samples,” is the title of new data that we are presenting at the 2024 ASCO® Annual Meeting.
-
NeoGenomics
@NeoGenomics
𝐖𝐡𝐞𝐧 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬, 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐰𝐡𝐨 𝐲𝐨𝐮 𝐚𝐬𝐤. When cancer leaves you and your patients in the dark, NeoGenomics is here to help light the way.
Our revitalized brand embodies the innovation and inspiration that fuels our mission to serve healthcare
NeoGenomics
@NeoGenomics
professionals and improve patient care. Learn more during the 2024 ASCO® Annual Meeting from June 1–3 at booth #31093.
#asco24 -
NeoGenomics
@NeoGenomics
NeoGenomics: A revitalized brand. Check it out during the 2024 ASCO® Annual Meeting at booth #31093.
care.neogenomics.com/ASCO24
#asco24 -
NeoGenomics
@NeoGenomics
𝐘𝐨𝐮𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐫𝐞 𝐮𝐧𝐢𝐪𝐮𝐞. 𝐒𝐨 𝐢𝐬 𝐭𝐡𝐞𝐢𝐫 𝐜𝐚𝐧𝐜𝐞𝐫.
During #braincancerawarenessmonth, we want to highlight the importance of genomic profiling for brain tumors.
The NeoTYPE® DNA & RNA – Brain profile can help you determine a prognosis,
NeoGenomics
@NeoGenomics
therapeutic decisions, and clinical trial options for your patients: neogenomics.com/test-menu/neotyper-dna-rna-brain
#neogenomics #braincancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
This testing program was designed to help reduce barriers to IHC testing
NeoGenomics
@NeoGenomics
for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients.
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx
NeoGenomics
@NeoGenomics
may indicate eligibility for treatment with the associated biomarker-driven therapy.
To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
At #asco24, we are thrilled to unveil the revitalized NeoGenomics brand, embodying the innovation and inspiration that fuels our mission to save lives by improving patient care. One patient at a time. Come check out our new look at booth #31093 from June 1–3.
-
NeoGenomics
@NeoGenomics
(1/3) Join us in congratulating our 2023 Quill Award recipient, Qingyan (Sandy) Au, PhD!
This annual award encourages and celebrates noteworthy contributions to the oncology community. Each year, it is given to a NeoGenomics team member with prolific authorship and a strong
NeoGenomics
@NeoGenomics
(2/3) focus on innovation within their groundbreaking publications. Sandy Au, who is the Principal Scientist, Senior Director of Multiplexing Operations on our Pharma Team, presented many publications at AACR, SITC, and more and was one of the authors of a timely paper on
NeoGenomics
@NeoGenomics
(3/3) Antitumor Immune Responses in DLBCL, which Clinical Cancer Research noted as a significant contribution.
-
NeoGenomics
@NeoGenomics
You won’t want to miss this during the 2024 ASCO® Annual Meeting. We are hosting a unique photo opportunity where you can take a fun picture for a good cause. For everyone who snaps a picture and posts it on their social media with #neogivesback, we will be donating
NeoGenomics
@NeoGenomics
$25 (up to $10,000) toward Conquer Cancer®, the ASCO Foundation.
Come by and help us raise funds that support their mission of accelerating breakthroughs in lifesaving research and empowering people everywhere to conquer cancer.
#asco24 -
NeoGenomics
@NeoGenomics
𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐬𝐤𝐢𝐧 𝐜𝐚𝐧 𝐡𝐞𝐥𝐩 𝐩𝐫𝐞𝐯𝐞𝐧𝐭 𝐜𝐚𝐧𝐜𝐞𝐫. #skincancerawarenessmonth is a time to share tips that help protect against harmful UV rays. Help us spread education and embrace sun-safe habits.
#skincancerawareness #sunsafety #protectyourskin
NeoGenomics
@NeoGenomics
Reference: www.cdc.gov/cancer/skin/basic_info/sun-safety.htm
-
NeoGenomics
@NeoGenomics
This Memorial Day, we remember and honor all those who made the ultimate sacrifice for our country. Join us in taking a moment to reflect on their legacy and express our deepest gratitude.
#memorialday #memorialday24 -
NeoGenomics
@NeoGenomics
The number of Americans being diagnosed with melanoma is rapidly increasing each year. Almost 100,000 new cases of invasive melanoma were diagnosed last year¹. For those whose melanoma has spread or can't be removed completely, targeted therapies, such as BRAF and MEK inhibitors²
NeoGenomics
@NeoGenomics
are potential treatment options.
.
.
.
seer.cancer.gov/statfacts/html/melan.html
www.ncbi.nlm.nih.gov/pmc/articles/PMC9038522/
www.mycancergenome.org/content/gene/braf/ -
NeoGenomics
@NeoGenomics
We're excited to share that we are the first company to ever receive the Lee Health Partners in Wellness Award. This program recognizes organizations that provide resources to promote healthy outcomes, like preventative screenings, wellness education, & chronic disease programs.
-
NeoGenomics
@NeoGenomics
Artificial intelligence is starting to play an important role in healthcare, but how is it impacting oncology?
Join us today for “How AI is Advancing Cancer Patient Outcomes.” Register now: webinar.datavant.com/datavant/How-AI-is-Advancing-Cancer-… -
NeoGenomics
@NeoGenomics
𝐒𝐞𝐞 𝐲𝐨𝐮 𝐢𝐧 𝐂𝐡𝐢𝐜𝐚𝐠𝐨! We can’t wait to meet you May 31 – June 4 at the 2024 ASCO® Annual Meeting. Stop by our exhibit booth #31093, or book a meeting with us here: care.neogenomics.com/ASCO24
#asco24 -
NeoGenomics
@NeoGenomics
May 19 is #worldbakingday! Today, we’re spotlighting Amanda Collins, a NeoGenomics Client Success Specialist, who competed on the Greatest Baker, presented by Buddy Valastro. It benefits The Andrew McDonough B+ (Be Positive) Foundation, which supports children fighting cancer.
-
NeoGenomics
@NeoGenomics
Biomarkers play a critical role in diagnosis and therapy selection for brain cancer patients. Mutations in IDH1, IDH2, and BRAF, MGMT promoter, H3K27 methylation, and 1p/19q co-deletion status are a few important markers affiliated with brain cancer that NeoGenomics can test for.
NeoGenomics
@NeoGenomics
Data plays a vital role in precision oncology. To learn more about how NeoGenomics has the scientific expertise and innovation to support pharma companies, we invite you to visit: neogenomics.com/informatics-data-solutions
-
NeoGenomics
@NeoGenomics
If you’re attending Spatial Biology East Coast US 2024, come see us at booth #23. We’re looking forward to meeting you June 10-11 at the Hyatt Regency Boston.
#spatialbiologyec24 #ogomics -
NeoGenomics
@NeoGenomics
#womenshealthweek may be drawing to a close – but women’s health should remain a topic all year long. Help us spread the word about statistics and screening recommendations from the American Cancer Society.
www.cancer.org/cancer/screening/american-cancer-society-g… -
NeoGenomics
@NeoGenomics
#womenshealthweek stands to encourage and empower women to make their health a priority. The 2024 theme centers around supporting women to take charge of their health journeys and spotlights health issues.
NeoGenomics
@NeoGenomics
The CDC shared this blog about how taking care of yourself includes physical, mental, social, and emotional health: www.cdc.gov/healthequity/features/nwhw/index.html
-
NeoGenomics
@NeoGenomics
Nearly 𝟓𝟎% 𝐨𝐟 𝐔.𝐒. 𝐰𝐨𝐦𝐞𝐧 skipped preventative healthcare appointments in the last 12 months. It shines a concerning light on the impact that not receiving routine healthcare services can potentially make in the detection of cancer.
www.health.com/womens-annual-checkups-important-7229213
NeoGenomics
@NeoGenomics
#womenshealthweek is a reminder to make your health a priority and speak to your doctor about screenings and what’s right for you.
#nationalwomenshealthweek #womenshealth #healthcare -
NeoGenomics
@NeoGenomics
Meet Lisa, Melody, and Dana. These amazing, special women are cancer survivors.
It is National Women’s Health Week, a time to promote awareness of health issues and topics and encourage women to prioritize their health. It’s also a time to spotlight women – and we are proud to
NeoGenomics
@NeoGenomics
introduce you to these three incredible ladies at #neogenomics. We celebrate the strength and courage of our employees who triumph over cancer and inspire us every day.
Follow @NeoGenomics all week long, where we’ll be sharing information and resources dedicated to #womenshealth.
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Happy #mothersday! We are celebrating each and every one of the amazing women who inspire us with their boundless love, patience, dedication and wisdom. We are so proud to support mothers at NeoGenomics, from lactation rooms to gifts for new mothers.
#lifeatneo #mothersday2024 -
NeoGenomics
@NeoGenomics
“How AI is Advancing Cancer Patient Outcomes” is May 21, at 12 pm CST. Lindsey Gasparini, Vice President, Informatics, NeoGenomics; Jeff Elton, CEO, ConcertAI; Alan Ma, Customer Success, Datavant will be discussing how artificial intelligence has the potential to impact oncology.
NeoGenomics
@NeoGenomics
Register here: webinar.datavant.com/datavant/How-AI-is-Advancing-Cancer-…
-
NeoGenomics
@NeoGenomics
In collaboration with our Women&Allies@Neo Employee Resource Group, we are proud to host the @DFS_SWFL Dress for Success SW Florida Women Empowered Through Employment Series at the #neogenomics headquarters in Fort Myers, Florida.
NeoGenomics
@NeoGenomics
Having a positive impact on our local communities is essential to NeoGenomics, and we are pleased to support this organization. To learn more about the SWFL Dress for Success program, please visit: swflorida.dressforsuccess.org
#dressforsuccessswfl -
NeoGenomics
@NeoGenomics
How does artificial intelligence have the potential to affect oncology? Hear a panel of experts discuss “How AI is Advancing Cancer Patient Outcomes” on Tuesday, May 21, at 12 pm CST.
To learn more and to register, please visit: webinar.datavant.com/datavant/How-AI-is-Advancing-Cancer-… -
NeoGenomics
@NeoGenomics
Meet some Patient Support Team members!
NeoGenomics takes cancer personally; every person is unique, and we believe in walking hand-in-hand with you and your care team during your personal cancer experience.
neogenomics.com/patients
#neogenomics #patientcare #empowerment -
NeoGenomics
@NeoGenomics
NeoGenomics is pleased to share a newly released lite paper, “Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor-Agnostic Era.”
Visit us online to learn more: neogenomics.com/informatics-data-solutions -
NeoGenomics
@NeoGenomics
We had a blast at the Partners in Care 2024 Annual Head & Neck 10K and 5K Run/2-Mile Walk at Jaycee Park in Cape Coral, FL. We enjoyed meeting everyone who visited our table!
-
NeoGenomics
@NeoGenomics
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.
-
NeoGenomics
@NeoGenomics
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.
-
NeoGenomics
@NeoGenomics
The 14th Clinical Biomarkers & CDx Europe took place at the Millennium Gloucester Hotel in Kensington, London. We enjoyed meeting everyone who visited us – thank you for stopping by!
-
NeoGenomics
@NeoGenomics
#flashbackfriday to last week's #labweek24 festivities! We loved celebrating our team with fun, food and more.
Want to join in on the fun? Apply today: jobs.jobvite.com/neogenomics
#fbf #lifeatneo #neospirit #workatneo -
NeoGenomics
@NeoGenomics
April is #volunteermonth! We're passionate about giving back and want to take a moment to honor Neo employees who volunteer with nonprofit organizations, events, & more. These are pictures from NeoGREEN beach clean-ups, the Relay for Life of Greater Lee County, & more.
NeoGenomics
@NeoGenomics
Want to join a company with a culture that extends far beyond the walls of the laboratory? Apply today: jobs.jobvite.com/neogenomics #nationalvolunteermonth #volunteer #lifeatneo #neospirit
-
NeoGenomics
@NeoGenomics
Multiple studies associate an HPV-positive status with an improved prognosis¹ for head and neck cancer (HNSCC) patients. Our data shows that 41% of HNSCC patients tested at NeoGenomics were HPV-positive.
Post not available here, view on X
NeoGenomics
@NeoGenomics
(1/2)
1: Aggarwal N, Yadav J, Thakur K, Bibban R, Chhokar A, Tripathi T, Bhat A, Singh T, Jadli M, Singh U, Kashyap MK, Bharti AC. Human Papillomavirus Infection in Head and Neck Squamous Cell Carcinomas: Transcriptional Triggers and Changed Disease Patterns.
NeoGenomics
@NeoGenomics
(2/2) Front Cell Infect Microbiol. 2020 Dec 2;10:537650.
-
NeoGenomics
@NeoGenomics
Join us in sharing facts and spreading awareness during #testicularcancerawarenessmonth.
Screenings and early detection are crucial. Speak with your doctor about what’s right for you.
#testicularcancerawareness #cancertesting -
NeoGenomics
@NeoGenomics
Today is National DNA Day! #dnaday24 celebrates the power of genetics and genomics.
Visit genome.gov/dna-day to learn more or see what activities are happening near you! -
NeoGenomics
@NeoGenomics
(1/3) April is head and neck cancer awareness month. The scientific team at NeoGenomics is committed to helping advance #headneckcancer research.
We recently presented new data at this year’s #aacr2024 conference looking at differences in spatial organization and gene
NeoGenomics
@NeoGenomics
(2/3) expression changes across the tumor microenvironment between smokers and non-smokers with oral squamous cell carcinoma (OSCC), the most common form of head and neck cancer. The study revealed that tumors from non-smokers are distinct and have a more immunogenic tumor
NeoGenomics
@NeoGenomics
microenvironment which may help improve treatment of OSCC in non-smokers. Visit us online to learn more: neogenomics.com/sites/default/files/literature/AACR-2024-…
#hnscc #oscc #tme #tumormicroenvironment #spatialbiology #multiomyx #geneexpression #nanostring #io360 -
NeoGenomics
@NeoGenomics
The 14th Clinical Biomarkers & CDx Europe is underway at the Millennium Gloucester Hotel in Kensington, London. Join NeoGenomics for “Liquid Biopsy Testing in Oncology, Perspectives on Comprehensive Genomic Profiling Testing,” presented by Greg Jones, on Thur., 4/25, 4:30–5 p.m.
-
NeoGenomics
@NeoGenomics
(1/2) Today is #earthday! #neogenomics has many employee resource groups. One is NeoGREEN@, whose members explore environmental sustainability opportunities that contribute to our Neo culture and global responsibilities. NeoGenomics is committed to upholding sustainable solutions
NeoGenomics
@NeoGenomics
(2/2) that build trust with our employees, clients, and stakeholders. We strive to minimize our environmental impact to benefit the global communities where we operate.
NeoGenomics
@NeoGenomics
Want to join a company with a culture that extends far beyond the walls of the laboratory? Apply today: jobs.jobvite.com/neogenomics
#lifeatneo #workatneo #neospirit -
NeoGenomics
@NeoGenomics
The 49th Annual ONS Congress is just around the corner – and we can’t wait to see you there! Come visit us from April 25-27 at booth #5090.
#onscongress -
NeoGenomics
@NeoGenomics
It has been an incredible #labweek24 here at #neogenomics. We had a blast with games, activities, sweets, and treats all week long. These were some fun ways to say 𝐭𝐡𝐚𝐧𝐤 𝐲𝐨𝐮 to our outstanding Neo colleagues.
#nationallabweek #labweek #lifeatneo #neospirit #workatneo
NeoGenomics
@NeoGenomics
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
Lab Week celebrations continue to "pop" off at #neogenomics! We are having a blast celebrating our Neo teammates with food, fun and festivities.
#labweek24 #nationallabweek #labweekThis media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
#labweek24 festivities are in full swing! Neo teammates played 𝐞𝐠𝐠cellent and 𝐩𝐢𝐞lightful games. Continue to follow us every day to see how we're celebrating "more in '24"!
#lifeatneo #workatneo #neospirit #labweek #nationallabweekThis media couldn't be displayed. See it on the original post. -
NeoGenomics
@NeoGenomics
Our Lab Week 2024 festivities continued today with #neospirit day! From costumes to photo ops, our teams had fun while showing their NeoGenomics pride.
#labweek24 #nationallabweek #labweek
NeoGenomics
@NeoGenomics
NeoGenomics
@NeoGenomics
-
NeoGenomics
@NeoGenomics
#neogenomics will be attending the ONCare Alliance Spring 2024 National Leadership Summit! This event takes place at The Wigwam in Phoenix, AZ, from April 17-18. If you are attending, be sure to stop by and say hello to our NeoGenomics colleagues.
-
NeoGenomics
@NeoGenomics
Capturing smiles, one caricature at a time! Today's #labweek24 celebrations featured custom caricature portraits, sweet treats, and more. It's just one of the fun ways we are saying thank you to our outstanding Neo colleagues this week.
#lifeatneo #neospirit #workatneo #labweek
NeoGenomics
@NeoGenomics
Check back in tomorrow to see how our "celebrating more in '24" Lab Week festivities continue!
-
NeoGenomics
@NeoGenomics
It is Lab Week! We are looking forward to a week with our Neo teammates that will be filled with fun, friends, and food. Follow us all week long for a closer look at how we are celebrating "more in '24"!
#nationallabweek #labweek24 #neogenomics #lifeatneo #neospirit #workatneo -
NeoGenomics
@NeoGenomics
(1/2) Did you know that diagnosing paroxysmal nocturnal hemoglobinuria (PNH) can take 2-5 years on average? Diagnosing PNH can be challenging. A patient’s clinical presentation is often subtle, with nonspecific symptoms that can be easily misdiagnosed. However, a recently
NeoGenomics
@NeoGenomics
approved therapy is giving new hope for PNH patients. This is explored in our new lite paper, “Paroxysmal Nocturnal Hemoglobinuria: The Current Testing Landscape and Emerging Therapies.” Visit us online to read: neogenomics.com/informatics-data-solutions
-
NeoGenomics
@NeoGenomics
It was an outstanding week at the American Association for Cancer Research® (AACR) Annual Meeting 2024. We enjoyed meeting with attendees at our booth and want to thank everyone who visited us and attended our Exhibitor Spotlight Theater. See you next year!
#aacr24 #neogenomics
NeoGenomics
@NeoGenomics
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association
NeoGenomics
@NeoGenomics
for Cancer Research; (AACR®).
-
NeoGenomics
@NeoGenomics
It was an outstanding week at the American Association for Cancer Research® (AACR) Annual Meeting 2024. We enjoyed meeting with attendees at our booth and want to thank everyone who visited us.
-
NeoGenomics
@NeoGenomics
(1/2) An article in Nature Medicine featured a publication from groups at Kite/Gilead, Moffitt Cancer Center, and collaborators.
The study used NeoGenomics’ validated nCounter® PanCancer IO 360™ Panel on samples from patients with large B cell lymphoma to examine the association
NeoGenomics
@NeoGenomics
(2/2) between pre-treatment tumor characteristics and the efficacy of their novel anti-CD19 CAR-T cell therapy versus standard of care. To view this publication, visit: pubmed.ncbi.nlm.nih.gov/38233586/
#nanostring #io360 #cancerimmunotherapy -
NeoGenomics
@NeoGenomics
The American Association for Cancer Research® (AACR) Annual Meeting 2024 is underway at the San Diego Convention Center! We are:
· Exhibiting at booth #915
· Hosting an Exhibitor Spotlight Theater today
· Presenting 10 posters
To learn more, visit: care.neogenomics.com/aacr-2024 -
NeoGenomics reposted
NeoGenomics
@NeoGenomics
Don’t miss our Exhibitor Spotlight Theater during the American Association for Cancer Research® (AACR) Annual Meeting 2024. "Next-Generation Solutions in Drug Development: How NeoGenomics can Streamline Translational Medicine from Discovery to the Clinic" is 4/8 at 12:30 p.m.
-
NeoGenomics
@NeoGenomics
As the Community Oncology Conference draws to a close, we want to thank everyone who visited us during this fantastic event.
-
NeoGenomics
@NeoGenomics
NeoGenomics colleagues at the Community Oncology Conference! We appreciated meeting you and talking about how NeoGenomics can advance your patient care! #coa2024
-
NeoGenomics
@NeoGenomics
Don’t miss our Exhibitor Spotlight Theater during the American Association for Cancer Research® (AACR) Annual Meeting 2024. "Next-Generation Solutions in Drug Development: How NeoGenomics can Streamline Translational Medicine from Discovery to the Clinic" is 4/8 at 12:30 p.m.
NeoGenomics
@NeoGenomics
on the second floor of the Sails Pavilion, in Spotlight Theater E.
.
.
.
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those
NeoGenomics
@NeoGenomics
of the sponsor or presenter and are not of the American Association for Cancer Research; (AACR®).
-
NeoGenomics
@NeoGenomics
The 14th Clinical Biomarkers & CDx Europe takes place April 23-25 at the Millennium Gloucester Hotel in Kensington, London. NeoGenomics colleagues will be attending, and can’t wait to meet you.
-
NeoGenomics
@NeoGenomics
The Community Oncology Conference begins today! NeoGenomics is exhibiting at booth #226.
#coa2024 #orlando #conference #neogenomics -
NeoGenomics
@NeoGenomics
Don’t miss our Exhibitor Spotlight Theater during the American Association for Cancer Research® (AACR) Annual Meeting 2024. It takes place on Monday, April 8, at 12:30 p.m. on the second floor of the Sails Pavilion, in Spotlight Theater E.
Post not available here, view on X
NeoGenomics
@NeoGenomics
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the
NeoGenomics
@NeoGenomics
American Association for Cancer Research® (AACR).
-
NeoGenomics
@NeoGenomics
NeoGenomics is thrilled to be sharing posters at the American Association for Cancer Research® (AACR) Annual Meeting 2024. We’re proud to showcase our research in precision medicine, cancer testing, and more.
To learn more, please visit: ir.neogenomics.com/news-events/press-releases/detail/263/… -
NeoGenomics
@NeoGenomics
Last week, the #neogenomics Headquarters in Fort Myers, Florida, hosted the Relay for Life of Greater Lee.
#neospirit #lifeatneo
NeoGenomics
@NeoGenomics
Our partnership with Relay for Life of Greater Lee is the perfect fit – bridging cancer survivors and lab team members together both fighting for the same outcome. Want to work with NeoGenomics in our fight against cancer? Apply today: jobs.jobvite.com/neogenomics
#workatneo -
NeoGenomics
@NeoGenomics
On this #nationaldoctorsday, we are taking a moment to say thank you.
To all of our NeoGenomics physicians – working at #neogenomics is where passion meets purpose – and your dedication and expertise help bring to life our mission of improving patient care.
#doctorsday2024 -
NeoGenomics
@NeoGenomics
In honor of #nationalkidneymonth, we're spotlighting a testing solution for when your patient’s tissue is insufficient, unavailable, or not practical to obtain. Learn more about the NeoLAB® Solid Tumor Liquid Biopsy: neogenomics.com/test-menu/neolabr-solid-tumor-liquid-biopsy
#kidneycancer #cancertesting -
NeoGenomics
@NeoGenomics
NeoGenomics is thrilled to be sharing posters at the American Association for Cancer Research® (AACR) Annual Meeting 2024. We’re proud to showcase our research in precision medicine, cancer testing, and more. To learn more, please visit: ir.neogenomics.com/news-events/press-releases/detail/263/…
-
NeoGenomics
@NeoGenomics
We're pleased to share a picture of NeoGenomics colleagues at USCAP. We invite attendees to visit us at booth #1017 to learn about our broad and targeted NGS profiling options, services, and more.
#uscap2024 #neogenomics -
NeoGenomics
@NeoGenomics
USCAP has begun at the Baltimore Convention Center!
Come see us from March 25-27 at booth #1017, where we will be sharing information about our broad and targeted NGS profiling options, services, and more.
#uscap2024 -
NeoGenomics
@NeoGenomics
We enjoyed meeting you during the 2024 SGO Annual Meeting on Women’s Cancer, which took place at the San Diego Convention Center. Thank you to everyone who visited us.
#sgomtg #neogenomics -
NeoGenomics
@NeoGenomics
Come see us March 25-27 during #uscap2024 at booth #1017, where we will be sharing information about our broad and targeted NGS profiling options, services, and more.
-
NeoGenomics
@NeoGenomics
𝗝𝗼𝗶𝗻 𝘂𝘀 in showing support and spreading awareness about #multiplemyeloma this March.
#multiplemyelomaawarenessmonth #neogenomics #patientcare
.
.
.
Source: www.cancer.org/cancer/types/multiple-myeloma/about/key-st… -
NeoGenomics
@NeoGenomics
NeoGenomics is proud to share our inaugural ESG (Environmental, Social, and Governance) report. This comprehensive document highlights Neo's commitment to environmental stewardship, corporate social responsibility, and ethical governance practices for the benefit of all
NeoGenomics
@NeoGenomics
stakeholders. It's an exciting milestone to underscore our dedication to transparency and making a positive impact on our people and in our communities, and provides a roadmap for our journey toward a more sustainable and socially conscious future.
NeoGenomics
@NeoGenomics
Read online: ir.neogenomics.com/corporate-governance/esg-report
-
NeoGenomics
@NeoGenomics
Kidney cancer symptoms could be unnoticed for years, making it extremely important to speak with your physician about testing and what’s right for you.
#kidneycancer #neogenomics #cancertesting
.
.
.
Sources:
www.cancer.org/cancer/types/kidney-cancer/about/key-stati…
www.cancer.org/cancer/types/kidney-cancer/detection-diagn… -
NeoGenomics
@NeoGenomics
Anna Juncker-Jensen, NeoGenomics’ Senior Director, Head of Scientific Affairs is presenting a poster at The Keystone Symposia on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance.
-
NeoGenomics
@NeoGenomics
Patient Safety Awareness Week (PSAW) is March 10–16, NeoGenomics is proud to offer site location testing services or in-home blood draws for liquid biopsy assays through our national mobile phlebotomy program.
#patientsafetyawarenessweek #neogenomics #phlebotomy
NeoGenomics
@NeoGenomics
Our national mobile phlebotomy program provides safe and convenient specimen collection by licensed phlebotomists for liquid biopsy with no added costs for patients. Learn more: neogenomics.com/patients/mobile-phlebotomy
-
NeoGenomics
@NeoGenomics
The American Association for Cancer Research® (AACR) Annual Meeting 2024 will take place at the San Diego Convention Center from April 7-10, where we’ll be exhibiting at booth #915. 📅 Save the date – on Monday, April 8, we invite you to join us for an Exhibitor Spotlight Theater
Post not available here, view on X
NeoGenomics
@NeoGenomics
This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association
NeoGenomics
@NeoGenomics
for Cancer Research® (AACR).
-
NeoGenomics
@NeoGenomics
We are proud to share that the College of American Pathologists has granted Inivata Ltd., a subsidiary of NeoGenomics Laboratories, the Certificate of ISO 15189 Accreditation for the Babraham, Cambridge facility.
-
NeoGenomics
@NeoGenomics
Anna Juncker-Jensen, NeoGenomics’ Senior Director, Head of Scientific Affairs will be presenting at The Keystone Symposia on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, on March 18.
#neogenomics #cancer #immunotherapy -
NeoGenomics
@NeoGenomics
Come see us April 4 - 5 at the Community Oncology Conference! The show takes place at the Hilton Orlando, and we will be exhibiting at booth #226. #coa2024
-
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for
NeoGenomics
@NeoGenomics
novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may
NeoGenomics
@NeoGenomics
indicate eligibility for treatment with the associated biomarker-driven therapy.
To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
Around 35% of ovarian cancer patients are expected to be positive for folate receptor alpha (FRα)1, meaning over a third of people with advanced ovarian cancer may have a different treatment option.
Testing for FRα expression is performed using the FDA-approved
NeoGenomics
@NeoGenomics
immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. Learn more about the FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma: neogenomics.com/test-menu/folr1-fda-elaheretm-ovarian-car…
NeoGenomics
@NeoGenomics
1: Matulonis UA, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445. PMID: 36716407
-
NeoGenomics
@NeoGenomics
We can’t wait to be exhibiting again at #uscap2024. From March 25-27, visit #neogenomics at booth #1017.
-
NeoGenomics
@NeoGenomics
Today’s #testmenuspotlight is on Neo Comprehensive™ – Solid Tumor. It is a broad, next-generation sequencing panel for pan-solid tumor indications.
Complete gene list: neogenomics.com/test-menu/neo-comprehensive-solid-tumor
For requisition forms: neogenomics.com/diagnostic-services/specialty-testing/neo…
#neogenomics #cancertesting #oncology -
NeoGenomics
@NeoGenomics
We've embarked on a transformative collaboration with ConcertAI, a leader in EMR and RWD. This collaboration is set to revolutionize how we approach hematological malignancies, combining the strength of ConcertAI's extensive longitudinal clinical data with NeoGenomics'
NeoGenomics
@NeoGenomics
comprehensive biomarkers derived from hundreds of specialized hematological tests. Join thought leaders Derek Lyle, MD, Chief Medical Officer of NeoGenomics; Lindsey Gasparini, Vice President, Informatics of NeoGenomics; and Claudio D’Ambrosio, Chief Revenue Officer of ConcertAI
NeoGenomics
@NeoGenomics
in a dynamic discussion about the potential of this collaboration: neogenomics.com/informatics-data-solutions
-
NeoGenomics
@NeoGenomics
February is National Gallbladder and Bile Duct Cancer Awareness Month. Though a rarer cancer, it is commonly found in later stages or after it has metastasized*, which can make it a very deadly disease. It’s especially important to bring attention to these less common cancers
NeoGenomics
@NeoGenomics
because more than 12,000 Americans* are expected to be diagnosed with gallbladder and bile duct cancer this year.
These #gallbladdercancer and #bileductcancer facts were derived exclusively from #neogenomics data.
*www.cancer.org/cancer/types/gallbladder-cancer/about/key-…; -
NeoGenomics
@NeoGenomics
1 in 2 men and 1 in 3 women will be diagnosed with cancer in their lifetime¹. The prevalence of cancer is extremely personal to us - 73% of NeoGenomics employees have reported that they’ve been impacted by cancer.
1: National Cancer Institute: www.cancer.gov/about-cancer/understanding/statisticsPost not available here, view on X -
NeoGenomics
@NeoGenomics
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.
NeoGenomics
@NeoGenomics
Visit us online to learn more about the FOLR1 FDA (ELAHERE™) for Ovarian Carcinoma: neogenomics.com/test-menu/folr1-fda-elaheretm-ovarian-car…
-
NeoGenomics
@NeoGenomics
Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance takes place from March 17-20 at the Fairmont Chateau Whistler in British Columbia, Canada.
-
NeoGenomics
@NeoGenomics
The 2024 SGO Annual Meeting on Women’s Cancer runs from March 16-18 at the San Diego Convention Center. Visit us during the event at booth #419.
We can’t wait to see you in San Diego! -
NeoGenomics
@NeoGenomics
It is estimated that over 12,000 people will be diagnosed with gallbladder and bile duct cancer this year¹. Gallbladder and Bile Duct Cancer Awareness Month is here, and it is an important reminder to speak with your physician about what screenings and tests may be right for you.
-
NeoGenomics
@NeoGenomics
Looking for something to read? Check out the library of blogs on our website: neogenomics.com/newsroom/blog. You can search by topic or keyword, such as 'KRAS' or 'next-generation sequencing.’
#neogenomics #blog -
NeoGenomics
@NeoGenomics
We believe that patient care isn’t just done within the lab, and we’re passionate about ways we can support patients of all ages. @cheeriodicals facilitated a #neogenomics teambuilding exercise, in which Neo employees packed 100 “cheer kits” for pediatric patients at the
NeoGenomics
@NeoGenomics
Children's Hospital of Orange County @chocchildrens. These kits were full of toys, games, activity books, and a personalized note from a NeoGenomics team member. Our mission is at the heart of each Neo employee, and it warmed our hearts to participate in this memorable activity.
-
NeoGenomics
@NeoGenomics
Today is the big game, and it has us thinking about how oncology is a team sport. It's a subject discussed by Dr. Derek Lyle, NeoGenomics' Chief Medical Officer, and Dr. Hatim Husain in this video: neogenomics.com/newsroom/videos/breakroom-video-series-ep…
#superbowl #superbowl2024 #superbowlsunday #neogenomics -
NeoGenomics
@NeoGenomics
Congratulations to Jennifer Humphrey, Territory Business Manager, who was awarded TBM of the Year; Michael Gatto, Oncology Sales Specialist, who was awarded OSS of the Year; and Betty Clauss, Regional Director, who received RD of the Year during our Global Sales Meeting!
NeoGenomics
@NeoGenomics
We have a saying that working at NeoGenomics is where passion meets purpose, and we’re so proud of how our Neo colleagues are helping empower physicians with cancer testing to provide the best possible care for their patients.
-
NeoGenomics
@NeoGenomics
#icymi NeoGenomics announced that the company has signed the Working with Cancer Pledge. By taking the pledge, NeoGenomics demonstrates its commitment to supporting team members living with or caring for a loved one with cancer. To learn more, visit: ir.neogenomics.com/press-releases/detail/259/neogenomics-…
NeoGenomics
@NeoGenomics
#neogenomics #workingwithcancer #oncology #patientcare
1: British Journal of Cancer and International Agency for Research on Cancer (IARC) - Est number of new cases. all cancers, sexes, ages (2020
2: National Cancer Institute, www.cancer.gov/about-cancer/understanding/statistics
3: Publicis Custom Research -
NeoGenomics
@NeoGenomics
Neo Comprehensive™ - Myeloid Disorders utilizes next-generation sequencing (NGS) to detect alterations in 164 genes known to drive a spectrum of myeloid diseases. To learn more, please visit: neogenomics.com/test-menu/neo-comprehensivetm-myeloid-dis…
#myeloid #cancertesting #oncology -
NeoGenomics
@NeoGenomics
Today is World Cancer Day. This international, annual observance seeks to raise cancer awareness, encourage cancer testing and more. #worldcancerday is a special observance at #neogenomics, where our mission is to save lives by improving patient care.
-
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
This testing program was designed to help reduce barriers to IHC testingPost not available here, view on X
NeoGenomics
@NeoGenomics
References
-www.cdc.gov/cancer/ovarian/statistics/index.htm.
-www.cancer.gov/publications/dictionaries/cancer-terms/def….
-Chen CI, et al. Technol Cancer Res Treat, 2022 Jan-Dec. PMID 36426547. -Matulonis UA, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum
NeoGenomics
@NeoGenomics
-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445. PMID: 36716407
-
NeoGenomics
@NeoGenomics
(1/2) January is Thyroid Awareness Month. Join us in spreading education about thyroid cancer, which is estimated to be diagnosed in more than 43,000 people each year.
This infographic, derived exclusively from NeoGenomics data, shares insights about the disease – and underscores
NeoGenomics
@NeoGenomics
(2/2) the importance of precision medicine. Equipping physicians and pharmaceutical partners with cancer tests that enable precision medicine can unlock targeted treatment options for patients.
#neogenomics #thyroidawarenessmonth #thyroidcancer #cancertesting
NeoGenomics
@NeoGenomics
Sources: 1= American Cancer Society; 2= NeoGenomics Data
-
NeoGenomics
@NeoGenomics
Neo Comprehensive™ – Solid Tumor is a one-stop solution for accurate, comprehensive genomic profiling. To learn more, visit us online: neogenomics.com/diagnostic-services/specialty-testing/neo….
-
NeoGenomics
@NeoGenomics
NeoGenomics announced that the company has signed the Working with Cancer Pledge. By taking the pledge, NeoGenomics demonstrates its commitment to supporting team members living with or caring for a loved one with cancer. Read the press release here:
ir.neogenomics.com/press-releases/detail/259/neogenomics-… -
NeoGenomics
@NeoGenomics
NeoGenomics is pleased to share a newly released lite paper, “Examining RET Fusions: How Real-World Data (RWD) can be used to support a Tumor-Agnostic Era.” Visit us online to learn more: neogenomics.com/informatics-data-solutions
-
NeoGenomics
@NeoGenomics
#neogenomics proudly offers a comprehensive portfolio of more than 500 diagnostic tests covering all key testing methodologies – including broad-panel DNA and RNA-based next-generation sequencing. Browse our test menu online: neogenomics.com/test-menu.
#cancertesting #oncology -
NeoGenomics
@NeoGenomics
NeoGenomics’ Chief Medical Officer, Dr. Derek Lyle, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management in this podcast: soundcloud.com/modernmedicine-network/biomarker-testing-a…
-
NeoGenomics
@NeoGenomics
We are pleased to share a picture of Courtney Todorov, NeoGenomics' Senior Scientist, Scientific Manager, presenting at the 2nd Annual Spatial Biology for Immuno-Oncology Summit, which took place last week at The Westin San Diego Bayview.
-
NeoGenomics
@NeoGenomics
(1/4) NeoGenomics won a Platinum Design Award for NeoAccess™, an online ordering platform for oncologists. DotCOMM, an international competition honoring excellence in web creativity and digital communication, recognized the precision oncology platform for its user-friendly
Post not available here, view on X
NeoGenomics
@NeoGenomics
(3/4) menu. Oncologists who use NeoAccess can also check patient benefits and estimate out-of-pocket costs in real-time. NeoGenomics is proud to be recognized for its innovative new platform. We invite you to learn more about NeoAccess and request a demo to see
NeoGenomics
@NeoGenomics
(4/4) how it is helping advance precision oncology testing: neogenomics.com/diagnostic-services/technology-solutions/…
-
NeoGenomics
@NeoGenomics
The American Cancer Society estimates that more than 13,000 new cases of invasive cervical cancer will be diagnosed this year. During #cervicalcancerawarenessmonth, join #neogenomics in raising awareness about the importance of cancer screenings and early detection.
-
NeoGenomics
@NeoGenomics
Thank you to everyone who visited us at The Precision Medicine World Conference at the Santa Clara Convention Center, and attended our presentation by Harry Nunns, Senior Scientist and Scientific Manager at NeoGenomics.
#pmwc24 -
NeoGenomics
@NeoGenomics
Thank you to everyone who visited us at the 2nd Annual Spatial Biology for Immuno-Oncology Summit and attended our Program Partner Presentation.
-
NeoGenomics
@NeoGenomics
NeoGenomics is a bronze sponsor of The Precision Medicine World Conference. Harry Nunns, Senior Scientist and Scientific Manager at NeoGenomics, will present “High-throughput interrogation of the tumor microenvironment using digital image analysis” today, 1/25, from 1:15–1:30 pm.
-
NeoGenomics
@NeoGenomics
(1/2) NeoGenomics is exhibiting at the 2nd Annual Spatial Biology for Immuno-Oncology Summit, which kicked off today at The Westin San Diego Bayview.
We invite you to attend our Program Partner Presentation by Courtney Todorov, Senior Scientist, Scientific Manager, on January 25
NeoGenomics
@NeoGenomics
(2/2) at 2:00 p.m. It is titled, “Optimization of an Integrated MultiOmyx-RNAscope hyperplex assay for co-detection and characterization of multiple protein and RNA biomarkers within the tumor microenvironment (TME).”
-
NeoGenomics
@NeoGenomics
The Neo Comprehensive™ - Myeloid Disorders assay utilizes next-generation sequencing (NGS) to detect alterations in 164 genes known to drive a spectrum of myeloid diseases.
To learn more, please visit: neogenomics.com/test-menu/neo-comprehensivetm-myeloid-dis…
#neogenomics #cancertesting #oncology #myeloid -
NeoGenomics
@NeoGenomics
Visit NeoGenomics during the 2nd Annual Spatial Biology for Immuno-Oncology Summit at The Westin San Diego Bayview, from January 23-25, where we’ll be exhibiting at booth #4. We'll be sharing a Program Partner Presentation; join us for that special program on January 25 at 2 p.m.
-
NeoGenomics
@NeoGenomics
NeoGenomics will be exhibiting at the Precision Medicine World Conference from January 24-26 at the Santa Clara Convention Center. Come see us during #pmwc24 at booth C945.
We are proud to be a Bronze Sponsor of this event. -
NeoGenomics
@NeoGenomics
The American Cancer Society estimates that more than 13,000 new cases of invasive #cervicalcancer will be diagnosed this year. During #cervicalcancerawarenessmonth, join #neogenomics in raising awareness about the importance of cancer screenings and early detection.
-
NeoGenomics
@NeoGenomics
(1/2) Dr. Derek Lyle, NeoGenomics’ Chief Medical Officer, sat down for a podcast with OncLive, where he discussed the field of precision medicine as it relates to lung cancer and how it has evolved over the last decade. He examines emerging issues, developments in the setting
NeoGenomics
@NeoGenomics
of early-stage patients in adjuvant treatment settings, and more.
Stream “Biomarker Testing and Targeted Therapy in NSCLC: Review and Update” here: soundcloud.com/modernmedicine-network/biomarker-testing-a… -
NeoGenomics
@NeoGenomics
#neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
To learn more about this program: neogenomics.com/diagnostic-services/sponsored-testing-pro… -
NeoGenomics
@NeoGenomics
#testmenuspotlight NeoTYPE® DNA & RNA - Lung detects genomic alterations that are most relevant to therapy selection, prognosis, and clinical trial options in non-small cell lung cancer. To learn more, visit: neogenomics.com/test-menu/neotyper-dna-rna-lung.
-
NeoGenomics
@NeoGenomics
NeoGenomics received a platinum award for NeoAccess™ from DotCOMM, an international competition honoring excellence in web creativity and digital communication.
To learn more, check out this blog: neogenomics.com/newsroom/blog/neogenomics-honored-platinu… -
NeoGenomics
@NeoGenomics
Neo Comprehensive™ – Solid Tumor is a one-stop solution for accurate, comprehensive genomic profiling.
To learn more, visit us online: neogenomics.com/diagnostic-services/specialty-testing/neo…. -
NeoGenomics
@NeoGenomics
NeoGenomics’ CEO, Chris Smith, presented yesterday at The 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Thank you to everyone who attended!
Through January 11th, Neo team members will be on-site discussing partnership opportunities and oncology solutions. -
NeoGenomics
@NeoGenomics
#specialtytestingtuesday is a series created to share key facts about our suite of specialty tests. Today, we're spotlighting NeoTYPE® DNA & RNA - Lung.
To learn more, visit our online test menu: neogenomics.com/test-menu/neotyper-dna-rna-lung. -
NeoGenomics
@NeoGenomics
The 42nd Annual J.P. Morgan Healthcare Conference kicks off today in San Francisco. Meet with the NeoGenomics team, including Chris Smith, Chief Executive Officer; Warren Stone, President, Clinical Division; and Vishal Sikri, President, Advanced Diagnostics Division.
-
NeoGenomics
@NeoGenomics
#sundayreads
Looking for something to read this weekend? Check out the library of blogs on our website: neogenomics.com/newsroom/blog. You can search by topic or keyword, such as 'KRAS' or 'next-generation sequencing’. -
NeoGenomics
@NeoGenomics
NeoGenomics is excited to be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. From January 8-11, Neo team members will be on-site discussing partnership opportunities and oncology solutions. We can’t wait to connect with you during #jpm24.
-
NeoGenomics
@NeoGenomics
NeoGenomics is attending the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11 in San Francisco, California. Join us for a presentation and Q&A with members of our management team on Monday, January 8th, at 5:15 p.m. PT. We look forward to seeing you during #jpm24.
NeoGenomics
@NeoGenomics
Can’t make it in person? You can visit us online, where a live and archived audio webcast of the presentation will be available: ir.neogenomics.com/news-events-webcasts.
-
NeoGenomics
@NeoGenomics
Looking for something to read? Check out the library of blogs on our website: neogenomics.com/newsroom/blog. You can search by topic or keyword, such as 'KRAS' or 'next-generation sequencing.’
#neogenomics #blog -
Post not available here, view on X
NeoGenomics
@NeoGenomics
(2/4) was excited to exhibit and hold a fundraiser to benefit Conquer Cancer®, the ASCO Foundation.
We hosted an interactive experience called "Find it with RaDaR®." Each time an attendee played, NeoGenomics donated $25. We were thrilled to have raised $10,000 to support their -
NeoGenomics
@NeoGenomics
NeoGenomics tests over 500,000 oncology patients per year.
Learn about how #neogenomics is driving precision medicine with data solutions: neogenomics.com/informatics -
NeoGenomics
@NeoGenomics
(1/2) Despite improvements in treatments for head and neck squamous cell carcinoma (HNSCC), many patients with HPV-negative HNSCC develop disease recurrence, and fewer than 50% of patients will survive beyond five years. There is a clear need for more effective tools to help
NeoGenomics
@NeoGenomics
better stratify and monitor patients. At NeoGenomics, minimal residual disease (MRD) testing with RaDaR® is utilized for risk stratification and surveillance for head and neck cancer patients. Visit us online to learn more: finditwithradar.com/providers/head-neck
NeoGenomics
@NeoGenomics
Reference: 1. Flach S, et al. Br J Cancer. 2022;136:1186-1195.
-
NeoGenomics
@NeoGenomics
(1/3) Around 35% of ovarian cancer patients are expected to be positive for folate receptor alpha (FRα)1, meaning over a third of people with advanced ovarian cancer may have a different treatment option.
Testing for FRα expression is performed using the FDA-approvedPost not available here, view on X
NeoGenomics
@NeoGenomics
Visit us online to learn more: neogenomics.com/test-menu/folr1-fda-elaheretm-ovarian-car…
NeoGenomics
@NeoGenomics
1: Matulonis UA, et al. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. J Clin Oncol. 2023 May 1;41(13):2436-2445. PMID: 36716407
-
NeoGenomics
@NeoGenomics
(1/2) NeoGenomics is thrilled to announce a recently published paper in Clinical Cancer Research highlighting our MultiOmyx™ technology. Our colleague Qingyan 'Sandy' Au PhD and collaborator Ken Young, MD, Duke University Medical Center co-presented at the American Society of
NeoGenomics
@NeoGenomics
(2/2) Hematology. The article can be accessed here: aacrjournals.org/clincancerres/article-abstract/29/23/480…
-
NeoGenomics
@NeoGenomics
Join NeoGenomics at #ash23, booth #851, to uncover the latest breakthroughs shaping the future of heme oncology testing.
#neogenomics #ash23 -
NeoGenomics
@NeoGenomics
The NeoGenomics team is at the San Antonio Breast Cancer Symposium (SABCS). Stop by booth #841 and meet the team!
-
NeoGenomics
@NeoGenomics
(1/2) NeoGenomics’ team of experts are industry thought leaders with over 18 years of experience. We look forward to partnering with you to help improve patient lives. Join us at booth #851 at #ash23from December 9-12 to meet with someone from
NeoGenomics
@NeoGenomics
(2/2) our Informatics/Data Solutions team today. Learn more at neogenomics.com/informatics
#ash23 #hematopathology #neogenomics #informatics -
NeoGenomics
@NeoGenomics
Learn more about our oral and poster presentations at #ash23.
NeoGenomics: Leading the way in heme cancer testing with groundbreaking insights.
#ash23 #hematology #neogenomics #hemecancers -
NeoGenomics
@NeoGenomics
The NeoGenomics team is on-site at the 2023 San Antonio Breast Cancer Symposium. We are excited to discuss our RaDaR® assay along with NeoGenomics' other breast cancer offerings.
-
NeoGenomics
@NeoGenomics
(1/2) Join us for an insightful session at the 2023 San Antonio Breast Cancer Symposium! NeoGenomics is hosting a product theater featuring the RaDaR® assay. Our featured speaker is Dr. David Cescon from Princess Margaret Cancer Centre, panelists alongside him are Dr.
NeoGenomics
@NeoGenomics
(2/2) Pat Whitworth (Nashville Breast Center), Dr. Wolfgang Janni (University of Ulm), and Dr. Derek Lyle (NeoGenomics). Don't miss out on the conversation on Thursday, December 7, at 12:30p.m.
-
NeoGenomics
@NeoGenomics
(1/2) Join us for an insightful session at the 2023 San Antonio Breast Cancer Symposium! NeoGenomics is hosting a product theater featuring the RaDaR® assay. Our featured speaker is Dr. David Cescon from Princess Margaret Cancer Centre, panelists alongside him are Dr.
NeoGenomics
@NeoGenomics
(2/2) Pat Whitworth (Nashville Breast Center), Dr. Wolfgang Janni (University of Ulm), and Dr. Derek Lyle (NeoGenomics). Don't miss out on the conversation on Thursday, December 7, at 12:30 p.m.
-
NeoGenomics
@NeoGenomics
Save the date for 2023 San Antonio Breast Cancer Symposium! Our Poster Presentation, led by Daniel D. Stover, Anna Juncker-Jensen,et al. promises valuable insights. To learn more about 2023 San Antonio Breast Cancer Symposium, visit: www.sabcs.org/2023-SABCS
#neogenomics -
NeoGenomics
@NeoGenomics
(1/2) We are excited to announce the latest RaDaR® data being presented this week at the San Antonio Breast Cancer Symposium. Mitchell Elliott, MD will present an updated analysis of the TRACER cohort.
NeoGenomics
@NeoGenomics
(2/2) To learn more about 2023 San Antonio Breast Cancer Symposium, visit: www.sabcs.org/2023-SABCS
#neogenomics -
NeoGenomics
@NeoGenomics
The San Antonio Breast Cancer Symposium (SABCS) from December 5-9. It takes place at the Henry B. Gonzalez Convention Center, and attendees can visit NeoGenomics at booth #841.
-
Post not available here, view on X
NeoGenomics
@NeoGenomics
(2/4) quarter. For the first week of December, let’s look back on the first quarter of the year, which saw several tremendous launches. NeoGenomics debuted the Neo Comprehensive - Myeloid Disorders and Neo Comprehensive - Solid Tumor and DNA & RNA - Lung. We announced the
-
NeoGenomics
@NeoGenomics
We look forward to seeing you at the 65th ASH Annual Meeting and Exposition in San Diego from December 9-12. Be sure to stop by and visit #neogenomics at booth #851.
To learn more about #ash23, visit: care.neogenomics.com/ASH-2023
#ash23 #neogenomics -
NeoGenomics
@NeoGenomics
(1/2) We are pleased to share about a recent article that’s been published in Nature Medicine.
NeoGenomics is a proud contributor to the new publication describing an integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease.
NeoGenomics
@NeoGenomics
(2/2) In this high-impact study, MultiOmyx™ technology was used to identify subpopulations of scar-associated macrophages (SAMacs), Kupffer cells, and tissue monocytes in MASLD tissue sample.
To learn more and view this publication, visit: www.nature.com/articles/s41591-023-02602-2 -
NeoGenomics
@NeoGenomics
Looking forward to seeing you next week at SABCS. Come by and see us at booth #841 and say hello.
-
NeoGenomics
@NeoGenomics
(1/3) A collaboration between Professor Xin Lu at The University of Notre Dame and NeoGenomics Laboratories, using the MultiOmyxTM multiplexed immunofluorescence (IF) assay to analyze the spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in
NeoGenomics
@NeoGenomics
(2/3) bladder cancer, has been published in Cancer
Communication. Follow the link below to read about our findings and the potential clinical implications for anti-PD-L1 immunotherapy onlinelibrary.wiley.com/doi/10.1002/cac2.12491
NeoGenomics
@NeoGenomics
(3/3) #neogenomics #universityofnotredame #multiomyx #multiplexing #spatialbiology
-
NeoGenomics
@NeoGenomics
(1/4) #neogenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to
Post not available here, view on X
NeoGenomics
@NeoGenomics
(3/4) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria,
NeoGenomics
@NeoGenomics
(4/4) and to download the test requisition form, please visit:
neogenomics.com/diagnostic-services/sponsored-testing-pro…
#ovariancancer #cancertesting #oncology -
NeoGenomics
@NeoGenomics
NeoGenomics offers minimal residual disease (MRD) screening with the RaDaR® assay for lung cancer.
To learn more, visit: finditwithradar.com/providers/lung-cancer -
NeoGenomics
@NeoGenomics
DYK: Sarcoma is rare in adult cancers (1%) but common in pediatric cancers (15%). See testing: care.neogenomics.com/l/434902/2018-07-11/hghcnb/37865 #sarcomaawarenessmonth #sarcoma #pediatriccancer

















































































































































































































































































































































































































































































































































































































































































